var title_f20_22_20832="Phonocardiogram calcific AS at 2nd right intercostal space";
var content_f20_22_20832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/56063/asc2rics_conv.mp4?title=Phonocardiogram+calcific+AS+at+2nd+right+intercostal+space\" style=\"width:398px;height:478px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phoncardiogram of calcific aortic stenosis as recorded from 2nd right intercostal space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram and phonocardiogram of aortic stenosis due to valvular calcification as heard at the second right intercostal space. S1 (mitral and tricuspid valve closure) is followed by a mild systolic ejection murmur of aortic stenosis. A single S2 is from delayed aortic valve closure which occurs simultaneously with closure of the pulmonic valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20832=[""].join("\n");
var outline_f20_22_20832=null;
var title_f20_22_20833="Insertion inflatoball pessary";
var content_f20_22_20833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflatoball vaginal pessary in position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Milex Products, Inc., Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20833=[""].join("\n");
var outline_f20_22_20833=null;
var title_f20_22_20834="LCDD tubules IF";
var content_f20_22_20834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light chain deposition disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in light chain deposition disease involving the kidney. There is intense staining with anti-kappa light chain antibodies along the tubular basement membranes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20834=[""].join("\n");
var outline_f20_22_20834=null;
var title_f20_22_20835="Milrinone: Patient drug information";
var content_f20_22_20835=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Milrinone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     see \"Milrinone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"     see \"Milrinone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Milrinone Lactate Injection;",
"     </li>",
"     <li>",
"      Primacor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702531",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to milrinone, inamrinone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are getting inamrinone.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11988 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20835=[""].join("\n");
var outline_f20_22_20835=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196740\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015988\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015987\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015992\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015993\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015995\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015990\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015997\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=related_link\">",
"      Milrinone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=related_link\">",
"      Milrinone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_22_20836="Hydroxyprogesterone caproate: Pediatric drug information";
var content_f20_22_20836=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxyprogesterone caproate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=see_link\">",
"    see \"Hydroxyprogesterone caproate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/38/22116?source=see_link\">",
"    see \"Hydroxyprogesterone caproate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11507626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Makena&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F990804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Progestin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F990816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=see_link\">",
"      see \"Hydroxyprogesterone caproate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Reduce the risk of preterm birth:",
"     </b>",
"     Adolescents &ge;16 years and Adults: I.M.: 250 mg every 7 days; treatment should be initiated between 16 weeks 0 days and 20 weeks 6 days of gestation, can be continued up to 37 weeks gestation (ie, 36 weeks 6 days)  or until delivery, whichever occurs first.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12608996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Makena&trade;: 250 mg/mL (5 mL) [contains benzyl alcohol, benzyl benzoate, castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F12602961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The Makena Care Connection&trade; is a comprehensive program for patients and healthcare providers which provides administrative support (including insurance benefit investigation and prescription fulfillment); financial and co-pay assistance for eligible patients; and treatment support (including educational information, home health care service and scheduled treatment reminders). The Makena Care Connection&trade; is available by calling 1-800-847-3418, Monday-Friday, 8 AM to 9 PM EST.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F990817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Withdraw dose using an 18-gauge needle; inject dose using a 21-gauge 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     -inch needle. Administer by slow injection (&ge;1 minute) into the upper outer quadrant of the gluteus maximus by a healthcare professional. Solution is viscous and oily; do not use if solution is cloudy or contains solid particles. Apply pressure to injection site to decrease bruising and swelling.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F990813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store upright at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; discard within 5 weeks of first use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F990805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To reduce the risk of preterm birth in women with singleton pregnancies who have a history of spontaneous preterm birth (delivery &lt;37 weeks gestation) with previous singleton pregnancies (FDA approved in ages &ge;16 years and adults).",
"     <b>",
"      Note:",
"     </b>",
"     Not for use in women with multiple gestations or other risk factors for preterm birth; not intended to stop active preterm labor.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11507625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hydroxyprogesterone caproate may be confused with medroxyPROGESTERone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F11507714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Pain, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pruritus, nodule",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Injection site cellulitis, PE",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F990807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyprogesterone or any component; current or history of thrombosis or thromboembolic disorders; carcinoma of the breast (known or suspected) or other hormone sensitive cancers (or history of); undiagnosed vaginal bleeding unrelated to pregnancy; cholestatic jaundice of pregnancy, liver tumors (benign or malignant); active liver disease, uncontrolled hypertension",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13227578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in women with diabetes; decreased glucose tolerance may occur. Use with caution in patients with depression; discontinue if depression occurs. Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes, pre-eclampsia, cardiac or renal dysfunction; specific studies have not been conducted; elimination may be decreased.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F990808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arterial thrombosis, DVT, or thromboembolic events may occur; discontinue use; contraindicated with current or history of thrombosis or thromboembolic disorders. If hypertension develops during therapy, monitor patients closely; consider risks and benefits of continuation of therapy; contraindicated with uncontrolled hypertension. If jaundice develops during therapy, monitor patients closely; consider risks and benefits of continuation of therapy; contraindicated in patients with cholestatic jaundice of pregnancy. Clinical benefits related to neonatal mortality and morbidity following use have not been demonstrated. Long-term effects of hydroxyprogesterone",
"     <i>",
"      in utero",
"     </i>",
"     exposure were evaluated in a follow-up safety study of 278 children (mean age: 48 months) whose mothers were part of an earlier hydroxyprogesterone-placebo efficacy trial; no significant differences in physical development, neurodevelopment, and health status were reported between the treatment and placebo groups (Northen, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains benzyl alcohol and benzoate which may cause allergic reactions in susceptible individuals. Contains castor oil which may cause allergic reactions in susceptible individuals; discontinue if allergic reactions (eg, urticaria, pruritus, angioedema) occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F11576113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate), CYP2A6 (strong), CYP2B6 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12608747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inducers (Strong) may increase the metabolism of CYP2A6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F243254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11507628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not observed in animal reproduction studies; embryolethality was observed in some species. Teratogenic effects were not observed in human studies following second or third trimester exposure; first trimester data not available.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Maternal serum concentrations of hydroxyprogesterone caproate are widely variable and may be decreased in women with increased BMI. Hydroxyprogesterone is metabolized by the placenta and reaches the fetal circulation. In one study, the cord:maternal concentration ratio averaged 0.2. Hydroxyprogesterone caproate was detected in cord blood when delivery occurred &ge;44 days after the last injection (Cartitis, 2012; Hemauer, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13227598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of thromboembolic disorders; signs or symptoms of depression; signs and symptoms of jaundice; glucose in patients with diabetes; or blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F990814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The mechanism for reduction in risk of recurrent preterm birth is not known.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F990815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensively bound to albumin and corticosteroid-binding globulins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 and 3A5; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~8 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum concentration: 3-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~30%) and feces (~50%); primarily as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F990819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/38/22116?source=see_link\">",
"      see \"Hydroxyprogesterone caproate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain a regular schedule of injections as prescribed. This drug can only be given as deep I.M. injection by a healthcare professional. If diabetic, monitor serum glucose closely. Report rash, radically increased weight gain or swelling, anorexia, muscular weakness, fever, or unresolved nausea or vomiting. Report immediately any swelling or warmth in calves, chest pain, respiratory difficulty, severe headache, acute dizziness, or numbness and/or tingling in extremities.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Northen AT, Norman GS, Anderson K, et al, \"Follow-Up of Children Exposed",
"      <i>",
"       in utero",
"      </i>",
"      to 17 Alpha-Hydroxyprogesterone Caproate Compared With Placebo,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):865-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20836/abstract-text/17906021/pubmed\" id=\"17906021\" target=\"_blank\">",
"        17906021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16766 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20836=[""].join("\n");
var outline_f20_22_20836=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507626\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990804\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990816\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608996\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12602961\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990817\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990813\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990805\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507625\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507714\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990807\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13227578\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990808\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11576113\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608747\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243254\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507628\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13227598\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990814\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990815\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990819\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16766\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16766|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=related_link\">",
"      Hydroxyprogesterone caproate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/38/22116?source=related_link\">",
"      Hydroxyprogesterone caproate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_22_20837="Open fracture of the lower extremity";
var content_f20_22_20837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open fracture of the lower extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AZEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDBNwq8E809ZlYgVh24eVjI7cdqsiUhgM199HVn546VjE8YabkGaIfMvP1Fccrc5Nel3ciTwMjYyBXnGsIIL51XgHnFcWMiovnR6+Xzco+zfQdHMFHWr1rqBTHNYqtmnbsdK5lVsdk6Kludxp+qggZNbUNzHMuGwRXmkF00bZz0rc0/VAQAWrpp109zz62EcdYnYz2ltdQlGRSCMcivK/Fvh59KumlgBNs5zj0r0C3vwdvNT3yRajZvDJjkcfWssXhYYiFl8XQrB4meGn72sWeK+4oPWt/VtAmhmfycEjqtYMiPExWRSrehr5ZxcXZn1CaauhBTX+7S0jdKRSLOnyYJQ/hWmM7cZ5NYcLFHVh2rdt+cN7V3YR3XKcuIVncmC4UCopx8hNWAu/k8UkqfIfTFd0o3RyKVmc8i7pmz61eig3YqvCv+kP8AWtSDGQB1FfP1HZs9ulHmsRmzJ4C1FLZSKcKOfSugs4zIuXGDV+Oy3r8qjNYupY6XQucNJFJGclSDSrO4wrn5fauuvtHMygjK461hXmlyxAkKWFa067WzMKuH8iKC7Kkc8VsWd/jAB5rmWVo26Ee1SRTFSO1enQxjR5lfCKR3trqGVGWzWjFqDY61wlnfFSOc1tWt0GxzXt0MSpo8WvhOXdHUpch8AgEHgg1y3ibwss2+60wBZOrR9j9K1baYZ61oRy+hrqq0qeIhyVEc1GpPDT5qZ5VDK8MhjmBV1OCDWvaXPvXS+IfD0epoZYQEuQMhh3rh/wB7aXDQXClJF4IPevEqUamDklLWPRnt06tPFxvHfqjq7S4BIwea1SFubZ43A5FcpZTjjNbENwSAAfxr0qFVSiefXotSujG8wwySL12Zre8Jzma2LHrurC8QMISwGAz1r+ClzZOfQ189iKspzcHsme9SpxhFSXVHXSnKrVK5TIxirMzYRTUTLlTms4ouT0KGwlq2/DESi9kYjhYmP6VnKmK1tDIU3J25/dGraMCHwqdum60/Zv8AGs7XH36igA6RgVf8OjGi6mfVgB+dZ2rqTqB7EKKVhorqWR8MCD71YTCbc896jhYuQsvzAd+4q0AqlmflalpFXMq6kfzGdkdY84DY4NRwTlZAVbP416L4a+z6laGOeFHiXhQRUup+C9NuUYwKYJMcFegNaRjpocspq9mZHge+e618yuf3VtFwD617NoKBbf7RIwZ5OfoK8P8ACthPphv4ZGDymTYpHcV7FpBaGxhjbrtFVFHPVSvodE4SVRURtRk4FVFuSpHerkdyrDGeKtmOhB9li/ur+VFWvMT0FFZk2Z897hDCozziqslzj61XuZHbkkgVn3FwI+rc+lfUSq8p50KNy3eXvlR53c1wuo6gJ7+RsgjpU2tahJKxRM49qwfLf0rwsZjnN8sdke7g8Gqa5pbs1UuVPWpRIh/ixWNtcdM0b5B3NcqxUludboJ7G1u54ORT45dpyDg1jRTup71djnSRck7WraGKuZSo2Ohtb1hjPStBdT8nBLfhXKRakkHbdUU2oK8hf9K6njYxWj1Ob6m5PVaG34m1VSsVxEds/TA7isV9SiuVxcRq3visy4maeQs5+lQmvKxFX2tRyR6NGl7OCiXZooGOYWx7VVeMrx1qPdRuPrWBtYUKQOa2LB98arnnvWNuJ4zWrY4QgCujDStMyrq8TWXnA9KJuFOOaWLGB6UO6+WTn2r2tOU8vqYkA/0pwTxmtqxVeEUZJ71jqga6lA6GtzT3VE/T618ziNJM+jwusUX4wYnxtJHrW/Zx4VSvJNUrFRgF1BB5+la0CkjMaj2FcE5HrQpXRK0IKgMuM1XnsFMe3Ax71o2rSzyLEFDMf0rP8U3+m6NaOs0zS3p6RqelTBtvQqpGMF7xz+qaHAI90jrG3bPeuWvdLliJZPnT1FaS30t6fO1GQMh4VQfuioyptd8kc5YfwDqG9q64ycdDhqUVJcyMIO0TYbIrQtLsqRg10dhYWOuQlGTybpRlkPFZ994Su4HJtWDL2Brro4x03ZnDVwDmrpE9rdggHNa1tdg45rjCZ7KXy7mNo3Hr0NaVtedOea97DY5SseDicE43O0guM96zPEWkw6nDnG24X7riqdtqCgYJ5rQS8SSMKD+Neq5068OWWqPLUJ0Jc0dGcMqy2lyYLgFXX9a0rebnrWtrlnHeW3mADzo+QR3rmYpMDB6968iUXhp8t7roevCaxEOa2pY8RAMIZM/N0rb8GPiyZR1Lc1y2o3HnMoH3VrpvBnFu3ua8vFTU6rlE78PFxgkzrZ8iNKftyvA4pzR5SPcORTwMmlAKjskV1TsBWvods0ouhEuZDGe9VVhOM45JrpmtbfRdOaSCYTX0kRL45UA/1q3oZdDmNDTy9Fv1Yc+YAfzqnqkaSXrEHD4A21qaVG0ehXRkRlZ5ARkdeazNQ5vXPfikNEbWTwYJGRjOalmtz9nTI+9Vi0uGXiT51PHParN4AIkC8+lQyrm34bs1tbOPH5V0M58u1Zhw2M5rB0yQ+TGScYHNaepThNPds87a0icU9zK8KW7XN3JNIM4cmu+hIH4VzHhlRDpcZIw7kk5rft5lIx3qloZz1ZbDEtmrcZBOe1UEcZ9MVaiYMD6YpszY77bF60VQ3xf3KKgm5863l5cup2LgVHaWM0yGW4J56Ct/yoyvKCh1BGAMV2zrTnuzohTjH4Uc5LpkZJ4qs2mxg9K6OWLIz3qm8Jya53FG6mzG/s6PFNbTY+mBWqYjSeWRS5UVzMyP7KjbsKYdIXtxW0VxQFzU8i7D52YLaIpB9agk0ULnBNdI5xmqkhaQ4UcUnCPYpTkc22luWwpqtPZPEfWuqddowOtULlM54rKVNGkajObMZHUUmw1ozR88VAUIPIrLlNeYhhjJcelXYz5TAnpTYwFWiY5Q1UXy6ol+9ozVhlLIB606c7QACPpVe0G9IwOgHNLOPnLHtXqub5E2cHKuaxWjGZnIHBNbFrGrhd5xjpiqdpAzFAF5Y10umWO91KgAJ1Y18/iJ3k2fS4OlaKuW7KMNEFcMD2963tPs5rgCKFQF/ik/uioQbWFQ87BI/wBW9hWH4v1bWNJRJLGJ7SwlGCepP1rjjHnZ6kqnJG6NjVdYe2gubfQY1KwcSzP96Q/7Ned6nFJf3W6WN45uuX71MddcyRSbh8o7dz70XF/dXcBgypZznd3H410Qjy7I5KsozW5WsdOEsckc5KyE4U54FWbqynsfJjS4jlcc7ewNUhI+nSGO8y0nUHPGKuW2rWscUitGsrN/Eeo+lNtkU1C29mTWmqSDUUnkh23EPDFejCvXLO0t9W06GVQY2kGQR2NeUWZa3iW7tbcTRycMX7V6p4JuVbSUULt54rnr6K6OzDK+jZSvvD6tutdRt45QfuOBzXC694PutNZptNLSwDkxnqK9umhW7jBbCyr91qypVWRnjfCuOvvWdPFTpO6Lr4KniI6rU8EiuPmKMCrjgq3UVbtbkoxBNd34m8MW147N5Wybs6VwuoaNf6dJ8yGWPswr3cLmalu7M+bxmUTp6pXRetrzfuD/AHTWDeov2hhGMLmrukWsl5ciF3MY6nPWm6lbiC9aIdBW2IxartQW6OWjg5UIub2ZjzLiuu8GDNsB/tVzF0mK7LwPFm0U45zXI0ap21OsdfmQEdqmQID05oZSZgOwFSxoolQyAlAcsB1IraCMpsVAeqEAdwatwxgWN0SSFC59akvGgnuQ1qhjhAwAev41q6VbytY3a2sYeZkwARmqM2YkV3NfaBI84UFXCKAO1YV8n+nOp46c1vQxtaaLNbzIfM83czDoKyLwrLeMydDSaGmJHEVK45HqKsXnKLimWxKuNp47in3udgwO/SpGzZsUZ4Y1HVsCrXiaeODTW8qWKRlGCFYHB964Txvrstjp0Om6bMFupVzLIp5Qen1rzqye9s5t8V07BvvqWJzRz2MlR5tWz1S18UXCYV+nStqz8Ungs1eLP4gu42I2oasQeIp/L3SRDnpimqiB4d7nvdp4ljk4JFan/CR20MQkdvavArLxGzxs/lsoXvUjeK0yVnLsh7Cq9ojJ0Gz2f/hJ7f0H50V43/wktn6SUUudEfVmdHnikCk5zUkcRfk1My4OMV1DKbLkVE0fPSrrpTRHQCZntCSTxULRHOK1/L56VC8IzSsVcymj55FDJgVpGDnpiopIuPeixVzLeIsdo71ItrtXpzWlb2ufmp7wnoBSsHMYUkGSTiqU9uSTgcV0r2/HAqF7UEdKlxLUjkZrU85FUpYMHpXXS2g5JFZd1a85xWUoGkZnPMMVG/K9K0LmDGeKqhDg1i0aplqykHlYXt1qx5LSHIHyjrWdZPtcxj7zHit0Dy9kePr71rWxKjRS6jw+Gc6t+iLemWmSCTgVvhIbWL5iSDyFHVqqWuy1gN1csFRBhV9azjqEr3xuH2KFGY1J6CvHa5mfRQVloJdX076kftluWVBmFV/h96hnuLnWLUW1xebwWxsc9KyoNauLTU5LldswY4Kt0p+oTWdxA06Epdk5wvQVfKJVVqlqupV1PSn0y5RJmUoe45xT2McSQ+QGO1su3ZqnhjMmnGe4YO44Csck0+0eRoCkUPJ5yw6UOb2NIYaEXzd9i34kNpqUME1jtZwmJAe1U9LWzh05kaAPOzYLt/CKhtozJcv56mJFH3l6GpGV57Y+QoCA4z3NDb2J9nCT9o1qdbawaTbaGymWQ3kp2oO3Nd/4d006ZYW8cxyxXcRXmvgHRZdY1qITlmgtR5jZ9u1exQYnjaSUH5OMe1ctfRcp10pc2tizvjYAZ4qlqFmHizHwQc5HeppQ8aq+zMR6eopY51EYY5A9K5WzqWiujMgtppyQ6KMDGfWsq708SNIhAO3muj89XmyhKrVS4RTO8iHAxz704uz0IlruecX9lHFdiRFIYdwK5nVAZL5mZcGvVNShjkU7VAyOteca1GUvSD1B/OvSwk7z1PIzGn+6bRzd6uFNd34Hh/4lsbn61xN8M9O9eoeDLbbpkCqOor0HueEn3NCILLKXUYUcZNXrWymuWAghZz7Ct3TdLt8K0/P+yOlddZiK3jUII4lr0sPgpNXm7HkYvM4U5Wpq5yNp4U1CYAlEi/3q2NL0XU7GZliVWfHJB6rXRi9t14Mm49OOa3tLsxexTgSGOQJlHq8RhoU6bkuhz4XHVa9ZQklZnnN54P1nxCHfRLBo7UcM0hxvbvXL6t4X8QaLGYtQ0aUQ5z5qLuxX0/oV3BHpVvFJNEkiLtYZA5rVyssZAKupH1FeS6jW6PejTi1oz4++zQSjdbHDovKng/iKxb2WaFJ5ByVUtivpjxp4D0jUs/ILO6YErcRDGT6EV4P4x0a50gz217HhtjBZQOHFXzJrQhqz1PA2uZmuJp5SWMrEknnFEM+6UDPBq7HAHWQAchjkVTe0MVyoPCt0NZmmhDLCd5ZiAuetRSS72VIh1+UVObWRGdZQdh4rT8DaS2p+LLO1K5VTvb6Cl1C6SuyeWza0tY4mHzAZaspYvMuORwvJr1LxNon76TCcZxXDWtl5Ot+VIvysK1lGxhGommzP3Q/3TRXZ/wBi2392ilysn2qOiUcU1+DUvRR2qJuT616JyDACTTgvB4qQJ3pSO1A7kW2m7efWpiMD1pu35hikK5GVGOlQ7A74xVqXgUW0e45xQVckjiCqOKYYsnpVzbxzTduG5oFfUpmEVE8Xy4xW1p9hNqF2ltbIWkc447Vuaz4E1SywbeP7QmMnHUVLkk7MtJtXR59LBnPHFZ1xbZ7cV0ktu0cjxSoVkU4Kngis7UInWJtg+apltcqL1scbq0Xlg5OBWQEAU4Oa2b+2nZz5ikk1mRwMsjLg59K427s7lG0Q0i33XJmYcLwPrXS6bAj3BkmX9zHyxPeqOmw8pEq5Zu1O1i8MTGxVtiLyT3JrhqS5pWPZwtLkhdkl9Kl7fBJS0dkf9X7H3qmILSGeV9Ql8yBQdpQ1qaRewXk1uL6BcR/fX++KzfHFtbHVQ+mx+TA2MxA5AqFrKx1yfJT5rHNSEyzP5CEQ54J64q/p9iX5fPHNWbA27I0U3yuOmB1rfsbCI7ImJDOOCKKk2lY1wWDhUlzSlfyItA0iW41AbV3oFOOM59qtXPh28QSGCKUAZYp3UVvwW03h+O0nuVaJJW/dzA/KfrWv4iluW09r3T5t68LKw6kVze0ketPD0ltrf8DzCIctbS5QZ4z1NMh0+4imleJGmto+WYUaq8n9ptLNxGuOa34VfT7jT1EjJbXZBbPIYV0rRXPDqv3nDsd/4Lt3tNDS58kRNcDhR1xXSxtCtsGkfywTg57mqk0iRNbQwnMSoNuOmKnhxMu6VV2g8AiuGcuZ3OynHlVkWS21vlJKEcg1k3IVCSrkHP3a158FQwIxVG8gJGWA5FYnRTZTNwdm1tuO5qpdXJRwpH7sjqKZcBkRggDKDzWc8i5xuLKeCPSnFalyh1JL25VQEBBXsc1xviREkQyRYJHWumvPKjUIF+UjgmuX1Nv3EqFR9a7MO+WaZ52LhzU5LyOUnXfIi+pFeteGWCW0IztRVHNeUYzcRj3r1Hw6B5UJkXOPup6/WvosJG87nxmLdqdjt7CaWcEQqEjHWR+9akQgXADNcyk/gKx7OCSeUGYnH9xeFAret3t7chUYD2QZr2/aQpRvN2PmpUp1ZWgrlmCScMqR24XJ5IFei+GLffbSyytt2LiuAjvAB8sRJHQk13/hW5kudLkCIGfuAa8vHYunUhywPTy/BVaVRTqKxk3UcDLJ9oOIsk7s4qnp9+kRxpl/NFg8bzkGsrxDqslvevZ3Vswgzkt0NV4brTpFVYZjG4+6JBxWtCvSqRtJ29TlxOFrUZOUV53R3cXifCC38QQBoScC4iHT3NYHxmsbOX4el4GjnG7MMg+8AayLqae1XzJJA6Ec91asDVpxc2L7Gf7Pg5hJ4U+orSWXwbU46L8CqWaVUuSevn1Pne1tjHNI3UhjVjU9MElmJ4uEz/3y1bM1qgu59pH3ycVasYgCyuN0Mnyuv9a8a1nY9xz0ucxJAt1o/nYAkj+Vx7+tb/wPs/O8V3VwRxFCRWVq1s+k309s5zFMuUb1Fdp8ArX/AEfW7sjnIQUW1QpO0Gzr9WtVuC2AK808R6d9l8RWbAcPxXrqKGDsegNcR8RIFVtOuFABEuK1exzQk72M/wAj2oqbzDRS07kiP90UkS5bpTm7YqeCPauT3rsEJtHApjLirBAphXNFgINtIVPBqxt4qGQ4oBFVwXcir1sm1RUMEW5810Hh6wN5qEUe3Kg5NJuyuUtXY0LHwnc3tssqPsLDOCKrXvhTV7ZlAt/OBPDLXsdhZeTEgC4AGMVZUBX+70rh+tSTOtYeLRg+APCyaTarLKoa7lGWJH3a7lbdduCM1ni84+UDNWYtQHG5SK55VHJ3ZvGCirI5nxR4DsNb3y7RDcH/AJaKK8g8ReDNW0aZ/NgM9oPuyoM/nX0bJcLJGdhwa5jV9Yu48pPZ5th1IGfxqliXT32HHC+1fu7njGg/D3Udf2yPGLW0zy7jk/Sp/ip4f0PwT4L8q1gWXULttolYc/hXd3vi1Gmit4ZFiif5cnjH4V4x8XNWl1vxJDaSSbreyXk9j71lPFe1dlodtLLpUrOZw8fmWdisy/NM5Bx3C960PEbaXr2r2Eumt5RMIR0IxhhWXd+bNODHyjfLtHYVUvZ4zJKoiKNGNqsONv1rnV72R7KUIRU5FLVLuS3lKQt/pCMVYD2oiuJ71okmOWY9qi0uEnUQ0j7j6nvUkim2cSxOA4fj2rblSPOdSc25Mu2MUkFwwRFd1yQGHWup8NfZbmNf7QnMUjvlivWMVxTak5ukkmfAXk7a6fw1BKlhd6pfQM8EgKQJ3J9azqxvE68BV5Kydrnoa2N1LZSaXdMs9hId0ErDOf8ACvP9Rnl0ueS1mnkijRsFCflce1bWk6vqUemF1uUeGLrHJwy/Ss3VNUt9RtZ4rq2SVZeVfvGa5YLXU9jESag3DuYF4qXVrcXVucwKRuU9TV/T7m21L+z7aJ2CK44Y8rVbRdNXULO9C3SW8EKk/Mfv1S8M2jSeIbBUkwDJwa6dEmjxJc0pp9z3URCG4jjLKRsAFbFhZOIWaRw6k8DHSuet4JUvzgeZzt3HpXSwNOq+WSDHjkd681s9TlcRfI4beBs9qzdQtZXmjkSYrEvVfWprldtykiOwUfwU2aRj8r4CnpWTNIpmJqtud25SRn0rnPLuVuXWPBQ/xeldjqABhwSN/aqKRpGoLgbz1xVxlY15nY577O80XlzYJ67ga5zVBGVkRGBKdTWx4rvRbstvZ5WWQ8kdhVA2SxaZINp3MMknrXXTdrM5q65os5CIZvYx717R4I0V7iFJZCQv868o8MWH9oeIYYE5UHLewr6O8PwiFI0VQI0GAK9uFd017u7PjKtFT0lsEtkQoSMYApgtHgO4Lmuyt4bdwCyjNPlsI5BhVAFZOblrIXIlojjGuOMbDkUWOr6jpt0txYuVYfwnoa6kaHGSSRTm0FAv3aNA1KGoeMbjV7M2+o6Xbszf8tVHIrlpra3OSGaOTtnoa606Iq5wcYqF7CJR+9CsvoaL2B6mVZw3MEAJ+aFh908g1j64FiR57c4i2nen92usubyGG0MMS4H8q4vWWwkrA5R1KkV2YTFToytf3WceLwcKy5krSXU+b9Q1m6j1a82SEp5pwPxq9pviieNwZeVrO8R2Qtr+ZwODIc1n+UU2n+Fulcs7qTO1Ri4o6rVNZGo7Sf4eh9K9X+DERg8DXk54M0xGa+f2LRqcdK+jfg7AZPhjbvjOZmzTg7yMK8eWmdGq4hA7nmuT+JMBOgxTAcxyg12uzpgdqyfGNh9t8M3sePmC7h+FbPXQ44vU83+1D1/Wiud8yX1NFY2NOU7WNdxq/EuFGar20ZKg1cxwBXooyZGy8g01lqUjJ4pPWmBBKMAVWI3MKsSZY8URw5OaQ7j4ECjNeofDrRGW1W6lT/WNlfpXDaHp0mpajbWcS5MjAH2FfRNjpcen2lvbxABY1ArnxM7Rsb4ePM7iragwjjmqrWoLGtby2x7VXC+ZKQvOK81s9CMSnDp4Zj6Vc+woFA25NXIISo+YY96nY8YUc0irGQbL59uKetgufnAK9CDyDWtGgHzGnvGCuBQPY4bxZ4M0XVLKWSeAQvEhcSJxjAr458Qz7Lm9IZnzIUV+5ANfaPxTvf7J8A6tcA4YxlF+pr4cu7maO5tSq7mB34xnNQ0rndh5yas3oNM0iQK8YMbJ0J71Hcut2Nw+Vjy/uabqGpi/mwYyrA8gdBUNmguJJI1k2bF3En+L2ojHqdFWtf3ehGiPuLKcFT19q6bTU0SbQNQj1KzeXUpBtsWjbo3ctWNpaiS6kJ6KM7asaXB/xOreKAgSXMoRST0z6VVzBrSxe8M6ADZPcXMJbyvvEjIrvLcw+Wvl2/yhA2OoX3ArBv8ATNX0K9v/AA6JjEmQ370ckH0pUubnw/fWRt1eQxjc7ScpIvcVzTTlc9yhyUFGXdEWqhrubEcKqU5YIK53VRPZKWFnJsPO4DIr2uxi0nXrJLtLY2V3cfNGU5DY7Edqr3E1laPNFeGERyIY2yvIP0rOErM6q8XUg7Hg9+m6OC4inURSfeiU9D71uaTOj6zpQTy1YuBhetZN3ZKt1eRKAkasSoPXFP8ACtqs2s27NJ5ckTgj3rd+8rnkJulJq2578uEneEsAp5/GrVvL8wyT7HFc3f6gbW8j3jOQCSe9dLpd7bywhiwGegNeY2ek4O1yLUJWG4iPI6hvWs175WCNKh3jtWvqe17ctG3I7CueW0klbzFcMc/dqGa04pq7LU4Fw25SNuKxdavYrC0YkkyNwg962DILZSHAHGSawLaxOraqZmB+zRnjd3qoJbsd0lqUtF0zzwbq9XfO3Iz2FWNbtGWzdkGBjpXRzWyxrmHhh6VQ1MiSxkVhztrRTuzkqSucH8LojL4wkH90HOK+g7GPaAK+dvhtqCaf4/KSEASkqM+tfRUd2sQJeM4HpXtrufI1HZ2Ny0zxxWh58cS5kcCuTg1dlYiElmbgKe1NN/ErsHkEso+8SeFpmdjr4ruOchCxCE9RW3Ha2bQ7pL7DY4XNcBb63ZoAZbiNR2xzXZ2174dj0JriW6jmkZc8dQfQCnZgjM1AmJyPMV17EVg3s2c4rNu9ZiZnNvMrrk/KxwcVRGoLKvnREkDhlPaq5bE3J7yQFSK57Ucm2lHYAnNbzLE672kGD2Fc/wCM9TtdM8NXs6j5tpVSe5NC3Cx4TroF5DdOBkrIcVg2777Yo33l6Vt6MTcWk4Y/M2WNYUo8i6YdjVz6MceqJNokj49K+h/gNeg+AhbOAQkxr52t38uco33W6V7f8BnaTS9Qt1PMUgbFRD4rkYhXgeoLFiRlHrxRcoGikjlT5WUrV6YLbSLK/wB1hzUtmsd06y9UzjFdEnZXOCMW3ZHk3/CGTf8APE0V7z/Zrf3RRWPOdPsn3PBbdPlqXFJEPlp+BXpI5GNAAOe9QuTkipm6moiPWgBqrn61ZiTC9Mn0FT6FYNqmpR2qHaW717L4Z8A21mEe4QM/+1zWc6kYbmkKcp7FP4PeGmiD6vdxlWYbY1YfrXpsyfvAKsWsKW8CRRKFRRgAVBcTLHLz1rzKtRzldnpUqfJGwjIRGeOahhtxDlh1apzN5kbBRUVwGSAFeo61g+50R7FmJGYYI4qTylB4FYFtqM81ztjzheoroo8+WC3XFEJKWxVSm4aMQqOlJjmkjkMjlcYAol4Gaog8f/aavmg8CJAjYM0vPvXy3LG9lAt6m1pEXG0+le+/tY33kafpdrnJJLEV806teFrSNIi4dx8yms3qztoPljcxb7UGlvnmRQm/7wFRwF2VnRiuDnHrTxZMYSf4jVqwg3WkiumXA6f1rXRIxSnKWvUv6bcCBDcBs5GCB61DdyssyPEx3qwZCvUNmk0v93cCHGUdSA3oangt2nnQQxO9zHMpAUZBGaTWprF6HqcS3ut67BNqbm4uFtkyzfeAx3qn42ntDrNvapPgQR5KHpmov7SktvHpWOVVMkCqxU5GcdK5nxlGyeKBds4aJhtPsfeoT1Oybfs427HZfD3WbjToNQS0jSeZW3/Oc7F9QK2/FuqaTqGmQNYK73TjMtwRjLVzHwrFm3iedLtz9laE4Yda6TxDokltY+ZokDXFtv3Bz6/SuSek2ke3h5c9KLZ5ZqU8Vpc7piJpGGCxp+irbpr2nleVZwcVva94RcWcl5c20iqy7wR61z3hi1VNZsvNDBvM+U1tfQ8ydNqXkeo+IreKe/ijSTMmB9BViK3aC2UjJYelOkRLvVDuXaw4Bx1rWNs4CbCAR2PevMmetCaskxlpBcSRh4zgEZ2nvVazuPt0cps4WUxsQ1aUa3CTrtIIPYdBUttbGwjlIYLuO4kd6hLQTmkn3Mop5qYlTB7q1JG6xEoiYHpWk1vFLmXzN7kVTcRrkE/MOmaLkNplC5dkUmNqx7+7LWsm7hgDmrms3CW8HBBkY8AViahKH012bhytb01qjCsuWDZ5NfTyRao1xAxWWOTcrD1r6M+Gfjax8R6ODdTRwX1uuJUY/ex3FfNt5k3EmOpaul0COLTEWbaRdsM5zwK9puyPlOT2jZ7jrniO3a5ZdPBRQMeYRjP0pGv9L1jQY7YWdxFqkZyZ0b5ZvrXByanc6ikEk8ARwu1McBvetzQHktrUvdTCMc8Drit6Ue5lVSitDbtbTYkYleBGyBtJya9u1CwsLD4fRvJDEr+WP3iJ3Pevn2O/tOGtY5Jhu4JHJNe4eI9fa3+GVu88HmvIgQpEMkD6VrJO6sc8bWdzyPVmtWVhaIGkU5DZxmubuNam0+4Uxkqx4KN0NWTfQzybXjeKTtkYrnfEdwgIikcsc/KVHQ1TSejJVzttO8T2Dxst/mynVckP91voa858ea42uNtiytlGcIv94+tO1G5bVbYWVwVYRr97GCKxEZJ7OWONtxhO0n1rOMUmXcztBO27ZD0NUdbg8u4cDscirVn+6v1Occ1b8SQgyhgOGWm17o07SOYf5o1YdRXrP7P2o41bULZmwzx7vrivJwNrMprp/hdenT/Gdu2cLIpQ1itHcuouaDR9Py3aT2jRMcleRW34VTcUEaZXG5wa8nt9SmvPECWUGfmbB+le7+FbMJb7METkcfSrqPSxz0YW1LXn+9Faf2I/3RRXMdFj5jRvkqT0qtGeOtS5r2keUx7ECo+p4pHPGKdCMt0yTwB60MEafhq5lsdWglgQu24cDrX0nokpmsYpZAQzjOD1FcB8M/CCW+m/2lqMf71/9WpHQV6DbHawA6CvNxMlKWh6WHi4wszT3YrPMRmnJPrVz/lmTUB3rAzIPmrlZ1RRaigCimToZVZF4qKDUEMX735XXrVuFlkXeuCD0IpXuXZxZlWGnC3vXlYcuMVs0hHOaKSSWiHKTk7sQADoKZIM1LUFzJ5SAnpmmSfK37VMsl34vs7aPlYosn2rxLULBrWW3DuHdxlgP4RXqn7Q+oCb4hXLocrHGBXkl7csyeYctIRj6CoV7nfTcVS13I5wF5jGCDU+mQfJetO+xnj/AHZ9T6VnxyorASk8jipTOWlUZygq2hRmt2PsI5DOqg4KdPrXX+A9Vis/FEdpLCG85WTcBkqfWuStiwk3BvlJ5rV0Z7nTvENldRLGLvfhA/RgfWgm3umz4Y0qK58aXSzFjZWru+c85960r7QZ/FFtdC3eJbgMTH2BA/rTNMv306HXZBAFvL6Xyh3Cg9cVteFZpBGQqBVtXBUL1b1zXPUlZXPYw9FSkoeX5lL4YeHNRtNahfVofJgiyue8ntXsuuuljYhbLYgUZ2t0J9Kk+xadqWlpf6NdklBl4W/hbvXnHi5ru9v4LYStHKjg53fK1c/M5O7O2nRioqMNl0Ny/ngfwZc6nfRSm6kBQJn5E98V5HoFrcp4ksjIoa3LF1NeneL79V0210a5CopTLsp4JrgtBbyfFKK0yvHCh24PFWmcrhzXfmdrbX8b6jJGiZOeW9K2/NLoR/F2Nc94dTzbiWbCnc5ziuoi8qUsqDLY4+tckkdFuwls43AFue9LcszRnAyh45pIYWAIK7e5qOW4zkLzGODWUi1DXQhGwfcGNo5qnfoksI8wcZ4Iq8rIR1BY9qragg+zZzj0FJPUrl1OS1S0a53qsnzL90muf1QTLaFWOQi4J9665VMuFkXBBrE1tEKXeP4VrqovU5sZJqPKeXRxbr5Mj+LNdO1utzHGsUbrck/Mzfdx7VN4T0IXE32y7/1YPyqa1fFOrabZRxm0ZXuk48odK9twuz5em+SLuXNP0t1SL7RMSEHAJ4FbqJYwNuupVL+7cV5uPEV7qKsseIsdRWxpM2nTJsvVlM/cseK6YKyuclWVz1HQNc0K0ljZ2t2XpyK7238U6BNaYGo2aYGNrdK8Ms9OtHlREWFoyeGB6fWk1Ows7OV0ZYtv94Nwa1cU9Tnueg+PNc0KCxeUG1uGlIAaHqvvXG3Oh2l/axz7+H+dWQ1zE11plrDLHHtkeQYI61iw31/ZAC1uW8rOdjHgVPoUo6HTNoUttevOs3nCT71crZW7R6lqMZ+UEn5T3re0zxT84j1BPLP98dK2rqwtr6H7VAA0hXhx3qUrhax5nONl0CPWtXVVEtjAw6461R1WIw3LKwwQa1IwJdFIxnbzRbdA9LM4y5XbIfY1LpkxtdWsrlTjbIOal1SLZIGxwaNE02TWdYstNhOJLiQKD6VzyVmbrU+kPhLpKX2qXWrTBmZABFkcD3r37R1BiNwFw+3aprkPBejw6XplvaRoAsSBHI7nHU13FoUhKRYLKecAdBUydxRjbYXf70Vc89P+eBorM05T5Fj7VNkColGBTiRXsnjXHZzXReCbe3l163N6AbZDlq52PBYCr9rHI1zEtuzLMxAXFKavFpFQlyyTPpgXUM1vElqQYgOMelSQj5sYrB8OW8lnpkEUxzIFBY+9blvIDIM15MlY9KLuXy2IiKkhX91z3qozhpQgNXFU7TjuKzZsmU7mO0ZXhaVVdxVrT4FtbSOJW3he9cze2EgEpDkvnOfQVr+Hh5NoqSS73J4Gc1jGd5Wsdc6dqfMnc2KTpS0Vqc412CqWrI1GcyW7huFHetRxng9Ky9ZTNqcdKT2HHc+Lfi5qKnxrqath9w2q3pXArFLdRp5EZI6M1dH8Rt0vjvVlx8iyEVgyXLoBGpMcI9O9KPkdjWiuUJ7OWJ2ikwzfeUjt7UWvCLsOGz82e1WGlZbhtzdR19qjsiBcuuAUJyTVohpX0LKiMnfuKsONvrW9oaQ3WsWi33+pjUyHJ5GOlYn2dG3MjnZnha7T4U3OmW2v6lrOu+XLp+n2jKbZ+shI4xQV9kqTSD+zL6SWfZ50uYoxySK6TwIyWbRrJkmT7wc9Qa4uK6tFle8kt5FgkZmhB5C5PArY02eOc29y0/8Aqjn72PwrkqRbR9BhKkHUaa6HoW5tJ065VbiSG8u5dsCqP4fU+1cb4jurqMrb3ExklHRouc12cfiuw1G7SG7tm+0SQlEcrgYA6V5xc3f2XUpH03c9sHJ2SDLIajkS1OihiZSbiUbq/ivI4obyedLqNtoR/SprWw+z+JLaNbhX81eCD+lM8R2y6q4v7RWaZV/eqRisvT2gtri2ummcSI44Y9qtJW0OKopKdmeueECiNOjEKYzjB710sduQ3nY2n0FclprCDUfNyGjnUOldXYXQcNl8qO3vXBI7ErbCXN+7gRiFt2cZxihrZ41LYABHOau27faYm6Ag8A9abdTA277gGZR+dZtFKVnZIyYnQhigyR3qjcySiQiTDKegrVjEQtjJhVj6nHXNVktBMfOQZT3qUzZNK7ZjzMHIWMYYck1z2qFTI8YHL8EetddfRhX3KAPpXF6xcpBqKSSEKmcEmuvD2c0jz8drByRn61qP9nWK2tsy+Ywwcfw1w9zAVYtJks/O7vWpfOk2oSyyNlSeMVDMAhUnDDqK+hSPkKkruxSgRlKtGxB71vxODArNgMepHesz5JTmNceoqxErR4KjPtVxlymMlc6LT5rO3z5ryAMOdprCv5oDKw8+V485Ck10WiWMurRTolsAsMe95W6D2rlr6J3dhGmMHp3NU6nkQo+ZELmEkJDCxPZjVuMM+fMVlP8AOq0A+zukpHI6qavNcyXEiPs2RrwBU3bK2FWHcQGUMp42kVb0bU5tKvlt3k32h6r/AHfarSRmZBjCnsfWs7UoAt3awxgNI0gJA701oK9xfGSRSXS3NqpEUg7jvTNJIk06RPatPx63l3lnb7VVUj6DpWPpBWLerHANPqS1oY2oL5sB9VNdN8F9IXUvEslw8bM1qu5HHRT71z053SzKvI61638AdPVLC7dUffO+HrnqPU6Kaue/eF/NksI/NJ3Zyx9a7q2iKRGTbh2GPwrntChSNYkzwuMiutRgeB0rFsrl1K2w+tFWvl9RRU3Hynxyp6U4fMw9KiGWxU2Dx7V7R4g+FMNuPevQvhloour4384Bji4QHua8+XJKgdzXrPgnVLW3sYrXcEYd/esq8nGOhpRjeWp6DG3A4p4yHU+nWq9tPGyjBDD61aDK+AtedY70yW1DeYWbueK14m4APWs62wMZ7VP5+SSO1QzVMkmiXceOvWqENvDp7PKGJc9B6VPPK+3jqari0Z2UuSfWuad09EdtJ6e89DTguo5vlVvmxVqsq1VFu8IpDCtWrg21qZ1IqL0K1wzB1OPkHWo9SUG1c46KT+lPv7iO3WPzEZ97bQFHel1DP2KXjnYf5VZL2Pgbx7MG8T6q8eN4uSG/Oua1GFYuZH4PzYrqvF0cbavq0pGB9pYE++a5LUPMvPJkI4UYxUQO+orpehWkdJ/L8sFQRgfWorcNE5tjwx6v6CrKx7rdgv3oznFPMKzBZEPznrWlzFQZoWuIIYhndtyc+tXfCF5b2E+rS6la/aLKeEpIo6qexFVIohJeLGg3DAXipLYeVb6kJH2RlhGFx940rlJapGnpSLLo8sMSSSWWdwRuStXILWzDW0gTbtYF4ycBhUeiWl3NiSwBYw4eSIHqvfNamsaYk+tpDbsqm4UMoJwFzXJJ63PoqS91waRv6hdx3dg88ptzbRcLHEMOPoa4S81EhJPssJ3k5Ddx9a7l9PSxlsNKXy3vh128qc9zXYw/DjTYbBTK+28cZcHoxpN3Kp01TV72TPCr/XGnh8pZVgcrhgBjJplvd6bJpL2s8TPdqMqy9jVv4p+HYtIuQYxh8/cHU+9chos8kN0uBktwCR0raMU43PMr1pQrez6Htugs1x4XsZpIyrxjacjkV0Fk+bZbi3IGOGWuT8DaleXTyabqsZUBN0UgHDV0MDC3lO44GeAO9cFaNpM9KhO8SzLd7buN1Jj9VPerK3c9wWZYgoXv61Se8+0SFZEQp2JHIq1ulhdJesQ6isNkehyprVaj5bdpYsopjB5YGnW6+VHiNsoetTC8Sd9qHIx0qu7CIkKMe1Kxzzb2ZVv5EVTk815t44i227yg5IOcdq9A1DYVPOCeorz7xzII9OdM5z0row2k0cWKdqUvQ5qC9t9RijURiJ1GGA71bmswNOXAyynOe+K5OElcMp2sO9dLp2tqsCx3IAz/ABetfQwqJ6M+PqQa1Q+xhUckcVqw2kXLOcLTrdrS7TCMisR2NTaW1vd3R03zVEx4VieDWhlqdBptw1voz2yN+5kOTjqa5y9MRmJ2bT61qarZXmjRiGba0XZ1Oc1l3GpaddaPJDOjQ38RzHIOjj0NSCRlXkQfL5yq/rTPNDIoXgCoDMZCqucA9hUrG2WGQO4jcD5femOxqW1yViZnwyY+UdwauaDFC1wt7OrGWP7oPQ1iaNKLh0WRvlHpXWNsjhAXAAHaqWqIemw2bwprfjTUIxpFuHcvh5mOEjFeyeD/AII6Ro1us2uSnUb7GWx9xfauF+Futlre/t/9IeOBsyx2/wB7616/oSw3dsLqy1K7khzgpKMc+lc0qzcnFHWsLakqrejPKvix4Gtra6W90K0VIWwssajp7iux+HWnR6LoglCYYgbiRitbXbSe8vVPmBbVfvitjw9pa38yls/Y4ucetYS0d0dSqudNQlsjotMVvs0RHVuSfWuoiXy4UUcMetVrOBMZCDyh9welXsc0bGEnd6Ddn0oqSigR8bRjH1qQEA1ApqRQT1r3DwSwhHXvViCea2cNDIfoarRjC896lXpmk0nuLma2Oq0/xTdW+A5YfTpXW6Z41Q7FkwSxAzXl6Nx1p6HHzL94dKxlQi9jWFaSPoq01SzeNSbmMEj1outVs7O2klMyED0NfM0s+shiY7psE9M1Wmvda58y4kKjtniuSeGnbQ7aeIhdc2x9P6HrtpqMWfOXOe9bqTQvhkdT+NfKOi+L73SpVFwmU7mvUPBHxB0m9nWO6n8kk4G48VyunOOjR3OUHrF6Hr9vLG906j72KuVUs3tpY1khZWBGQw71aApKNhOVwOO4B+tZ2t3KxWE3zAHYep9qvum7ua5bxpp2dIuZhIw2IT19qZLufEniuQyaxqagkIblj+OawxDNJceTAubh/uoe9aWrMZb69kySxlb+dYkUl4+rh7cn7Qv3cdqiHU9CrKyRYtSUvfKmTbIQUf2PpTtEtZLqW5hiwJY1LDPTAqATyy3ZllHzq/zE9z3qZ2+z38xRioZc/KetN7FUWrq5paXF5Wnvcu+2U52+tU9IW7uYri32eYs7ZYnqp9RThdtPFHsjwB8u2rHhq4mtr64cx7oV+8R2PalJ2TaLw8FOrGL7mnpEN9p17PbySPbTmMkOejr6VNJe6fftboJ3t5FG1mbqpqXU7m81O90/7XGY5VOVZRn5e2av3mix3GrwNOkY87rgYBxXLzo+gWFm5NrRI6Hw9PpEeuabLNqCr5a7WkBzlveug1fxFf6ndNbWiySJG/yuq9R9an8C6RDfxXUT+G0jlh5W42/IwHv611ep6vonhswNqLRQ+anyxoOR+FZSXNsdCqexdpq7Xp954T8Yr15r+yZgI7iOPaxI6+1eZxSSKV8zEbA5BNd38Q9QXWtanmCkW6N/rSMH8BXEa1DEvlNbStMnRmPrXbRT5bM+czCcZVnKB3Hh3xiyapYrKVMUfyhAPvfjXaa5qhjuVDwmGNvmUkV4gs8i6fiAoBGwYN/EDXrcOuReIvA6Mdpu4E2t6muevTtZnRgqznLlvY3NMuo7+EqpUN2Oe9aStNHiKUfu8cn1rjPD9kkmnRbZHil9jXRK+qWCAxqt9COWU8MPpXDOOtj1o1ZLVmpBENzGE7cdKkZmfDS8Edao2OqWl7IREWt5jw0MvBBq1OxhXbPyh6VCTQ5z59TL1KRFl3HoK868cziW3OfWu61hxg4OQeleb+M5cBEHUmuvCr30cGOdqLOXHIAA4qZYy2OMj0pIInZhxgVoRRFV969dOx8zylNLYxyZSRkz6GrYgIdXSRkkH8QPNOMLb8mtCO13xhyePStYO5jUjYpvcXjLte6lfH95s1XaKZzkyGtQWtSpaZAyCCK0SMW7GTBa7nAaUjPWpf7LJnZdxbjIJrbisUMgG3jvVtbbym45FOxLkYVhA1nMrE/KTXVb1ewIUbnI59qx7q3xk84zmrds7LZugwMjJNO1ib3LHwY8RS+H/iOQpzFdjynUjO6vrG4iWKAPGqxq4yQoxXw5pl4dO8WWd0p2hJhkntzX2hpF8NSt7NllDRogdz/erjk2pnbZOmvUJ7OWcLHBlhIRvJ7Cuz0mzWK2jihwP79UNPt5JJt4GEfkCujhiWIgIMM3UVPW4OXuqKLCBVGF4HSnCkAHTtTqTBC5ooxRSGfGMYz71ZjFMjGFqWM4PNe6jwWx6gnHpUijg001IvTigkVORUqA7aaowaegP4UA2TxAEc08qpByBUcYxUygmqsK5AbGCfKugII9Kw9Q8MqHL25ZD1BB6V00Yw/FTuoOCTUuKe5cZtbG/wDBDxfJa6hJ4e1yXqP3Ejnr7V7wF2jIfjtXyh4g015VS7snMd1AdyMvWug0j4xTQaOlvfo5vYDgj+9ivNr0XB+6tGethqsa0dXZo+i7m6js4Hnu3WOFBlnJwBXNeKtcsLjwpeXFndQzQlCpKtnFeAeJPGPiHxsrRyyNaadj7i8ZHvXnU+pXGjLcWdpdyvC/DKWyKynTcI3kaUn7afLEzdaEUepSRWIEh3FzVPQ0jt9dF9OAIlRgw9GqjLcSJdpPCDvJ61bt1lSOeWRMxycsDXK207o9iNKNSDjLcxpcm5mzwHYtVaIsZRg7m6detaN1Z3FmEmkiY2z9Ceopmk2SHUlmJBVG3YNaJ3OezRBJBexlgw8njcR7V0Pgy0JvUWRi/mDcQfQU/XIUklDRgncMvnpjtil8NapbxatEkqkBBhiorOo/dZ2YONqsWei+Hry0/t1rdrcSCX5RIR92prqwhutdmtbqNwgH7mRTgKfesWLULa0vTPZMpAPLueBUw1uLUb6a3t7tYo5Rh5WHf2NedTi73PscVXjDZ7o6/wAM/E2Lwzo97pUg+13LvtijHdunPtVY2GQ+oavEbzWbo5RGHyQKegFcv4V0rSf+ElsI7KQ31+0+WQjPT19q9k1+ymgnjk1KOKKaZtqrGeNtbVL20PJoODlzNfF+Nj5k8dF4/FJ067ZoI8hm2jOT61y+tQrBI0dvIfLHPPf3rovFksz+Or5YEaZ1copbkgVh6pbOl7FHcqVdmAYGu2LskfPYlc05PzMuzkVXbzB17DvXTeDdTtLLXYlulYWU3ySKDjB9awdVtWtLksqYQHg1ZhijuPLeCMuzjB9jTmlJamdGcqUtN0eziSG11Dy4gGh6pj0rZtrhHcFciuN8NXQu9NRLhSl7afK3uK6i2mITOFII6rXkVI2bR9PFqUVJdS/qOnWd/Hm6j+b+F14ZfxrFlg1HTFIaX7ZYHoW++lbEFzmErJ17U2dt6EMflIrNPoyGrbHI3l0szgpnHTBrgfFswfUVUc7a7zWVVHLx4AHXFeY6rKbjU5W64OK78JHW552ZVLwUV1JYpMsuBWhF6HpWbAmSMVpxYAHNegeKTKikewq/p4V1ZDjIqkvHfNXLNlDgYxn0q4bmVVXiXFi+bAAyO5qVIQcg9KdxtC4PHenhgqgDgH1rdHE9R6QYAJdVJHFNf7vzYIHWqUqv5pGc57+lPRHdCVJ44qosmUdAuWVjgEbfSo8BIiQe1P8AsRcb2fntUUkJUEZLKPSm2KKOPvLeS71eK1h/1s0gVT75r7N8Caamn2OlaffyAS+WN7A9QBXzf8LvD/8Aa/jH7dchVs7I7gf7z19M6VbPJeyTvzhRtU1yT3OpbHfRXESXWY1Hlj5Ux0ArQjAMrSdyMCs2G2EdvCyYXcMla1YVAjUVLBEgGBS0lLUGgUUuaKAPjtU44qRVqkLhscClFw30r3LnhNGgRkYFSxhQuDyazRMxweanjd25FMk0Y8c5qQbQKz1ZyakRmNMRfRlHepA6gH0qiAx79anVTimIsCUAjFWGcFcis8CrK5MYosCJfNG3HY1iTaPA9804jHPtWoo61ISEjZjj5QWpNFJ2Oc8RX4gRNMsiFnm4bHYVxGtRpbTL5g4UYY+tVLie81DxK9/A5wshG0+1afiZo7nTTKMef/EvpXgYms51fI+swlBUKFur1Zzts8bQyALlmPye1TWE09rKFuEMiKd4U9GqsllIsKzwc7eStQxa3NHeCSePcANgGKiSOmk76dy/4m1O5nZ2mVVE+NqgcKPQVlaTGZLtLZzsaZsFvQVpeMbaUWtlNwwkXJA/gqTwJEsHiWwuLqMTwq3JBzt9zRFpIznTcZ8i6Emv28kU32YKyRxAbTnkj1NS+D4Y5Lgl0BQknp1qLXRJd6vrBSUnDF0P+zUngf7U10kDx/uHUmNh3NTP4Wb0E41Y+pu6VpttqN1dRW4yY8kITwa6b4bLprzanpmq2Ue50OGcYCkdMH1rmNNt5dO1mOKF9l1JJkg9xmu98Rx/2SY47ex893XfKFHJz3ri5rM+uVJTTh1f6HqXwl0LR9K0k3BsbRNVOf3qkFivasL4kSO7faLmQokRO0L2rmvBNqxMd7qxvLDTopBtkJPzE9AfarHxD1CGdbmxgkaYRN5jyjlUGOOa2cuaNjzY4d0sRKad7/geCafdIvi+aW9JNrJMQ02eV96g8fXMFzrv2izlEsKEAOO+KZolyE8VxySRpPC85Bjb7rCk8dWkdrq11HCiRqx3KkZ4Uelda6Hz00m5MNcMM2nc8SEBgPWubt764sUCx4ADbhW3fKtxFZyROGIj2vjsaxzGPtDJLyT0pq2zMqqkrTR2unatG93Z3EM2GmGyZexPvXd6SSJpIpPlTqp7V5JohgitJB96VnwR6CvS/DF0LiJo5DkoPlrhxELao9vCVnUhd7nXNEFsmKjJx1FZb3I8nbJw3bFXhdBLXG773GK5zUt65QHHeuOx1w1Wpk6xOY4LjefugnmvN428x3IByxJrrvFF2RYuGOXbiueskVY124zXqYWNo3PBzCV6luwtvHNj5Rmr0UDHG9se1SRkoAQtTx5cnjB9TXUcARwncAOR3q1AuHyfvDoabtYKB0+lTxpuYbQaaM5FhJScl/wFSbhtIbnuKZbw7jn+IetSTRbVwenoK1TdjlcVexGWDbVA+brmpbd9rcqQ3TPamFVCgqOR+tEQG795kL6UXe4OOliZXZi+SF2dvWq1zN5cUjsgJI5x2prON7A5GDx9Ko3LMziIHhjjiruZcp6z8FtMji01559peZ9wUHoPevY9Omja1djIvytgEnmvANC1qPSI1to3AdUGSDW/b+KA9rvilMvPODXM5Js63RkoptaHv+lX6yPEDIJB3IP3a6ZJVOApzXzN4f8AFktncMWYmJznbnoa9I8J+OYJJCtw564zSumRZo9WpaqWl3HcIrxsGUjINWs0mik7i0UmaKQz4xjU45FTpGCKdGuQakCDFe4keE2LHCCKlhUAnihcjFSAce9MkcABUgUbcimgcDNPi6YpiHqMCpRjHFNUDbT19KYhjDvT4nJjxmmyU2E4crigCc8VW1GQrZzj1Q1afnB9KzNVk2owPQjFJlLc8mt5pIrW5FvnzhITj8ajv7+KS2V0fEzcSr71JNObPV5U2cZOT7Gk1zSIRpX2lQULdCO9fOzXLOzPsoKVanzQeiRc0lyYipHFX77TrdrdbuKEF4+WT+tc74W1Ubo7W4Gc/KGrsbQgLc73xGEIOayqXjI0ws10Oe1YXd3bPKIx5JTbgHpWP4VUxXsJErRsrfr71swEqZfJLSwhcMM8Kak8NWsUfiLY+GiCF2+tVeyszd03VknApXOsTG9voJYEkabKgqMGtXwW9zpupQw3kTROkZK7+hzWFFG76/LMybFLEKPx61vG7u7i+TzpElhUbVfvUz0TSLwlFympT76HY+EAmpeJjJNCZPKywcjvXfaGJbPW5brUmSUM2EB5wPSuL8AzKyPFD8syfNnHB+taOs6p9ltTeDJuxJhYj0euHqfUzWkktmjrPiXfXV5anSNCBguSu9opl+V1P92uTlx4U8MSaTdxvNdahEWndxzGcdPpVnw7qovYJ9Q8S3u37N+9RAcsD2Ue1Yd74lu/Fel64IVSUQRGQTOPnA9BXSpczPN5PZ03D7zyDQrIX2oOwlEMaSHdJ/d5pfFdvAl0xtpZJV/vSdTUngxIbjWFt7littKCXOcc+tR+MYFttQmghfzIx9x/7wrrPnEk1JshiaGVozEhiAUBlPc+tZOosY7wuBjBrpNQiRtN0nUIhhWXypMDowrC11VfDoR1xTj8Qq6vST7AEZZ0a3O0uMgdia6vwzczJc7cGOUfeU9D9K44ktbx5+Vx0ra0C8bT73F2xkEi8MTUVI3VjXB1FGSvseoTXG+JCpy4GTVO6uFli37snpVLT5y0AdAQOmDTtQtgtsJEPzHqPWvOcbM9lSSRxniqTfPHGOnU4qnZRgMM8A9Kfqi+ZqRCjhaekeCj56HpXqU1aKPnq8uepJmnDGEJ3jHpmrCpuO7OKlAW7iGFztHJp2wiFSSDg4rQ5mRIDsIbqT+lW1zhQpxjp71GQoXLYyT2qaKIuMdO4poiaJoAM8ZDHtVgxiQHbwRwfaq0B2SDbnHcmryHK/KPlJ5NbR1OSa1uQzwkRgMQPc1WdGUk8Yx3rSuXITbuEingg9qo3ILReXt+btTaJTMm9kbdkEGqUd46XSuyjA4FO1CTEgUtgA4rNuA6dDyOag0sbWrysmydejjBApmk6u9vMse7EfoKdpUw1CDZKACvarZ0mGCLp+8bkt6VzuOt0enGulT5ZG5Fdjja3Dc1q6Vqxspt3LqeorlrdTEhXJYDvVuKXjPTFOxwux9AeBvG8CwR29yxERPD5+77V6tZ6nHM6omGBGQwNfHNney2xyhJVuq5rt/D3xBvrB4lk5jX5evaquQ4n095i/3hRXi//CzIvUfnRSuiLs8ohIxipVOTiooRwalUAGvbPFY/uKlXmoh29KkU4pgSqckU9OOneolNTJ2polj1NSgfLUWOanTGOetMCOQ4XFRRkbxUzrlar9GGPWhjRePQ1ha7n7O1bnoe2KI/DGq65C32G2Yx5wWYY/KolJRV2XTi5SUUeHa+M3qTKcYOG96vxfaNT0yUJzHH1Aq18TfDOo+EtXS01JTtmXfG+ODUfgDVUtLs28wHlz/I2a8bGRuvaRPq8oqqM/YVDiXVrS4Zc4ZG3A12ujara3dncNdNtbysYPrWN41002GvTxuP3TfMjjoRWTDLGiwhjyp+b3FYu1SNzbl+r1Wuhv6HZ3ZMM2/y7OSbyyzcBjmt+7thpfieXz0aJTH8rLyCcdfpWFqPie1uYdOsSgihtn3EDoTWx/wkv9oagpgVc+WUYuMjFZTbTWh2YWKldxepgXbia5kFu8n2hcsX7Gp7COaOG0hl4nuSXGD0FUvtLSySkKEYbgSvervh2MHxDpiibzvNUgj+4fSm1oyoS/eRd+p6f4GmhsNLe4vJEUvlQfXHar9pLZ6xdpAiyPfzny44WXhB/ezXP2NnGunzSX5P2W3mKIvqfWtzwh4gSz1ZwLN7gPhYmRcsorklZSR7tKlOvTlJbR/H/gI0X8OaT4a1N1817uZ02vG/IVu9P1VdPXw3dx2dpHavHG2ZE4L57GjxRfo96ZoLZ4jIMiQjOD3zXI3Mz3VtcwbyxUGTzAf0IqU3znTLDf7Nd9EeQ2NsbmV4kkMcu47e2eelRa1DdQ3CJdNvcAKuK0vDtu954itbeLAeS4wCeg561o/EzSv7J8QPFHIXG4MrHufavSTPi5w6mzoukkaJceGr5kF5cKL20OfvY6pn1rgdVH308po9h2kN1BFbOta5c3t3p95GQlzaKpCjjGK1vE8Gna1YHVNBnXzJE33trIPmhcdSD6Ghb3M5NqFmefwuckOSRXQabb2GoxpD57JKOm49658AG33A85rX0Gwl1GcRWkTNP2IHFFTa4YV+/wArV0zvNEt5F06WIyKzxHjHUirV1OVtCW6Y/KrmkaPfaTbEXiJ86845xWZq5H2eRTxXnX5pHuz92KschaqzXsjP0Y81durUbCU4XtTLONFJ3EqM8Z71fZODXqI+db1GaI4UNHMGA/nVqQ5Xa2Ac8EelVN7RkY5UnkjtV2VVdkaPBH86ZA54wIVYjDKePenxBlkPzAZ/SmhmyyZDk9FoSVSVJwADimiJFlMIDxle59aswsCrDJAPTNV1xyUUlScD0p5G1MMG68+1aJmElctMn7sb1wtVLqRQAqqVb1qyZVZMEFio4qhPcCU7QMOOCSK15kzn5Wc9qYKyl+vcmsee5b5gwHPQ+lbGqhgJCRgdq5qdxyOtZPc3Wxr6RcvbBWXkE85rqobtLkfunDEdRmuEh1RI0WPYCFHOa1dHCXltNNYuySxnJWsHdHdaE4qz1OqI4ODx6UxWZDzyPWq1lcy3Fr5kiYI4JHeplmBGG5+nammYSg0XoZ+eT+FWYpcg571lgbh8jciplncDBAz602Zs0N496Kz/ALRJ7UVNhHWxjCj1NSgdauXWj3VocFCyjvVPlThgQfevcTueCxQMYqVRUYHzY7VKB0p2ESDlqljFMRalAppCuOI5qVMYqL0p6+namA8jHNVZSqk5IFWzjGKx7q6ib7SdpBg6571MpcquzSEHKSiup6N4K8JvqrRXV8NtsOVX+9XslnaQwW6RQRqiKMAAV5/8KdYXUvD8Stw6DFeh2z/rXl1KrqO/Q9SNH2TcThvi94Bg8deFri12hdQhBe1l7hh2/Gviq2SfSNTubHU4Cs8LmOVDwVI7iv0VYHGa+aP2qvh4/wAvjLR4uUAS+jQdR/frP4lym1ObpzU1ujxvUmj1nS0gL/vU4V261xVxZyo5iAy4ODV3Tp5JYSFbocirszqkTIMG6X5ifUVzqLpux606qxUVJ6M5ie1dGIIyR1Ndp4VtBNZSFRltv61zturyrJuHU9a3PDesrosrtLF5sTrtZff1pVryjZHRlUqdCtz1NrMq3FnJFZm7ikU73KPF3B9adpV22mzrIyjrlSByDTbZ0lvppVmVXclvLfpVm0hM1yn2VRLJE251PanbSzJT966PWtKnh1Oxi08tH5DgSs2edxrqPBNjbaJ4rWFV82cLmMn7pB9a8vaRNOtxKqiKbgkA9K2vDevtean5lxdmNFTDOOv4V585++mfXYfDtYeVPm36HXfEmQ22sv8A2TtEUgLSA8qrd8VwMU0EcYNqXW+IYTZ+4w9q6LxFbySaWlxHK0kLHr3NcoqL5qgN/Cc/lWPO3UTtuelKio4Xlvsn/TPObS8eyv2niYo6ynaw6rzWnr1xc6jcQzXTvdKF3bsdPrUHh+aK21955o0mjR2zE38VN1m+db64awYx2sx5iYfd9hXrH5zJ6mY7Qy3BQq2719K0obuLT9H1CzQfv7oDEh67fSqMVupy0oO1hlWHeqtv+9vY4y24E4GaozvfQitYwT5ZHBHU13nwt1UaU00ckasHOA2Oa4XUUMM7hT0OK2vCd8Y5QhKBh2bvWdZOUGXRlGFRJnvTJ9stfMVhhh0rzjxMhhnZCCAT3rq/C915ihHmy56L6Vn/ABBtwY0kQh3U8gd68+lpNI9eo26TOQkSPZknJA4pIC2Bv6jtU9vFEEw7AE+tPMI3KAQfcV6585zED4cFVAUjr71CWcFfLB+U8irMqGIjC/MTgD1pWYowwmT/ABUFJj2JEBZMFuvuKdb+XIQHABI5+tVo5XCsqr3zippIjGVxjDc8dqEJloxbSqq5VOx96lUzBiHAI6Z9ahY4j5OT2BqQM0keWPA6kdRVowY6RtoaNeO5NQXEiqoLKSOxxT49jREDJXPU9TSuQsew9BztNVsQzC1EBonJPHWuSuByeO9drqVsWiY9MjOBXI3seCwHShgloZVwAuAv4mtXwlqkOmag/wBqBNvOuxiP4fes8xhgRioGj5xUWLTtqj1iaNJLICwkRoiPlKmudltJ7Xe3mlc8muNhluLf/UTyIPY1K+o3rJ5bzsy+9Tymsaq6nVWWsR7jHK2xh/EehrUtr2KabyxIpbsAa89u7lriNFZQCvUjvUUTvE4eJ2Vx0INNIzlJN6HqWW/u0V5x/at//wA/L0Uybn3jcaVBOvzoK53U/CMUykqoPuOtduq8DHSlcLjmu6Mmjx2jxvUPDF3bMTGC49DWS8MkLYljZce1e6yQRSEB1B4rMutDtZ8gouM9CK1jV7kOB5BGc5NP/hqzq8MVtqtzFDxGjYFVQc8VumZDs4+lAOc4phOD0pw9aYEmTg89KzdRhVrWVVGXk61pou7j9K6HRvDvnsksiEMexrz8ZX/5dx3Pay3C2X1iotOnmS/BC8C28tqxxLEeQfSvbrUhlUivB47c+F/F8VwgKQXBCv6V7hpcm+JWDZBGRXKlZF1Jc02zUJytZmv6dDrOi3umz/6q5jMZzWjkDr+NQzyKobHWkJOzufAfxM8J3XgHxjJp0yEQON8Ljoy1yl5c+SoZQd5OQa+xP2g/CC+MPCEs0MQOp6eDLCwHLDuK+Pr2yY6VFcOCCGKMv900pJaXN6U5O6Ra0mdZFZ8ff6inRsI54Q0JYeYDt9RmotCgL2kmDgpz9a6TRbJ7m6t/LG6ZG3DAzmsZtJnr4KnKsmuybKfiu1tIf9JhCxlsFk6FfasfR7qMX8LLK8YJxx3+tWPF7vdaxcmcFWU8gdAaypNPudPvLEz4/e4dcelVa6OXncZrQ7p76D7UTq8MstoOCIzzW34Us28SzT22kwR28tqhkiJ/5bL/AHT71SktVtJbS6mj82xkwHFeqfDfQxo9nq16fL2y82YB5AIrjjaSPqffhU509dLdjJh8S232K3tLLTJnvE+SeAjIU9yK5y9hji1NwFIEgYhf7hx0rtvDV02m3V7LJbLHNMxAJGWPvXL6nOHvHLRYbzCDJ65rlStJNnvTdoTjFdN79zynQ3ii1x5LgLtjdu3Xmp9Yt4kv5pIwJCw34HQVUv7WWy8UT20a+ZmbO3+8D2pdWtb2K8lKwNHCeM9QPavT+0j4Kcl7OStqN02S3lScXaNtC/KF7e9AjsrO7tR5bxswLFjzx61V0+O8tb+JXjLR3HGfUCrMN5/xVEVzMU8gN5R3D5VXpVdTmi04qxnGZHupPtMe+3LHBHUe9UHJguN0RyoOVNa+p2ccOq3UcMgkhV9yuOjA+lZtxFtlKZyp5WmrbE1Yu3MeieBNbWdo0Y4kU85612/iNEkhSZE+UjnNeFaReNY38UqZxnDV7ppt3FqujDb82F7dq4MRT9nLmR6uBqe1hys4a9UNPkDpUaZRTtPParGpqVnkRR0PUVSRyi5YHjvXowlzRTPFqQ9nNx7FsynyRk5kXv6Uo+dUcNuzxTrBFuo2KED1HelC7WMOMSA7hjoRTIIXQodxByOD71JDlgCx+UHoaWZyzFeSyjoKTO2JeCd5wKAuSqQXLbgSOhNOhK+YQpOD1PY0W4zuRo9oXuRTmQiPeoyAe1NGbJBtUlQMqOc0EK6hsdeh9KAhcB1OAeoNSwR712gAKDljVoykylc4VCoAcY+Y1y2pWx3/ACx4VufcV1t2UWVkKbv7oHes3XbD7K0TLJ5olXcAv8PsaroTfU4YjbL+NRTptfPY1d1OMR3HAIqG4XfbBh1HWoZoiIRkgELxUUkf3j2q3bjzEGDyKWYM+4NjI9BQKxnBdy8U3FSoNsu31pSm2Qg0BYi5oqXbRQI/Q5W2qPWoZm5A96mC/vPYCq0p5z711o8odJIBzVK4uhHG7E8BSajurgKDk1zWu6oqW0iBhkjFNK4HF3j+deTyHnc5NRnhRgc0inPOeacwwBXbY5hpHBodxHGWfgU3d81QXcNxdTRW4iYI/wDEBWGIrexhzdTvy/B/W6yg9uvodD4V0p9VuI7qNv3aHlTXrb2iGCLy1AcDBxXBeD9Kn0tR5ROBywPevRYnDIjrxkZryafvXctz3MdPlko037q2Oc8Y6Ib7T9yrmVBkcVr/AA8vzeaUschPmw/IwPtW/BCLhRuXgjBrmLKD+wfGDwAYguhkfWtG+h53mdwQdnzHiqjDqGOR2NW5sGEgVUZf3eemKQzLvwN3y4PYg9wa+O/iz4ffR9V1a3to8wyS+aigdAa+xMh5myue1eEfHK3Qa3bIQEMi7WPtWVR2Vzqwtuez6ngnh1Wi0+9juImSYAFGPYV6J8Ko411aKc4aPaxJ684rgdYulXVLhYDugC+XgdxXT+C7p7LRTNbDaAGxn0rnraxufQZOv3zgn0ZzviK4265q4WNJElkJBb61H4uSNNR0xhIr7IF3KD92oYHEsuoXkigws/G7qTnoKra7EI9ZjhEZQuqkAnPBroWx5skudHocl49z4KjaGLckLAv9K674fam10beS1R3jQjepOQB9KxvB2ngaAYnORIOUPeq3gm6l0bU777CC3JUoegFebTd7xR9fX9y1T5M9N1S0W21Jpc48z5uew9q4DxE8Me4ICsUbb2bua6q615bmCGWaNjMvynHIxXM687XoYRooWVgij1rN/FqdtC8qT9Dy67u01DxILuJ9sTSAbh1q/wCJtTlgm+yJG8cEfzYxncfUmug+I3gIeHoNN1SxIS3ndVmXsj1dgtLlrhTZ263i3SCMsVyq/U12SqK1z5+jhpTnKF7Ndehw9teRLE+oq6mUIUEZ7Z71gR2he2kkY5bJYiu28TeBf7N/e2bm6mc/vbeLkD6Vxd3cFJWgjRoivylGHI+tbU2pLQ8nE03SqNS/4DLfkxSS2QV/LWddpLdmqrrenz2kvlzja46f7Q9RQ1xHJFDEykPGchu1dvJYrrXw4utQuGV57JwI2z8wHoarZij70NTzRG2uM84PNeteCNQi+yARqd2MEDvXk0ykFW6BhXVeD742NxGA3mbuo9Kzrw54lYKfsqjgdVqYT7e+Bjvg1VZIvKZDnB9u9O1djPqSyFtpI/OmOxaQdCR6VeH+BIwx6/fNrqVIUe1YSQtjnnNXROBmXjzj69BT0/0kt5wBmHChelQXGAAqqA3QqetbHGD5LZDfO3ei0fBMbZPv6GnzMAkSc+hqnK7W8sb7sLnH1oA0YbhiJIiDgdSe9PMpMJWL7q9cilCnb5hZcN1AoEQI2tyrdCKZmx/mlkznoOlOEqYC9yOcVXbdFMqKMqR19KlKY2kKCfWmmS0JF+5l85gM4I2nrTILW4uflgiLyS/dXvj1FPddytJL95efwohkDKrRSyRzDpIDjj0q0ZyVjj/FVqYZVBUhlOGPvWLa/OHj9RXbazY+fZzszHzF55/i964eA+XdKR64pNFRaZNpMTTXBhTaHPTd0q9LEwieNkGQeo9aqonk6qF7Ma2LmGNQSqMFHvSRbOVuUKTZPFTzJuRJB34qfVIvkEmME9qSzUTWkiZ5UZFBJUx7UUm1qKAsfoXn5Hesi/uljQtnpWhqsy2toSxwAK8k8Z+MYLPMayDP1612Ri3ojyDY1nWwpIVulcfd3klzLuJyuayl1E36+dk7T2qeJtwrohDl3M5SuXA3zexFSgkpVduYgfSrEXzKoH3j0rW5mld6D7GLz7yOM9M816XYadbNEmEGV6GvPbK1uYtQtnaJghbBOK9Otx5bqvqK86vVjVdl0PWpUKmGSk9Lmvb20axgKOB3q5CoO1R0FVrLJXHWtKOIKAe9YF8zerNLTcYxXP8AxAhMYtL5AQ0LjJHpXRWOM5pviK0F7pFxERklSRUMqKuSWcq3NhFKP4lBrNvDJuYZwO1Q+CpzLpCxMfniJQ1q3VvuO4H8KTKWhn2MQGS3WvEf2g40hiTUSpyjbB717ff3thpdr5up3KW0ZBILnGcelfNvxp8Z23iWT7JpX73TUGBnqzVnN+7Y3w8G6iaR4nqrR/bmmhXYHXt0zXR+Gpc6I8SDdIVbCisDV5RFpy2rxbWVsq3etfwV8zOqHEyxkqPWsp+9A97BXoYlvrZnLI0htWt0B3CQkg9uaRGnu9Xge6cs4IXd6AVr6lZywQtPEmPNY5b+dU9LiaS/jbgleprRvRnLCm3UjfueoeGLzzJktIQS3T8Kr3Eo0ZruWBg0zyFGQ9SKZ4QkWHVklfoPTrV6ZoL28eEqA3ml9xHJ9q82Gkrn2eIheCha6djQ0C2uEtX+1yEtMu5F/uj0qrK+bizVwVBnBH51oadqBur21sxtWXlATXM+LhcaVN5MtwDPHMCMdOtOT5ku5lSSw0pQ6WNv45Xc8UkNhu3W1wqsEPY+orltNvbmTRYrS2mmiWI4fy+prr/jlZXH/CH+G9QK7pHIG7HzcjpWR8N7lNOjA1WDyfnz+8XqD3rXl/dnFTqr6zbdWsZ82p3Xh4mHY8om+dJB95a8+8V3azagbiJcF+XJ6k1694x1Hw9banPC8r3E8w3RtH0WvGNYsmNxNKHLqWyAB0HvWuHWt2cOcVOaCit307FaxG9trHJbkVqLeSxW01qsjor9VB4b61lSW0lqYXzuB5yO3tVycrKoYHDAc1rPe5wYf3YOL0ZZnjtJvC0sikreRyD5ccEUyy1WKdbRPJENxGRmVf4x71JodzAgurW9XMFwmAf7rdjWfpunSTasLeA5CnOfaq05Xc55c0aia6nf6uY5jbMTjKjpVS7UxxoYckdN1JcCTzo43X5VG2malfLDb7QuNvFLDq0CMY71DQ05BMw+YRt6+9V9Qt5d4kgR5GR8NgZ49aw4r64kkU2/U/zre0ifV7K5+3Q3qRXBGBHIuVP1FbnIzQvrQparIwKhRuDEYz7Vj6tJu0pZTE0cgORuH61Y1T+058Ne6jEylt+wcCob69u54fKvYVktyNqyR9qBFqzaX7NGX2ksgYGpUbeA3IGeFo06FEtY4WmV+PlPepIQqu4b5Nnr3oRLAqfJYIduDzmpYvLVVCgsT1bNRxJhN4G4E9DSLGVR3/jz90UyGVrmfy5pI5D8xHAqnb3DJPGSPkf5SKb4kBt/IuAMknBqrHL5lgh4ykm4etUnqKSujoprcXEbRNlkAyR7V5zqcP2e+kX+HORXo8TeY6yIcErznvXD+KIdl42cZHPFW9UZRdipcsd1tOpwcda6sQIYo2ljfLpkZ7+9coi+dpHrsNdr4F1hYVSS5g+2SxIY4o2GetZdTd7GPqOludMedh8v8JNczpr7J8dm4rv9XcvHMCpAcEGPshrzxgYbnAPINU0SjS+yj0NFS/bPYUVIz6R+NPj6Gwn/ALN0+QS3CjkKeh968FmkuL64M105eRjn2FKkcl1cvPO7STSHczsckmtSC1wBxX1GFwXKj5itiVHQs6NePAQrHjuPWurtpBKgaPkHsK5Zbb5eBXXfDloF1bZfMPJPGD60sVhnBc6JoYhVHym1pmmXV8VhjiI3dM16BoXgmO3WOS8+Z15rXsYLe1kR4VUjGVNbttMZHyeVrwqtZz0Wx7VGl7J83UrS6ZB5aqIxleelQTWw37gOlbRUlyQODUTRDJ4+U1gkauTe5QsZdjc1uxYkAPrWBLGYZsDpXQaUu+FSaTHEvWo2n6VdIDoQehFUSGjYelXYzlQahmsTkdAzYeIr21bhH+da6K7mjgVnlcKvvWD4qU2OrWV+g+UtseneNYzd+GbhYmKuV3Kw+lQ27FRtfU8K/aE8bx6xJDotkB5Vu252zzmvGY/3syIXCN/CR0/GqPjC5uY9XuS1wZBvIY9wax9PvJXWZCcIOWes5U5M9jD4mjRio21NnxFE8xEUvEo5BHetL4fwSNq7GFd5SJjWUlyWgHmneTwrHtW78P43a/ngjvo7W6kQ7C/Af2rKV4xselRcZ1ud7NMfe2cl5YeeQY4g5Vwf5iuesWht7qWONtxJ4Irq/EUtxNFbWqIkPlghzn5XNcNEXW8kKDKg4bApJOSbZdSdOEoxitb6noeiEKPNReVouJTYa1BI5w8nKt2pPDuZEWNefMwpp3iuzFjBbySuWkWTYiHqBXLTV7n0GKny8i7tFuO9Uatb3G3EaPl3Hb3qP4nJ52nNcwjzIWYMJgOazkl2J83CsKvatrAuPCFhp02wKJDlcfeHrmlHe76DxlNPSP2k0zuvFDz678OPDaMAY0eMBm659683+JeqanHq0FlcRRxC0AICjhvrXpHhzVtM1fwA2mC4WK8tjuVT3A715/4mnXXbO4kcII4x80v8TkelaUVeVmeVXTpUm0ra6/5nF297BLNd3N8CLtl/d7Pu5rpfDukSXvwu1Oa0iF1fyXIDonLovrj0rg75UhVWt33A9QeorqPBWvS+GfFGnalZCSOymHl3UZ5DqevFd+x8zKXvXMzUNPFzaTW9qCRaLuYgc57g1yQmZTg5z3r1XxFf2OiapqjaBIk9jfN5qtIOUJ5Iry+eTzbqSZlA3NkgdKVPqmbYxWcZLR2L+kTRx3KXNxF5sEZy0efvV1fhlI/OuNRSHZHKSVGfuD0rifOEqBUGGJxgV3ejQRWumqs7MRjOBWdbSI6L5mupBf3sgunmPKAcVjATajcFEBI6muksbaw1N7mCe5EIxlATV3RtAM1rINMlHmKdrqeuPrWtJWgjjxM71GZFhJFpDbBGs87jjHO2m3Nte3cmZHaPecoRWvDDYaXBdt81zdrwqkcqe9SQOVtkijk4b94zMP8AVn0rQ52yh/YFvcaRK/2p5NQQ48sdMetYMi6lo0mwkvF1KnkV19jcCKORAAZs8MelVbmWCXzIpVD9yw7n0piRmRTxahEJbI+XdLyY/X6Vq2crXkR3AtMOGAHK1iatpBtVjvtLc7urKP4auaNqTTbb2IYnB2TADr70DaN2ySRlK5wB1z1p8sRzu5VO2epoUt9qWXfgt0Ud6s3Q2NtmyZGHX29qZkc74mQz6bIc7mTmuf0otNYyY5K859K6zUbfztNnSNSuBkE+lcd4ekxcTW+MhgRigq52emmO50jMjFbhSAuP4hXOeNoCkscnHzLya1vCs58qeNQHkXIwar+MMXOnb1IPlnDDHINao59U7M5jRsS2tzCeuMitHwlcvb3paJtki9D6Vj6G4jvFBPytwavKRZasuzBUNWZv0sddchrhpZGPOOc8FjXAanGY7twRxmu8nBkcEnO4ZyO1ct4mtfLkR+paqsLYxvMNFLs9qKmwrno1ha8jitmK2GBxRZ25AHFaax4AFfolKmkj86xGIbZQaIKOlQKXt5hJESrCtKRPaqc6cHinVpqUbBQrOMkz0vwB4o+2RCzu3w/RSTXq2nDy0Cnr3r5VhupLC5S4iJBU5NfRfgDW11vRoJd2ZFGGNfHZhhPYy547M+uweJ9rHle520XI4qTYrjaBVe0baTuqwh2ylh0NeadxnX9sxXIGCDWjoxwmKtNGsifWotPjKSEHpmpZSNJ0DpTIPl4qReOO1MIw2ak0KHiWy+36RPEB84G5fqK5+2uTf+G9jf6xFKEe4rs+COelcMkX2DXbyybiOX94lS9xs+T/AIg+Bru58VXMtnhIJDlwexrmtXsIdOgt9Jt1zNKcu/c19K/EPTvJY3UQ5zyBXg2s2P2nxNbyuSuDxihX2NISu1c5doXhOyNC4Tgj0qlLO/meap2lTwQe9bP2v7Nqkw2lgshBPZhVrU9KskuY7+M7bWUjKHsaxcrSs0e7Gg6lJShIZYJqWuQIbKEyQIQryu38VARtNkuo7iNXuMbEwOB6muksfs1uoaxJCgguoOB+NReLfEkl4ZbVbK3iFyFUso+YAelZKavZHoyw0+RTlqjT8AwK+oWiH7sbhm966T4iwW1xq80yqCFGRGOlc74UuRpe2e5XgJgetLr2rpc35e1OYivBPrXHdrY99U/ayV9rGBqMX2e1Qs26CUHaw/h9jWWiTXU9pbHPlckt6Ctq4KS2pyxQMPmXsT6igafBLorG0kl+14PI6N7VtG1jlquo3aS1/RHZeFvBv9o+DLvW9PnGYHKMg7gVi+ILmz8O+HPKFsLi6vB8kjf8s/Wuy/Z5vZD4E1mxmXc+58oTXmHjCG81QK8Dh4YHZCndOe9TT0q2ZwzrVMRhpKXTb0ZwUiSTvIgXLdavT5s9NhR5CJB8y56j2q1BK9qY4yiu6vx6k0++gMeqmXUVVhIOI/7tdjkeNGhdPv8AkWrbw5da54VudctpPNltjh7RRlgv97FchGEKSq67XPTPGK6rQ/FGreDru4XTkSF7hSu5xuUofasF3+3XM09wF3OSzFRgZq9ImNp1tJbkWmXNusIheJfPVsh/Wt9744CqcEjArkJ1Ec4ZOgNbCSmW3LZwQOKVSPNYihU5Lp9DsXsbOO2t51izPt3Pn1qTSdWubK3v0t9ii6GMeh9RVDT7yS48PCWQgvEdp9xWcrOFypyG/hrZLQ4W7u7L9xeyyEeYqtcxjEko/jFWbZ0+wsy5LHn5u9YrnzG2whsdwOtX9JcySNBjOVIUUwZbjYghlXJP5EVaitg6SCFC0jD7o7VU0xyIHgJGQ2M1qwxtFeoHnMaleq0EiaXcxvGiSKCF+WRf73tVOKzFtrNxLaQiG0mGDEf4asNbtDJN5Xylvuk9j61Nb+bO6xSEPKgyT/eoQmWZttvCrp8xAwM1GsgdUcliufvH+GmidZZWiSQBwMbCOlPhZ142qSeOen1pkFgBfJuImK72Q4B9PWvMrE/Z9f2k4y5FelwQmXc0gLZO36V5z4ijFl4iJQ5AcGga0NfSiINZnRiVUnnB61rauR/Z08Plbw4wrAdKxrpWbUhLCBlow4HrWpa3bXmjvJC4G3hlPJpp9BSjfU8+tsxXSg9VbmtjWYTFcRSj7rgGsm7zHfORxk10TZvNFRyQxj496drgnY2NMb7XaRKjbWJxknim+ILFP7OZCd0qH73Y1D4VzKrW4AGOa3jHstbkogfehQq/8PuKuKZnUkeceSaKt/Y5P7xoo5hcvmew28QwKmZMdKSHgCpsg8V+jo/LZSdyqy5qpOnWtGRc9KqyL602jSEjEuVzle/pXY/DXxQvh+Ka3lPyyNnBrj9UjcXCSL0FQNhnHv0rysTQjXvCR7mGruklOLPp7RfE1rqsCtBIN46rnrW/bajExAJAPpXyno+s3OlXSlJWC56Zrsbb4gTLy5O7Pevn8TlNWm/3eqPcoZjTmvf0Z9GwXaEFcj2q1bsobcDXgNr8SgoG/rWrp3xbhjX98mecVxvA1/5WdaxdH+Y91yOo6UjCvJYvjJpqBd0XBNXYfjHoriTzI2Xafl96n6jiP5GV9cofzo9NFct44tzHBBqEQ/e27c47rWNH8W/DpkjVmdQ/GfSpLnx94b1i4k0xLwI+M7n+6wrKeFrRTvB/cawxFKT0kjG8YFL7RRcRAMrDPFeA+IWitvEtujrtyCc9q9lbU7Wzup9O+0Rz2shJjKnO0+leVeM4Y21tJGGVUHj2rnszpg43szzu7sluLudopyoLEj0zVieZbvR3trz93ND91x0er9jDHvkyowW4Fat1pUElqBNH+7PT61xzqJOzPoqC5I6Lc5W1P2SyjnjYy2p+WcZ5FLeyR3V/Be28ZS2i+QKx5Y1N4i0mXTrMqrHyJeRIPu/Q1maGgzEZ33Ipwo7VTSa5kN15XjT6I7EGS4tQ2MEjhaoiKRdyFSJK3NPQX0irAQroOFP8VPntN0k0bMsUqDP7w43D0rBU0z1HmTpxSRzl+xhRVLD7vWuj0fVrObw81iWjhuFU7W/iJ9a53WLqG2ggLoHfOAuc1hXSFp0e1kQs5wTnoa0VLQ56+YqVm1c9K+HGqppLX6uD8yH5l7+tcTrviS2TW5rjSwZIkOHjPAYd66D4XwXd94gv7KVYzi1YsW+nUV57r9illNOEBVt53D15pU4LnfMLFYj93GdDRrc0dU1PSr62N5YqYLtOUi96pyGaS0W+u3BkPGw9QKyLaB1Edz5e2B22c9T9K0dWt5YtskTmWLbgZ6j61vyqOhwrEyq3nazt0/MzNRuHuJAcllH3Se1Q+fLFFwuFPWoll24JPf7tWb2K5iijedB5D8ritbdDz/aXvK+pTmcPg4wa2NO8shYUOWdcn2rNLiVAgj2uO9OsZDb38LH+9g1SRzznq7dTqvDGdl7a4J3KSBTbePCOC3zr0qKzlFn4ijOSI3/rUurf6NcyohG0tuzVEIgDCNmdXxNjqKuaQ0sd5HIrjdnOay0IYjPH+1W1pNqWnifAKjkj1pIpm/Yw293rzQrF5Ebpkydt9Xxp8H2cTzzbZRJ5Zt+/+9momjxKkhjK7hgL61buZBdW7QeVtcjDcc4ppGbKt5bJEs5dizIMK6nip9Jiiaz+0EHenDY6n3qlC4h8+NwslrGvzgH5vrVLQdUCzeXE+Y2f5Ceq/WgLGzJZWkWoNMWLO67lIHf0prRIrOYN32ply0cn3ceq+9LFcy3N3K7lSYz/AAjt61qy6cj2qzlwwI3ls/d9qCbDY0a3s7eZWB+0Jlnx90+hrzHx6v8AxMI5Wi8tjwT/AHvevSYpYhAzys0cB+6pOQK5b4heF5E8KW3iKS+ieWSQotqG+fZ/ex2oKsYMU42WUwBAUYOe9MT7VpN2xiR5LK4bdGyjP4VBauW0O2Y8qj9a6zToriS3LcC3ZcBR/CfWgHsef68yvfmREZN3VSMYrV8NkTW00Ibkjoav+LdOs4PDME8l2ZdXExUxY6J6k1gaBdLbXSluRnn3q47mT8ja0WU2uobTwT8tdXK48oKGYg9QBXFalI9rqJdVwrHcAa7bTJjf6dGttt3EZbPFaxkjKrBpXKH2a1/vD8qKufZF9RRVfMx1OujANBXHSoI5DgVMJOK/RT8zaaYZxxUMgz061Nwe9McUWHEzLtMjmsiT93MARx2rcuxzWRfrnnuK560bq56eGl0ZBfDKLIvY1IuGRW9agD74HU9RTlfbYhu4qI7XOlrSxeWMMvAFRlAG6VUiuwV6077SM8mpUkyPZyuXdo44p7KAOQKpi4B6EAUv2lBjDbmp85PIydlG3JxUZQbgQSD6imiYtyeB70xrqJMlnBp8y6jjGXQaxmhn3xTSBuxzVLWNbu5ZkimIYgfe70+S9V2ODxWFcS+dqmP4QK8bNIUvZOdlc93KnVdaML6HQ6dwiORnvXSwL9oiUSHK+lYemoNi5xite5m+zWDEcO3yrX5/UXMz9Hh7qsU9TJvrOTQjLGtmz795HO70zXB3VlNYXBj+YLGcKp713qWitYGJQZJMb2YdSaiurWLUrANMCHiGCD94VcZqKsCpXd5o5q2urjcskReKSJeSD3qDVU1KVVOsNMxPKEHGa9F0H4e2I0yx1nV7yTyXk5t1PzFa29W03RdR1GCCz3yIp2ICe1aOookSjCT5Wro8FuhlljLSIV6sTnNVhHc2BLJ828cbvT1r1jxN4Q0y0uriOJypXqOuDXF3Xhm+uAfst1FOq8BAeRVRrxZjPCpK8TV+FniWHwx4qGq3CPeQm3aN1PVSR+tYl/Na3erz3LuzpLKXCAdATVZtH1C0zm2k8xeRjpQYdSuQ0os2gdRjAXrQ0pO6ZorRio31DWWh+1IttIGT+HttNU5bi5s0aEqSx52kcD3q1a6PeXCrM0JdgfmUHmrU+lakyGWRQYwMY7qKLpaDbck3s2cg6l2LSdTzVm3idwFkkZox0UnpVme2ZJsMPlFLGVRjziul7HlRtzFW6i2FXQ89x6VVnbDK4PQitXCStyfvd/Ssq8TYzLnIBpxZNSPU6LUlVHsJ0csXUZPoafristzGWOSy5NU2dpdHs3zwjYz6Vp66J7me1dtmdgHy1RCG6Jb/AGlyjgkdQBXcWtpbQWdszPi5jOVjUZ3/AFrF0WFIbQmchW6KRwK0YTEJFb7S1vcdFb7ymkSzRdDNK0ySEKnJGM7fr6VWTUC5d45cyLx5mOMelRyvcRWNxPYPNsYbbkgZVjWM2qExqjxKqFeCo4J9KARcLJ5dwzMFkJyp9ayYbdvtHmwKRI33lX09aLK4wxMvzbwQn+yasWNz9ilfY4cAbQ56gmmM07SG4sbqMiTMJGX9x6VvTzAENvMUEww0Xp6GsFrpZ4INgCyoQDj+KteYTzQPJIiseMY7CghhZRfaLJopT+9RsggZytY/jexgl0p5EJZwuVO7kexFbRuLeKKNbS7SSZlz8vUe1UNdCnQLrhQSMkk/NQgvY8/00l9ClTnKMD9K7XRpfJ0lUXLl8E+1cboJ3WF7GvLYziun0C8iOm/vOiD5h61URS1Vin4ptmvNNecIqvD1x1NcPAcMDnFen37Jc6W3lYClTkjk/jXmCDbIR6GmQmdHqIN1psE5++nyn6Vp+ErgmGRWJKjoAazNCZJ4p7eVsErlc1BpU72l46qduTimnYprmjY7fzR/zz/Wisv7dJ/dFFPnM/ZnVx3JIFTLOWrOiJ4q2nTiv0VSZ+czgkXFm9af5uRVMAmnZIFXcxcEOlYEHNZt3H8pIq4zcVUuJBtIpStbU3pJp6GSvyyEHoafIv8AoDp3pl4MAMOoNSTsGgAXuK5UrXR6O9mZqW06oNp4p0dtMeXzitW1IaBc9uKmcLxisuRIp15XtYxZH8nh0Y00alFHjEZB9SK1JY1cjI70jW0LjlFpcsteUaqQ+0jPM5uB+8mCL6Cmn7Ei5a4B/Gr0ljCykFayJtDheUnkA+9YVJVI2tG5tSdOXWw24uoAp8txgVm6fmW4aQnO44qxd6PBFG3zNn60zRUIznoleHmtaoqfLJWufQZPShKpzRd7HWWsojdY4xk479qpXMl3cXjrBMrInzFT2xU9uyqpmY444rEmEqCUbtgZ8E9xmvmFA+xp1NToLDxZaW/l+ZEySg7WzWtBqllf3LGKNgHOSfWuPudDgnm+UmSULymefrWJY6tJYzS20zMAjYVu/wBKUqHVFRxC5vf67M9jGrRyaTcJbsFVeiyH09Kx9D8SQGAxyr5V/GxIcdGFcVb6iL252JcAQt94PxiuwGmabFpULO6uxPDqeTROK5dRwmubltp3JX1CDULqVVlxKy5csaoWVgkNz5kcpVgeSD1qnqWmC0RprNyWbk5NVkupIbUs5O9u9Y8l9iqq6xN3UrwJCzRvuIqp/bRljiKjg8ZrmVuJfJdi5MR4JqurMQrKzBVPSmqVtyfZ8yNrUZ5LefzrdihflsHrUVtcanMJpTA7IOj9sVV2mcAhj+JpZvtgjCQ3LBP4owcA1SSN/Z+7ZlDWpFkWNoVGP4vrWbdIi2m4qTIx4I7VbMFzL5kYwQgzxUMai5g2birdvrXoU7SjY+exEXTq36Mo7ysAAIweo71UuBnNTzxywSHzBkDg0BRMMgYFLUHJNFjSA0+kXKAE+Wd30ro7doGtbaUvlimCD2rC8LTm3vbu1Iyk6EGp9Mk2tLZOu7J+TParMUdBbXDKrRMm6A87vSta2aOYoLVFzjhG53VjWA8pvLkG/HYHoPei9uVspIJYZMMh+UDtSA6AaiwgvLeyfyyyfPC/GfpXILc4t9kg+SNsqPVqJ5zdzpcM58/djg9RVefd9rkVsbSegpgtDQ0ACaebzvvkZjHYn0rXh0B3086rE+23L+SwPXd6YqloUKLOHlP7lP7vXNdbC0b225wxgRt+1TwT60guZ2mWEa25B+Q5x8/+NT3Muo6dJtcI0RHVOQR71rTyLcwyh7dDGy5DbvumobW+8vT5URUhb/lqZPmyPagnc5rTUggkmnhtis0jZYN0FN16Z1ilknQKrDaI81q2kkd8sonuo7SJBndty0v0FVL63tbm1CBndgcGUjP6VSJ66nB6Q+yWdN23INb/AIeBdGQKGXowrFFs1rrr27Jy3QHuK39EhkieU52j0pg3obltYRRJJFZAqHHJbn8K8yvojBqE0RBBViMGvTUMrAMJD5mOMVwfim0e11Rmcli/zFj61SRG5W06cw3KNx1q7qsfkagH6K4DDFYqyfNW/dMLvS4ZVGXj4NJlxD7SPeiqHnJ/dNFTYdz0GK4PbpVpbk4AFY6Sc4HSrkL5HvX3sarZ8DOkjREzYzTjO2KrI3YUpOQav2jMfZp9CR7jjmq8kinOaQnIquwJOTwBR7VlxppEOqOIbYSdcnFLGc26E+lQag4MGH6Z4FOU4tgfao57yZ1KPuIS2m2ArnvVr7QCOTWC05Erc4pkl9t/irmdZLc3eGcndHQedk9eKcJlzyeBXMf2pzwaY1/LIdqcULFRWw/qUnudS90ig81Tku1J4asIljzPOFH1qJr+0iJBYuRUTxSW+hcMF21L+p3AZNqtyaXTEI5HQ1jRz/bJ8ouFFdJpsOE4r5rNcSqjsj6jKMM6UbvqOuopZinl8JF87Z7j0rLWe41PVzHbIGeQcIenFdNLGY9Fu5wM4GD7Vk6PpV1AF1qyYTG1w8ozgAeleRGV0e9CGpf0/TUh1Uf2600ISMkmPqRXKXVvbXl5O8CMtuXPlSHt9aua34ul1PxA96kbRx7dqR+lTWOhanfrJdxbIbefh1H88Vb93VkxvUdkrow7iJm1CGKYRRngeYh4NdfoEcAaWNrhpGjGV3HgfSo4vD1jYwF7omU9BUcUscQkSMKij86htSWhcIuEtTTvyzwP5TlmIwB6Vykt1cwbopMk+hHWtf7WVAO75e5p8/k3MIcjEqjPTtUJKJvzSnsYcF6pjKSHHPQ9KuR5umVUXGOuO9MmSCWRd0W3dwwqxa2RgnXyZiF9DRJoulGa+LYcwdHAQbR0J9KSKCUzvyXAGc9q2D9njhPm/OzdhVdrwR4XyuvTFZ2Oh1LLQrwiOJMg/P6VjanAbe58+PIR+Tjsa2lWW7R5I4wmPWoHiea2McpU1pTnyM4sTRdeHmc3K/mFi3U/rTIlIcYOBTtUt3s7oRkkq3RqYWwMCu291c8BpxdmFuwi1+BsblPGAas3AMWqsy8Mr5ArKlfbeQsT/EOa39Rt/I1W33urJKAdy0McTa1R0RIrv5UdkwNvc+9c/JMXfdIC279DWr4gdBJFbR/3QQPWqjLF5qbl8qPGPoaRQ2G2Eke5AQ45JrbltIxFDdSMivgAp/WmIsENoqSHPmc717Uzz4ZIgYo2My8cngigl3Ll3cw2xguLRVcq4by/4ZPY1Fe6q93dyXBjFssn/LJD8i+1ULh44T/opLIRkrj7p9KJJSbEXU6K0CsFdB1X3xQFiRLp53RI/NjU8HLcVq2ej3V0xWG78zuQxpdd8OS6QIXsLhbuxuYhN5y87c9hVBLW/DRPb3XbjBxTA3HtJrKSO6RkV0O1gy5Aqa3ubW31ouGzuTM277rk+lVbe/e01iyh1RGu9MY/6Uqfe/CotQmt5FvbW0wtqZN0e776jtzQtBNXOSuvNh8Thn3bi5K7vSt/TpDFf3Jdv3R5YntWBrIuW1G2uJVwMhVcd62ZZ1S985UWVYyCYT0eqJsapuAQx3ER/wADjvWbqdompQbJDhgMpJ7+lSpdSXDShY1gic7hGf4faq7uUOyVtg6gDvVIk43ULOW0k2yqQRVvQ7gbzbyH5JOB7Guokiju4jFNHuB/iPUVxeo2sml6iY2OQDlW9RSaBM3P7KP99Pzoqj/aI9TRUl3OrRvzqzFJjgdazvMxz+VSQMScV9pF2PjZQujagYEe9S5wMGs+KXDAZqUyZFbKSOaUCct27VDJjBJNMLVDJIWyBTvYIw1Kt2jTLnsOlSswWBFPeiQkgKeAKjmQtND/AHKzWl2jpWtkzLnT96xA61UnsAzDLNz6dq6h7RWGQvNOiskxuYc9K86VCpOXLI7I4qEFzI5D+zWAOyTB9DUP2e7QkEHA7iuwk05SSx69qIrbahR+T2NTHAylpqi3j4rVanFSwOy/MxrPmhw4A713F7ZLjdGuT3FYd9bgPjZhq8/FYSdK7k7nfhcVGs1FIm0O3CRbjXV6XF8pbHyisPTYcxoidutdAZRbWL4OCFPNeBXnzOx9Ph4ciuOurqF4ZIkf5mG1ox/FUfh3QS0EiXdxLGrn5oVOARWL4OhEmpSyzvvIyeegrvrdBM45wAOorGScHynbTmqtO9ij/wAIzpyOvkwqQOtP1EtbWpSEeWoGMitF4AsDGN2z+tZGozSx2218NnoO9C8zROxgqxm+cyl/LH3Pf1rJuJTGxQRlixyWxxWtGzCeZfKVcjhqjDKf3YKnsxNappGMoudmZkCBkJc5cngVYIZyUJxxyw7VNcW0luh2RB0PO8daZAolAt1JBJ3Y7mla+pvGppypakU2yGLYoLlj8pNS+ZgR7xtboalSwN5OiM5UwngU/ULGSIYZhxyPWpugXM9GSwbShXO4mrFrApBJ5IrNtfMZNx4H8Va1gSu7aQ+eg9KzkbWsJexeXaM0XDjnArOtJ0unCKpVz1J6VrDzBKRJhQe1SDTI9/mwrgntUpq1mD01Mv8AsW11W6W11Cc269Iph0Dehrkta0q40fUZbK7B3p91h0Yeor0PVLDMIwecc4rC8YxTalo9veMxe6sv3bgDqnrXVQndcp5ONpJv2iOAvAdgYdjW3KcWljcBs9Bz2rKuQGgYjpitJSr+HLf++GxXUeXsy/rEkcl9BIPkBUfMO5ps0gkwnWTOQexFWLHy9Q0k2zLm4i+aIjqarW8LttwCHPBz2NIq4qBvL2vuKZ4x2NTWhLqY0z5iHIX+9VqwtGjugsz/ADA52nt7n2qzezxJK9uVUShstIvQj2NMLj7a1mM8boQH28qV6VB9kUSuHcNKc7go4IpZL8LcKIHwAPvE/pWW9/5UsrhiJG4yPSkLU6XRtVWy0b+z5W81oiTBL22n+E1nXN4/nCWAhVHUelYqzHb8v+TUsReQhGOP61SYrGgt67lpFP3evuapO80kx3NszyT61MluTgqPlz81W4rdXk8pyQPWkO9ivr1ldReG7W83ILIy7VAOXDe9V3ieeGO6ibyzjDfWuj1JbKDSbzTtQDSu6B4GhOQre9c4juLC2XcOnOPWhCt1LUbyPEJAQccHPerUUqLatvQMwGcmsdJplbeRnHGDU4vAYGZvlB6fWrWqIZea7BhXC8kc1ieJR9ptI5iP3inH4VYFwfs5IGWFQzh57dlC7i1NvTUFBt2RzGTRWn/ZNx/s0VlzR7m3sKn8rOiD7n9hVlXCJnvVG26ZY1OzZGR0r7CEtLnyU462LNvId/PNW3k4HNZYvI4gASM1MsvmkYPBrSM0tLmU6bvexeVyRyeKaZAvQZaomlTGxW/KnLIkYy3J7VsnfQy5bDo42dgz9DUlw480AdEpYnOxpX6dhVZTlGLfeY8VT0VkJau5oRzDHrUqyDHXisqUmGJT371GbwpjdUOpZ6gqLexsySDFQM/zVQW8DDrQLgdc01UF7FotSSBUYmsG5bzpQT3NWb+6DAIp5NRW8Yd68POMUuX2aPoMlwvve0kaVkgWHKj5q0J7fz7Mry7FTwKgsosKMjJ7VelnSAqqfexmvkJO7Ps6SOb8MwS2sruoLHJV0b+Gu6to5Z7ciJgrdeKybACaUkrgnk4rpYzFHa/uRtlI4PY1cm5O5cEqceVEcjOIgWk5HWuXvTK9wXEuUzxmtKSSV0KTApIDzjoaoSrvVlH/AAHPrSSNHbYzZEnn3YcRgnBHeore2NtMVZN4zUyTqJfKmIWYH5l9fpV+V0KHPBA4NU29iUluFu6lWSQMozx6UT6csE8U0J3A917UllcnPONvcGrM9zhgsEYHv2JqGXGLbsiZbZYZA6A5xkk96r3aLdKxl+UdBU107zKN5COBnBrMJKqxcnzM/dPTFSXTT6j7Cw/fJHIx2diO9aU8UUEoS2Gx/wCJaqQXJlg2g7JAcinxT774ByWmAz9RSLm7ampFAihd+HJ9atfZ1Ee5W4XtWKmovGzNLtDZ4U1Y+3/anS3hZVduT9KlxIV5K5emKugK8isUborswEApcZjYHoQa1ZlCrgHBrE1a58q2bzOMchvSnBtO6M6kFKLizz/VLQ2Wo3VpIMGNiAPaotJnBWSxlPDHKH0NbfjGzlQWuoAboZ0/1h7mubsIjNfwhThi3Br1E7o+dnHlZraTeHTtSR5gdgOGx1rYkufLluiFElrN8yluCvuK57Ui5vpE4Z87eO9aF1OI4IIpPvovzD1oDctRXoW5Q5JAXBZvSqV1OFmBjbeM9O1U3laYbT09qbBESdoBPPApjLFzcea/yLtUnnFLbW/neYScEdAe9W7SzJD7lxgZOasobdCMcH+dBNxq2q7UWL74Hze9TfZmhKuwG49BTpL+0jB8pMSAfeqlPrKOpBT5+lOwrm/p0Yv3aKIoLoDIDHCmrsVv5WmySzqA6yBGTuR6j2rhf7SZZRJH8rir1p4ouopleVA4XpnnFITOtvre3/5dTmDbzIR1PpWDJZeRtYkDDZA7Gh/FwlURyQrtB4wMCmnXLKdPKmUoueMdapITY6aFijHAJPT3qqLRfJBlOwk96uSahYBCC5OPuY7VTmu4ZYly4bb1Bp7CvcpSurzJaKeS2cj0rV1pFs9KiaL5QSMnvXLLPt1dGDcZxXX30K3uloQcgHBFc1Zu67Hu5VBSpTt8Rh/ak/vUVY/sqP1orG6PQ5K3YpXF22NkQoivJEQhsk0scajnqaf5YJ6V9YlN63Pzv3ErWKYZ5ZsvWjDLJjalVJojuyOlJDcNG23HFRTbpv3mOS51obFurLlnOBU8MgkfOPlHes5pjIoTnHc1ZSZIYwO9ehCa+Rxzg/maU05EYXuamhiyQ8nA7CqFvKoxK+MVajuPMO7nFdcZp6s5JwaVkSyjzNxbp0FQNbq8TKfvAVbXGwZ61VdzFcbx0PWoqJPVkwb2RTazbb8jEMKqTm4h428etbjEbwVPFVNQI8rntWU6Vo3TOinVbaTRh27PLKd3Bre06EFsHqP1rLso90jFRzWxZglg5GMcV8ZjavNN3Z9rgKPLDQ2kRY1UDqf0qSWJQ6BsMexquNzsnXmtR0zAGYAMBgV5yep6qjZXGWcaQzcfdPOf6Vo3lxbiFCGw5bhB2rBmnMcW71OM5qS2nEd4sjRCVSuCPSt4oh6Gm7K8cgbBzyKzNu12B6gZGe9ItwkvmMkbLg4wapXDkvuywGMUNDTZia/apdyrPEzRXCcYBqS2up/six3OBIOMjuKjv1lUsANw6g+1JazBgFIye5PanurDUFfmRftgud24qR2Per0DAE7wV7qfeslmLEIVyn61oCZkiQ7Q+OCPaspnZSVi1cj5Aztl26n2qpc71ZPLw8Z7HqtPkTLDnGeQhP8AKmuU6SZ2/qKg25SK6YIvmM/lgDgVa0OeCYM0j7ZTwJKxNfLCCONWL7jwansSI7eOGQYdRux61dtLmEuzN7V7MIN0wyrjhx2qDSIobe5jkYmR/UdKr2OqpJKIrhvMif5cN1WtGNv7OLeYFMDfdx2qZaIKcmly9DVu8H5iwyeR7VyPiW4xBKj4wRWje3u9QyPwvJHtXF61qT3s3l4G0HqO9FKDkycRONOF2bXjN4m0DQ7ffgiLLL6VxNj+61CNWbClsBqv6hdveXSPNnKKEA9BVC7+5kD5gcg16cVY+ZqSuzdtYVhuLieUBpFOEB7n1qCaBmYyTuCzcmmmVrm3ilVuWGG+tUXeTcQxORQQmXgYIxknPtSvqCK2UQA9jWU2T1ppzigo1JtUndBHu4Heqr3jt1qqATUjW8wj3FCo7EjrSCw4znPJpSrMu8A7B/FWndWGnTaTb3GnPKLo8SRP0J9RWZAJmf7OVbOeV9KYWDjHvRuYgDsK2IPD1xPDIwdVmUblT1FP0/RIbmPM94luM4DN0z6GhMVjFSUBiGWleVXbKKFBGK9J0z4Va1PcW+Y4pIWAkV93yyD+7mma14KuU16a1tNOSGNV8yW3D5KheuDRcVkecqy5A6+tK3P3Aa6iaxtifOjjVLQ9CfvL+FNltrSVF8kKxX7zDvVCascRMSJQe4rstBu0ubQoTggdK5zXLZYJwY+jdqfo8rWVwN/RuorKrG6O/Lq/sauuzOq8j60VD/aC+gorj5GfT+3gZKSKOByamRg3ArNwV6U5ZGUcdK+ohil1PzWVHsajY2kVTmiGOOtMErEc5xTGm44rWdaEkRGnKLHw3WwFO9TRZlbJ6VmtjJNTwXJA296yhW1tLY0nT0ujcgUNgclRWvZpHj5+g7CuftLvYm0nrV+K7YgDoK9WlUi0ebWpyuajsZG2oNq+voKgvMYG37o70iXAdwq0l0275V7VtNpxZzRTUkV7aY7WD9jgVUvbnzn8sfjVe6ufIkOeh/nRpymZtx7nNeNi8b7Onyp6ntYHBe1qqXQ1tPhEUYcitGxHnMQvCjmq9nE0ilScAVqWtv5EbAdDXydSfM9T7SlS5UKm5cHIGPWtWFTPCJGzjoRWfFY+ZCzux2Vo6fcjymRkzxgH0rOKvqbNGZqUKlGEYwB0FGlz28UOw4Dj+9Ul/YG7ZljkaMk5yKrwaPLJcAT/AHI//HhW6kjNJ63JP7QjkkdBHhUOC/qapXUhG98DA6Cn3cccE7hchewrNvhIsQZTle9D1LgitcXO51DAjPWo3TYAU6099kkAY9R+lRJOWcRgZx1NHoactjYBRbdCwwSOaWNlfcqntjFVUmyMsp2jgA0y5k8tiYzww6+lZyN6asMWZxvjDEyxn5QfSr1rKEhDXHzl6xp7kW8scyEO5GGHrUQvsFypPPO30p8panbRlzUWSJ2Jb5T0HpVVrzzJIyowFGN9QujXK7pDtT3qjNKnnLGCdqVcYmFeqkal4/CzQjAHU+9StrcrxBZj8oHFZsk6yRgK2PaqUkoA21fJc4nX5HdFi71NnZhESqngj1qj5oVC/Vu1NOCfmOBUbHc2xTlRW0IJbHm18TKe7N/+zkvtKS7gIEy/fX1rIuITsOBxWloF0It8EmfLbrVuaFZZjtI8tuF961OPcwdHl2yPbOcbuVz2NajWTXKeaAFzwT71ianC1tctt4KnqK6nRpm/s5ZJMeU3XNAIzk00FwrfePapBpWw/OucVeuiYsNnIzlSKt206SRMJARK3ekaWMt9NVZI/lAXo1W9SsJpNFjdHBRCRt9BU9uv77fI3yDoD3qwkkZEobcc/wAI6UDOS0uXCy2/If7yH0NdFo9xDOPniXzCcP7mubu1ay1QMBj5sj6VrWYKX5aNSBKMge9AG3qUzLZuIPkkbuK5eCUtcNBdttWTuexremdm/wBYpU9x/hWbqdgJQrR/eAzg0yVobnh7xlruiwPpYvXayJyqvzj6HtT59QuZb1ZkuJmmAysgb9DXNQFrq2KMv7+L7p7kVesrnzIxG/ylTzjqaLvYLLcv28S3GqW0V0Qklw+GPYe9O1mKDTNSmgjUMEOFYH7/AL05cWswmBU7l+83IWlsNKS4kFwLpDcM+EWQ9c/0prQlq5zuupFdWIubchnU4ZB2rBjunBAcAr3rtvEmiPoGoumQ8cq5fH3TnriuU1PTDbAzQSK8Ldu4pvXclO2w3z4f7z0VS3r/AHaKjkRr7efc3XjxTfL46VdMfOcUnliu3lPMuZ8kZxgVH5X51oGPJ6Uhj46UrFXM14z1qPaVbdWm0XrVeeLg4FLVDHWkitgHANakULORtPHrXPgGNxitK0upAMK1elhK0WuWRyV6T3ibSqLeInq1LGxcZ9aqpMZUIfqKkjZkI/u16iae2x57g+u5l6vF5l6iD8a2dJtdsfH51ls32i+JXscV0NjIsarGcZr47MqnNVfLsfY5XRcKSb3LtkoaTZ3HWtcQb2RQOvBrFsw5uXkAx/Wulsjlo2I+teTM9tIW4h+z2Jjx8vXdWd5s0SKbdQxP3q0dfvUFnIkbAsOcViWt2Lhh5alQBzn1rSnotS0r7ktjdTzTNvTy0DVJrF6IrcvHLifOFHrSK0cm9Y2Il7j0rmtaM324IynbjKkdzVpJsifuou3LARK7PmRxk1VL/uispBx6elUorefZkbt5OQDUQklgYmVDycHPamzSMVZMt22CGXHyN0NUZmFu7YGVJ61PLerGqxxkNu6kdqo39wpKRKdzU4pinUUVdl63lZ4XIbJ7Vn3s0xOxQRkc1YskaJQp6nmo7yUrwuCT+lCWpMqtomaAU25bPcirkUsZdZQBhaoOGDkr+NOhDS5H3BWrjc5I4hRLt9d+YFSPjPNUmgAkDOSN3U1NlIgAfmYdKgmnySD0pxjY5q1dz3LEcUCZ+bNVJym5inzY/SoTKArAkqvp3NVSxY8E4NaRick6l9ESy/NIuGyD+lSCJo25GPSqw4kXPTNbuqRRGzt5ISScYJNXsZWuUom2nK9avJdcJySR/D6VShX5GPU9qbjkevagdixrUKtEJIjuJHze1S6O0kuluob5UOTk1TaVliZCeDUnh1gZJI2GVNMXU2/MWeJVDjp39afbgqT03gYIPf6VmJJt3LjO1vyq7DKVdWJGT0JoLLvzLEu4Yb1PaltC43owAfOfrUUjs7/PjNPlkAyqjIx19KQXM3X7bKmTO5u3tT9OnZ7aGVhkxnacdavyAyIBIoYEdap6fD9nvHhYkJJyvtQK5oysJiGUkKoyQRzUJt2eVX3cnkDtVj5ijGYbGHyhvWnRKEjH2ggnPy46UxMyNUs7iCYTQqcf7NJDLbyYaeNopAOSO9dFCWdswMpEf971qK7sIVZjcEGSTqq9qCbmQ7PDEdrefE3SrVsvlgSBssOR/s+1UWge0zsbcmcCpBOASuMcZzTQHR3t/Z31jFNfRO00I2goePxrmb+1jnXfbqfmGdvpUsfLCPdhW59vxqxZzLKdjgIEzljVoylocp9gl/uN+VFdR5kX/Paip5SeYYU45phT24oortOMTZk9KQp7UUUDGslQSRdaKKTWg0yjPF61BE5RyM/Siioi+WSaNLXWpo20+8+h6GrF3dBE2D7xoor0/bSVByW5yKlGVZRZTiDxIZc9Dmtu2jFwqvuKseRRRXy9XVcx9hRVmoo6jTygi2PjOOtX2uwNPZ7UhpYzhhRRXGlqd8lbYyrdfNkMtxwx6L6VNHbeSxdu/pRRWob6jonR5myAr+o71XvHiL4OCV9aKKBmddyHIKfLiodQjL6bnZ8x7+tFFCFN2sYN1bGGNXHU9apW6/6R5jtk+lFFbx1RxVviRckuj5hIOAKo3c7EfKc7j2ooq4xRy1JshyyjJb8Kj80R9GxRRVpHLKbIpLsnIA/Gq4LM4JY560UVpaxldvcdJlmyRSbelFFAiw8QKoQKvo5miSNm4XoKKKRaJVQKx7GopIySSg/CiihjIZo8oD61FpbFLiQA9OaKKaJkamqKsVxHJASY5EyarxsMgc7T60UUuoI0YHLblDZwOCaUCUSqu7g9aKKdgZMDLC5ikyR1Wqd/K7lCchl6EUUUElsXss0arKMhOhpWuRtyScUUU0SWBOPKR4W5HeoPty7jycnue5oopjsMF2HBVlAOeBUckjBs4HNFFIoQuXTaox61Zii2xhh8wYYOe9FFaRMqmwn2b/pkKKKKqxhdn//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20837=[""].join("\n");
var outline_f20_22_20837=null;
var title_f20_22_20838="Acute disseminated encephalomyelitis in children: Treatment and prognosis";
var content_f20_22_20838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute disseminated encephalomyelitis in children: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20838/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20838/contributors\">",
"     Timothy E Lotze, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20838/contributors\">",
"     Donald J Chadwick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20838/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20838/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20838/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20838/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/22/20838/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute disseminated encephalomyelitis (ADEM), also known as postinfectious encephalomyelitis, is a demyelinating disease of the central nervous system that typically presents as a monophasic disorder associated with multifocal neurologic symptoms and disability.",
"   </p>",
"   <p>",
"    This topic will review the prognosis and treatment of ADEM in children. Other aspects of ADEM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ADEM typically present with fever, meningeal signs, acute encephalopathy, and evidence of inflammation in blood and cerebrospinal fluid. Thus, consideration should be given to treatment with broad-spectrum antibiotics and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    until an infectious etiology is excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Antimicrobial therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35640?source=see_link&amp;anchor=H8#H8\">",
"     \"Viral meningitis: Management, prognosis, and prevention in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mainstay of treatment for ADEM is high-dose intravenous glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/1\">",
"     1",
"    </a>",
"    ]. Glucocorticoids may be started at the time of the patient's presentation and can be used concurrently with antibiotics and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    . Additional options include intravenous immune globulin and plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the effectiveness of these treatments (glucocorticoids, intravenous immune globulin, and plasma exchange) for ADEM has not been definitively confirmed, as there are no prospective clinical trial data to determine optimal treatment, including dose or duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several small observational studies, treatment of ADEM with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (10 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, maximum 1000 mg daily) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for three to five days, followed by oral glucocorticoid taper over four to six weeks, was associated with full recovery in approximately 60 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the only study that compared these two treatments for ADEM, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (n=21) was associated with a modestly better outcome, as measured by the median Expanded Disability Status Scale, than intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (n=25), and the difference was statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/5\">",
"     5",
"    </a>",
"    ]. The strength of this result is limited by small patient numbers, lack of randomization, and lack of blinded treatment or assessment.",
"   </p>",
"   <p>",
"    There is no convincing evidence that the use or duration of a tapering oral glucocorticoid regimen after intravenous glucocorticoid therapy influences outcome. Two small observational studies reported higher relapse rates in children with ADEM who were treated with shorter (three weeks or less) compared with longer glucocorticoid tapers, but this finding was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. In addition, the results from one of these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/6\">",
"     6",
"    </a>",
"    ] were confounded by the inclusion of patients who had clinically isolated syndromes. Such patients might have a higher relapse risk compared with those who meet all criteria for the diagnosis of ADEM.",
"   </p>",
"   <p>",
"    We recommend immunosuppressive treatment for ADEM in children, and suggest high-dose intravenous glucocorticoids as initial therapy. Although there is no consensus regarding glucocorticoid regimens, we use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, up to a maximum dose of 1000 mg per day) for five days. We use an oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    taper only in children who continue to show clinical symptoms after completion of the high dose intravenous glucocorticoid treatment. The prednisone taper is typically started at a lower initial dose compared with the intravenous regimen. We begin the taper with oral prednisone 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day up to a maximum of 60 mg per day and then reduce the dose by 10 mg every five days to allow for a total tapering duration of four to six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from small case series and case reports suggest that intravenous immune globulin (IVIG) is beneficial as rescue therapy in patients with ADEM who fail to respond to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/7-9\">",
"     7-9",
"    </a>",
"    ] or as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/10\">",
"     10",
"    </a>",
"    ]. Dosing of IVIG in these studies ranged from 1 to 2",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    given either as a single dose, or divided over three to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No studies have compared IVIG treatment with glucocorticoids or plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest IVIG for patients with ADEM who have an insufficient response to intravenous glucocorticoid treatment. Our preferred regimen is a total of 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    given in divided doses over three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that plasma exchange is beneficial in children with ADEM who fail treatment with intravenous immunoglobulin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. The largest series was retrospective and reported improvement following plasma exchange in six children with ADEM who did not respond to initial treatment with glucocorticoids followed by IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/14\">",
"     14",
"    </a>",
"    ]. In another retrospective study, plasma exchange demonstrated some benefit for patients with idiopathic transverse myelitis when used in combination with intravenous glucocorticoids. Therefore, it may be of particular benefit for patients with ADEM associated with myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest treatment with plasma exchange for children with ADEM who have longitudinally extensive transverse myelitis and who fail treatment with glucocorticoids. Plasma exchange also should be considered for other patients with ADEM who fail to respond to treatment with glucocorticoids and IVIG. Our preferred regimen is a total of six exchanges, one every other day, with each exchange consisting of 1 to 1.5 plasma volumes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute hemorrhagic leukoencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the prognosis for survival and recovery of neurologic function is worse for the hyperacute hemorrhage variants of ADEM, such as acute hemorrhagic leukoencephalitis (AHL), than for typical ADEM. (See",
"    <a class=\"local\" href=\"#H55051393\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A few case reports suggest that early high-dose glucocorticoid treatment may be associated with good recovery in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/5,16\">",
"     5,16",
"    </a>",
"    ] and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/17\">",
"     17",
"    </a>",
"    ] who have hyperacute hemorrhagic variants of ADEM, including AHL. Another case report of an adult with AHL noted that prolonged immunosuppressive therapy with multiple agents (plasmapheresis, steroids, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) was associated with a good recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, we recommend immunosuppressive treatment for children with AHL and other hemorrhagic variants of ADEM. We suggest high-dose glucocorticoids as initial therapy, using intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, up to a maximum dose of 1000 mg per day) for five days, followed by oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, tapered by 5 mg every three days.",
"   </p>",
"   <p>",
"    For children who do not have clinically significant improvement after five days of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , we suggest IVIG (2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    given in divided doses over three days); plasma exchange (a total of six exchanges, one every other day) is an alternative. In addition, we suggest plasma exchange for children with clinical deterioration or lack of clinically significant improvement one week after receiving IVIG therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EXTENDED FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up MRI shows complete or partial resolution of abnormalities in the majority of ADEM cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/3,19,20\">",
"     3,19,20",
"    </a>",
"    ]. However, residual gliosis and demyelination persist in some.",
"   </p>",
"   <p>",
"    Long-term clinical follow-up and sequential imaging by MRI are usually required to confirm the diagnosis of ADEM [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/2\">",
"     2",
"    </a>",
"    ]. The development of relapses with new lesions on MRI is not compatible with a diagnosis of monophasic ADEM, and suggests that the correct diagnosis is either multiphasic ADEM or multiple sclerosis, depending on the clinical and imaging features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\", section on 'Recurrent and multiphasic ADEM'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=see_link\">",
"     \"Differential diagnosis of acute central nervous system demyelination in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although no consensus exists, some experts suggest obtaining at least two additional MRIs after the first normal MRI, over a period of at least five years from the initial episode of ADEM, to confirm the absence of new inflammatory demyelinating lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55051393\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with ADEM make a full recovery, usually slowly over four to six weeks. At follow-up, approximately 60 to 90 percent have minimal or no neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/3-5,21,22\">",
"     3-5,21,22",
"    </a>",
"    ]. Although modern studies of ADEM in children report little or no mortality, earlier studies suggested that the mortality of postinfectious ADEM was as high as 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/23\">",
"     23",
"    </a>",
"    ]. The extent and site of lesions on the initial MRI do not predict the clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/5,24\">",
"     5,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following case series illustrate the range of outcomes for children with ADEM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study included 84 children from Argentina with ADEM [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/5\">",
"       5",
"      </a>",
"      ]. At a mean follow-up of 6.6 years, the neurologic examination was either normal or detected minor abnormalities but no associated disability in 75 children (89 percent). Residual deficits in the remaining children included mild to severe hemiparesis, mild paraparesis, partial epilepsy, reduced visual acuity, and mental handicap.",
"     </li>",
"     <li>",
"      In a retrospective report of 33 children from the United States diagnosed with ADEM according to International Pediatric Multiple Sclerosis Study Group criteria, one child with monophasic ADEM had acute hemorrhagic leukoencephalitis and died, and another died eight years later from lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/22\">",
"       22",
"      </a>",
"      ]. Nine children (27 percent) developed relapses: four with recurrent ADEM, three with multiphasic ADEM, and two (6 percent) with multiple sclerosis. In follow-up (mean 9.2 years), mainly by telephone, complete recovery or only minor neurologic impairment was reported for 30 children (91 percent).",
"      <br/>",
"      <br/>",
"      Diagnostic criteria for monophasic, recurrent and relapsing ADEM are described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link&amp;anchor=H17#H17\">",
"       \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a report from Australia, 31 children with ADEM were followed for an average of 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/4\">",
"       4",
"      </a>",
"      ]. Complete recovery occurred in 25 (81 percent). Mild abnormalities were detected in the remaining six patients; these included recurrent headaches, behavioral problems, esotropia, subtle hemiparesis, and minor gross motor abnormalities.",
"     </li>",
"     <li>",
"      In a study from the United Kingdom, 28 children with ADEM were followed for a mean of 5.8 years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/3\">",
"       3",
"      </a>",
"      ]. A complete recovery occurred in 20 (57 percent). Of the remainder, six patients had motor disabilities, which were severe in three; four had visual impairment; four had cognitive impairment; four had behavior problems; and two had persistent limb paresthesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis for survival and recovery of neurologic function is worse for the hyperacute hemorrhage variants of ADEM, such as acute hemorrhagic leukoencephalitis, than for typical ADEM [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20838/abstract/2\">",
"     2",
"    </a>",
"    ]. Brain edema and subsequent death may occur within a week of the onset of encephalopathy in these uncommon variants. However, immunosuppressive treatment may be associated with improved outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\", section on 'Acute hemorrhagic leukoencephalitis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Acute hemorrhagic leukoencephalitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with acute disseminated encephalomyelitis (ADEM) typically present with fever, meningeal signs, acute encephalopathy, and evidence of inflammation in blood and cerebrospinal fluid. Treatment should be considered with broad-spectrum antibiotics and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      until an infectious etiology is excluded. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with ADEM, we recommend immunosuppressive treatment (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest initial therapy with high-dose glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preferred regimen is intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, up to a maximum dose of 1000 mg per day) for five days, followed by a four to six week oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      taper for those with residual symptoms after intravenous treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with ADEM who have an insufficient response to intravenous glucocorticoid treatment, we suggest intravenous immune globulin treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with ADEM who have longitudinally extensive transverse myelitis and who fail treatment with glucocorticoids, we suggest treatment with plasma exchange (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest plasma exchange for other children with ADEM who fail to respond to treatment with glucocorticoids and IVIG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Plasma exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with AHL and other hemorrhagic variants of ADEM, we recommend immunosuppressive treatment (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest high-dose glucocorticoids as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For children who do not have clinically significant improvement after five days of intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , we suggest IVIG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), followed by plasma exchange for those without clinically significant improvement after IVIG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute hemorrhagic leukoencephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term follow-up should be performed to document recovery and to confirm the diagnosis of ADEM. The occurrence of relapses suggests alternative diagnoses, such as multiphasic ADEM or multiple sclerosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Extended follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with ADEM make a full recovery, usually slowly over four to six weeks. At follow-up, approximately 60 to 90 percent have minimal or no neurologic deficits. (See",
"      <a class=\"local\" href=\"#H55051393\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis for survival and recovery of neurologic function is worse for the hyperacute hemorrhage variants of ADEM, such as acute hemorrhagic leukoencephalitis, than for typical ADEM. (See",
"      <a class=\"local\" href=\"#H55051393\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/1\">",
"      Alper G. Acute disseminated encephalomyelitis. J Child Neurol 2012; 27:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/2\">",
"      Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. Neurology 2007; 68:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/3\">",
"      Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123 Pt 12:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/4\">",
"      Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001; 56:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/5\">",
"      Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002; 59:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/6\">",
"      Anlar B, Basaran C, Kose G, et al. Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics 2003; 34:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/7\">",
"      Kleiman M, Brunquell P. Acute disseminated encephalomyelitis: response to intravenous immunoglobulin. J Child Neurol 1995; 10:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/8\">",
"      Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 1999; 165:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/9\">",
"      Sahlas DJ, Miller SP, Guerin M, et al. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 2000; 54:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/10\">",
"      Nishikawa M, Ichiyama T, Hayashi T, et al. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol 1999; 21:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/11\">",
"      Stricker RB, Miller RG, Kiprov DD. Role of plasmapheresis in acute disseminated (postinfectious) encephalomyelitis. J Clin Apher 1992; 7:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/12\">",
"      Balestri P, Grosso S, Acquaviva A, Bernini M. Plasmapheresis in a child affected by acute disseminated encephalomyelitis. Brain Dev 2000; 22:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/13\">",
"      Miyazawa R, Hikima A, Takano Y, et al. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Brain Dev 2001; 23:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/14\">",
"      Khurana DS, Melvin JJ, Kothare SV, et al. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 2005; 116:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/15\">",
"      Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007; 68:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/16\">",
"      Rosman NP, Gottlieb SM, Bernstein CA. Acute hemorrhagic leukoencephalitis: recovery and reversal of magnetic resonance imaging findings in a child. J Child Neurol 1997; 12:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/17\">",
"      Klein CJ, Wijdicks EF, Earnest F 4th. Full recovery after acute hemorrhagic leukoencephalitis (Hurst's disease). J Neurol 2000; 247:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/18\">",
"      Seales D, Greer M. Acute hemorrhagic leukoencephalitis. A successful recovery. Arch Neurol 1991; 48:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/19\">",
"      Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990; 113 ( Pt 2):291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/20\">",
"      O'Riordan JI, Gomez-Anson B, Moseley IF, Miller DH. Long term MRI follow-up of patients with post infectious encephalomyelitis: evidence for a monophasic disease. J Neurol Sci 1999; 167:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/21\">",
"      Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002; 110:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/22\">",
"      Mar S, Lenox J, Benzinger T, et al. Long-term prognosis of pediatric patients with relapsing acute disseminated encephalomyelitis. J Child Neurol 2010; 25:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/23\">",
"      Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005; 62:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20838/abstract/24\">",
"      Khong PL, Ho HK, Cheng PW, et al. Childhood acute disseminated encephalomyelitis: the role of brain and spinal cord MRI. Pediatr Radiol 2002; 32:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6208 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20838=[""].join("\n");
var outline_f20_22_20838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute hemorrhagic leukoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EXTENDED FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55051393\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=related_link\">",
"      Differential diagnosis of acute central nervous system demyelination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35640?source=related_link\">",
"      Viral meningitis: Management, prognosis, and prevention in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_22_20839="Enalaprilat (intravenous): Drug information";
var content_f20_22_20839=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enalaprilat (intravenous): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/24/17796?source=see_link\">",
"    see \"Enalaprilat (intravenous): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/20/19783?source=see_link\">",
"    see \"Enalaprilat (intravenous): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13657030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13655454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vasotec&reg; I.V",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13655457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13657009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe congestive heart failure, decreased renal function, or in those receiving diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Avoid I.V. administration in patients with unstable heart failure or those suffering acute myocardial infarction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     I.V.: 1.25 mg/dose, given over 5 minutes every 6 hours; doses as high as 5 mg/dose every 6 hours have been tolerated for up to 36 hours.",
"     <b>",
"      Note:",
"     </b>",
"     If patients are concomitantly receiving diuretic therapy, begin with 0.625 mg I.V. over 5 minutes; if the effect is not adequate after 1 hour, repeat the dose and administer 1.25 mg at 6-hour intervals thereafter; if adequate, administer 0.625 mg I.V. every 6 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Conversion from I.V.",
"     </i>",
"     <b>",
"      <i>",
"       enalaprilat",
"      </i>",
"     </b>",
"     <i>",
"      to oral",
"     </i>",
"     <b>",
"      <i>",
"       enalapril",
"      </i>",
"     </b>",
"     therapy: If not concurrently receiving diuretics, initiate enalapril 5 mg once daily; if concurrently receiving diuretics and responding to enalaprilat 0.625 mg I.V. every 6 hours, initiate with enalapril 2.5 mg once daily; subsequent titration as needed.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13657010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13657007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Manufacturer&rsquo;s recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Initiate with 0.625 mg; if after 1 hour clinical response is unsatisfactory, may repeat. May then administer 1.25 mg every 6 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intermittent hemodialysis (IHD): Moderately dialyzable (20% to 50%): Initial: 0.625 mg I.V. over a period of 5-60 minutes (60-minute infusion duration preferred)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion from I.V.",
"     <b>",
"      enalaprilat",
"     </b>",
"     to oral",
"     <b>",
"      enalapril",
"     </b>",
"     therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: May initiate enalapril 5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: May initiate enalapril 2.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alternate recommendations (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% to 100% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary, although some removal of drug occurs.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13657006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary for patients with hepatic impairment; enalaprilat does not undergo hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13657027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1.25 mg/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13655455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13657011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. push undiluted over at least 5 minutes or as an infusion with a diluted solution; discontinue diuretic, if possible, for 2-3 days before beginning enalaprilat therapy.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13655528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in dextrose 5%, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, hetastarch 6% in NS, Normosol&reg;-R, NS, Plasma-Lyte&reg; A.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amikacin, aminophylline,  ampicillin, ampicillin/sulbactam, aztreonam, bivalirudin, butorphanol, calcium gluconate, cefazolin, ceftazidime, chloramphenicol, cimetidine, cisatracurium, cladribine, clindamycin, dexmedetomidine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin liposome, erythromycin lactobionate, esmolol, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, ganciclovir, gemcitabine, gentamicin, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, labetalol, lidocaine, linezolid, magnesium sulfate, melphalan, meropenem, methylprednisolone sodium succinate, metronidazole, morphine, nafcillin, nicardipine, nitroprusside, oxaliplatin, pemetrexed, penicillin G potassium, phenobarbital, piperacillin, piperacillin/tazobactam, potassium chloride, potassium phosphates, propofol, ranitidine, remifentanil, sodium acetate, sulfamethoxazole/trimethoprim, teniposide, thiotepa, tobramycin, vancomycin, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, cefepime, nesiritide, pantoprazole, phenytoin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Compatibility in syringe: Incompatible: Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13655459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension when oral therapy is not practical",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13655460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe congestive heart failure in infants, acute cardiogenic pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13655452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13655520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Since enalapril is converted to enalaprilat, adverse reactions associated with enalapril may also occur with enalaprilat (also refer to Enalapril monograph). Frequency ranges include data from hypertension and heart failure trials. Higher rates of adverse reactions have generally been noted in patients with CHF. However, the frequency of adverse effects associated with placebo is also increased in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, constipation, cough, dizziness, fatigue, fever, MI, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13655465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enalapril or enalaprilat; angioedema related to previous treatment with an ACE inhibitor; patients with idiopathic or hereditary angioedema; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13655466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Based on human data, ACEIs can cause injury and death to the developing fetus when used in the second and third trimesters. ACEIs should be discontinued as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Benzyl alcohol: Injection contains benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13382876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13382875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13655525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may worsen hypertension). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13655461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (1st trimester); D (2nd and 3rd trimesters) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13655462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Enalaprilat, the active metabolite of enalapril, crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. The use of these drugs in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13655463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13655464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enalapril and enalaprilat are excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13657014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit salt substitutes or potassium-rich diet.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Enalaprilat Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg/mL (1 mL): $3.41",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13657015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum creatinine and potassium; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13665795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13656999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: I.V.: &le;15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: I.V.: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: I.V.: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~50%  (Davies, 1984)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Infants 6 weeks to 8 months of age: 6-10 hours (Lloyd, 1989); Adults: ~35 hours (Till, 1984; Ulm, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&gt;90% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Bellissant E, Pussard E, et al, &ldquo;Placebo-Controlled, Randomized, Double-Blind Study of Intravenous Enalaprilat Efficacy and Safety in Acute Cardiogenic Pulmonary Edema,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1996, 94(6):1316-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/8822986/pubmed\" id=\"8822986\" target=\"_blank\">",
"        8822986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies RO, Gomez HJ, Irvin JD, et al, \"An Overview of the Clinical Pharmacology of Enalapril,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1984, 18(Suppl 2):215-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/6099737/pubmed\" id=\"6099737\" target=\"_blank\">",
"        6099737",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):66-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/10669188/pubmed\" id=\"10669188\" target=\"_blank\">",
"        10669188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lloyd TR, Mahoney LT, Knoedel D, et al, &ldquo;Orally Administered Enalapril for Infants With Congestive Heart Failure: A Dose-Finding Study,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(4):650-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/2538615/pubmed\" id=\"2538615\" target=\"_blank\">",
"        2538615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakamura H, Ishii M, Sugimura T, et al, &ldquo;The Kinetic Profiles of Enalapril and Enalaprilat and Their Possible Developmental Changes in Pediatric Patients With Congestive Heart Failure,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1994, 56(2):160-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/8062492/pubmed\" id=\"8062492\" target=\"_blank\">",
"        8062492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Till AE, Gomez HJ, Hichens M, et al,  \"Pharmacokinetics of Repeated Single Oral Doses of Enalapril Maleate (MK-421) in Normal Volunteers,\"",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 1984,  5(3):273-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/6091806/pubmed\" id=\"6091806\" target=\"_blank\">",
"        6091806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ulm EH, Hichens M, Gomez HJ, et al, \"Enalapril Maleate and a Lysine Analogue (MK-521): Disposition in Man,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1982, 14(3):357-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/22/20839/abstract-text/6289858/pubmed\" id=\"6289858\" target=\"_blank\">",
"        6289858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17094 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20839=[""].join("\n");
var outline_f20_22_20839=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657030\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655454\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655457\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657009\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657010\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657007\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657006\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657027\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655455\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657011\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655528\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655459\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655460\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655452\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655520\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655465\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655466\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382876\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382875\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655525\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655461\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655462\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655463\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655464\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657014\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322921\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657015\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13665795\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13656999\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17094|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/24/17796?source=related_link\">",
"      Enalaprilat (intravenous): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/20/19783?source=related_link\">",
"      Enalaprilat (intravenous): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_22_20840="Management of cardiopulmonary arrest in pregnancy";
var content_f20_22_20840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of cardiopulmonary arrest in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20840/contributors\">",
"     Carolyn M Zelop, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20840/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20840/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20840/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20840/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20840/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/22/20840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2271108705\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary arrest during pregnancy presents a unique clinical scenario involving two patients: the mother and the fetus. Management of these patients demands a rapid multidisciplinary approach, including anesthesiology, medicine, obstetrics, neonatology and sometimes cardiothoracic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/1\">",
"     1",
"    </a>",
"    ]. Basic and advanced cardiac life support algorithms should be implemented; however, the physiological and anatomical changes of pregnancy require some modifications to these protocols. Randomized trials of approaches to management of pregnant women with cardiopulmonary arrest are lacking so recommendations for these modifications are based on data from small case series and small cohort studies involving patients with cardiac arrest during cesarean delivery, and expert opinion.",
"   </p>",
"   <p>",
"    This topic will focus on management of cardiopulmonary arrest during pregnancy. Management of cardiac arrest in nonpregnant populations is reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"       \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link\">",
"       \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"       \"Advanced cardiac life support (ACLS) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"       \"Pathophysiology and etiology of sudden cardiac arrest\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=see_link\">",
"       \"Therapies of uncertain benefit in basic and advanced cardiac life support\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2271108991\">",
"    <span class=\"h1\">",
"     PREVALENCE OF CARDIAC ARREST IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of cardiac arrest in pregnant women varies from",
"    <span class=\"nowrap\">",
"     1/20,000",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/50,000",
"    </span>",
"    ongoing pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The increasing prevalence and severity of maternal obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/4\">",
"     4",
"    </a>",
"    ], rising cesarean delivery rates, and advances in reproductive options for women with chronic illnesses and at older ages have elevated the medical acuity level of obstetrical practice and may be elevating the frequency of cardiac arrest in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057205\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrest may be related to conditions unique to pregnancy or etiologies found in the nongravid state (",
"    <a class=\"graphic graphic_table graphicRef70707 \" href=\"UTD.htm?28/48/29452\">",
"     table 1",
"    </a>",
"    ). In one review, the most common causes in pregnant women in the United States and United Kingdom were: pulmonary embolism (29 percent), hemorrhage (17 percent), sepsis (13 percent), peripartum cardiomyopathy (8 percent), stroke (5 percent), preeclampsia-eclampsia (2.8 percent), complications related to anesthesia (eg, difficult or failed intubation, local anesthetic toxicity, aspiration) (2 percent), amniotic fluid embolism, myocardial infarction, pre-existing cardiac disease (congenital, acquired, cardiomyopathy), and trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/5\">",
"     5",
"    </a>",
"    ]. Reversible causes of cardiac arrest should be treated promptly (eg, electrolyte abnormalities, tamponade, hypothermia, hypovolemia, hypoxia, hypomagnesemia, myocardial infarction, poisoning, pulmonary embolism, tension pneumothorax). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057212\">",
"    <span class=\"h1\">",
"     RESUSCITATION DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitation of the pregnant women involves:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Call a maternal code blue, which should include a multi-disciplinary team",
"     </li>",
"     <li>",
"      If the uterus is above the umbilicus, displace the uterus laterally and to the left (ie, left uterine displacement)",
"     </li>",
"     <li>",
"      Initiate the ABCs using pregnancy modifications",
"     </li>",
"     <li>",
"      Estimate the gestational age of the fetus (See",
"      <a class=\"local\" href=\"#H2293214610\">",
"       'Determining gestational age'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the uterine fundus is &ge;4 fingerbreadths above the umbilicus, at four minutes, begin perimortem cesarean delivery and complete delivery by five minutes following cardiac arrest (See",
"      <a class=\"local\" href=\"#H9057240\">",
"       'Delivery as part of the resuscitation process'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"     <li>",
"      At 15 minutes, if resuscitation remains unsuccessful, initiate direct cardiac massage if appropriate resources and personnel are available [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Thoracotomy and open chest message would be particularly effective for patients with chest trauma, tension pneumothorax, massive pulmonary embolism, pericardial tamponade, and in patients with chest or spine deformities. (See",
"      <a class=\"local\" href=\"#H9057261\">",
"       'Additional interventions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ongoing interventions: evaluate need to institute cardiopulmonary bypass therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9057261\">",
"       'Additional interventions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Continue resuscitation measures until all resources and attempts have been exhausted. This will vary depending upon the clinical circumstances and resources of the facility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16030782\">",
"    <span class=\"h1\">",
"     ABCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ABCs (airway, breathing, circulation) of resuscitation are well-described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In pregnant women with uterine fundal height at or beyond the umbilicus, the uterus should be displaced to the patient&rsquo;s left to minimize aortocaval compression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9057219\">",
"     'Avoiding aortocaval compression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Active airway management is the initial consideration. Pregnant women are at increased risk of rapidly developing hypoxemia because of decreased functional residual capacity and increased oxygen consumption. Both intubation and bag mask ventilation can be more difficult in the late stages of pregnancy and back-up airway procedures, including cricothyrotomy, may be required in some cases. The increased risk of aspiration and narrowing of upper airways, particularly in the third trimester, require special consideration during pregnancy. Intubation via direct or video laryngoscopy using cricoid pressure and 100 percent oxygen is performed using a smaller sized endotracheal tube (0.5 mm to 1.0 mm less in internal diameter compared to that used for nonpregnant women). Endotracheal tube placement should be verified using capnography or an esophageal detector device. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34248?source=see_link\">",
"     \"Airway management of pregnant women at delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For chest compressions, hand placement should be more cephalad than in nonpregnant women to accommodate the upward displacement of the diaphragm by the gravid uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/9\">",
"     9",
"    </a>",
"    ]. Although specific landmarks have not been established, we suggest performing chest compressions slightly above the center of the sternum to adjust for the elevation of the diaphragm associated with the gravid uterus.",
"   </p>",
"   <p>",
"    Intravenous access should be established above the groin area since drugs administered via the femoral vein may not reach the maternal heart until the fetus is delivered. Access to an antecubital vein with two 14-gauge catheters can be as effective as central line catheters for volume replacement, but do not allow hemodynamic monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/6\">",
"     6",
"    </a>",
"    ]. In the absence of intravenous access, the endotracheal tube can be used to administer certain medications including:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , and epinephrine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057219\">",
"    <span class=\"h2\">",
"     Avoiding aortocaval compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supine positioning optimizes the vectors required for effective chest compressions in the nonpregnant patient; however, left lateral uterine displacement is necessary in the pregnant patient with fundal height at, or above, the umbilicus, to minimize aortocaval compression (supine hypotensive syndrome), optimize venous return, and generate cardiac output during CPR. Methods to achieve left lateral uterine displacement include: manual uterine displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/10\">",
"     10",
"    </a>",
"    ], tilt of the operating room table, or placement of a resuscitation wedge (eg, Cardiff wedge) or rolled up towels or blankets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/11\">",
"     11",
"    </a>",
"    ]. If a suitable wedge is not available, the patient can be tilted upon a rescuer (the rescuer sits on",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    heels and uses",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    thighs as a wedge under the patient) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/12\">",
"     12",
"    </a>",
"    ]. We suggest manual uterine displacement since it preserves the supine positioning of the upper torso for optimal chest compression vector forces.",
"   </p>",
"   <p>",
"    A randomized trial comparing manual uterine displacement versus operating room table tilt during cesarean delivery demonstrated significantly fewer episodes of hypotension and a lower ephedrine requirement in the group of patients undergoing manual uterine displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, a study that used a calibrated force transducer to assess the maximum chest compression force generated at various angles of inclination in late pregnancy found that maximum resuscitative force (expressed as percent body weight) decreased from 67 percent in the supine position to 36 percent in the full lateral position [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/11\">",
"     11",
"    </a>",
"    ]. Optimal compressive force was achieved at an angle of 27 degrees and was 57 percent (80 percent of the force generated in the supine position).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2271109417\">",
"    <span class=\"h2\">",
"     Defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of ventricular arrhythmias may require defibrillation during maternal resuscitation. The physiological changes of pregnancy, including increases in blood volume and decreases in functional residual capacity, do not appear to alter transthoracic impedance or transmyocardial current [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/13\">",
"     13",
"    </a>",
"    ]. Therefore, current energy requirements for adult defibrillation are appropriate for use in pregnant women. Before delivering the countershock, remove fetal monitoring equipment to prevent electrocution injury to the patient or rescuers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2293214610\">",
"    <span class=\"h2\">",
"     Determining gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnant women, determining gestational age is critical, as the likelihood of neonatal viability is a factor in decision-making. If the prenatal record is not available, physical examination can aid in establishing the gestational age. Uterine size correlates with gestational age, but can be misleading in some situations, such as when there is a multiple gestation, large fibroids, or severe oligohydramnios or polyhydramnios. The formula for estimating gestational age by physical examination is: distance from the top of the symphysis pubis to the top of the fundus (cm) = gestational age (weeks). Ultrasound is a reliable method for gestational age assessment, but may not be possible due to time and logistical constraints during maternal assessment and resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057226\">",
"    <span class=\"h2\">",
"     Fetal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the status of the mother should guide management during the resuscitation process; if the status of the mother is poor and deteriorating, the status of the fetus will be further compromised. Therefore, fetal monitoring is not recommended during the resuscitation process. If CPR is successful and the mother becomes hemodynamically stable, fetal monitors can be applied to assess the status of the fetus who is at a potentially viable gestational age. Intervention (in utero resuscitation measures, delivery) for nonreassuring fetal status depends on maternal- and fetal-specific factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link&amp;anchor=H26#H26\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Management of nonreassuring FHR patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057240\">",
"    <span class=\"h2\">",
"     Delivery as part of the resuscitation process",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite implementation of maneuvers to ameliorate aortocaval compression, CPR may not restore spontaneous circulation or provide adequate cardiac output. Blood flow during CPR is produced by mechanical compression of the heart between the sternum and the spine and phasic fluctuations in intrathoracic pressure. Despite appropriate use of leftward uterine displacement, the mechanical effects of the gravid uterus can decrease venous return from the inferior vena cava, obstruct blood flow through the abdominal aorta, and diminish thoracic compliance, all of which contribute to unsuccessful CPR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/14\">",
"     14",
"    </a>",
"    ]. Without restoration of cardiac output, both mother and fetus are at risk for hypoxia and eventually anoxia, especially when interruption of normal cardiac and respiratory function persists beyond four minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/15\">",
"     15",
"    </a>",
"    ]. Although it may be counterintuitive to operate on a hemodynamically unstable patient, cesarean delivery may be life-saving for both mother and fetus in this situation. Delivery of the baby empties the uterus, relieving the aortocaval compression. This results in a 60 to 80 percent increase in cardiac output, thereby increasing the likelihood of maternal survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Heart Association recommends cesarean delivery if maternal resuscitative efforts have not been successful within four minutes. The rationale for this approach is that [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Irreversible brain damage can occur in nonpregnant individuals after four to six minutes of anoxia",
"     </li>",
"     <li>",
"      Pregnant women become anoxic sooner than nonpregnant women because of decreased functional residual capacity",
"     </li>",
"     <li>",
"      If the uterine fundus is &ge;4 fingerbreadths above the umbilicus [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/20\">",
"       20",
"      </a>",
"      ], ineffective resuscitation efforts may become effective when the uterus is no longer gravid and potentially causing aortocaval compression",
"     </li>",
"     <li>",
"      Intact fetal survival diminishes as the time between maternal death and delivery lengthens &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2349341435\">",
"    <span class=\"h3\">",
"     \"Five minute rule\"",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there have been no controlled clinical trials in this area, a review of case reports of perimortem cesarean delivery from 1900 to 1985 suggested that normal neonatal neurological outcome was most likely when delivery occurred within five minutes of maternal cardiac arrest. In this series, 42 of 42 infants delivered within five minutes had a normal neurological outcome compared with 7 of 8 infants delivered within 6 to 10 minutes, 6 of 7 infants delivered within 11 to 15 minutes, 0 of 1 infant delivered between 16 and 20 minutes, and 1 of 3 infants delivered within 21 to 25 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors&rsquo; subsequent evaluation of perimortem cesarean cases reported from 1985 to 2004 noted perimortem cesarean was associated with spontaneous return of maternal circulation or improvement in maternal hemodynamic status in 12 of 20 cases, particularly when the delivery was performed within five minutes of maternal arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/20\">",
"     20",
"    </a>",
"    ]. No case of perimortem cesarean delivery resulted in deterioration of the maternal condition, although these case reports are highly subject to reporting bias. Similarly, neonatal outcomes were best when delivery occurred within five minutes; 9 of 12 infants delivered within this time frame had a normal neurological outcome (neonatal outcome was not reported for three infants); two of six infants born from 6 to 15 minutes after maternal cardiac arrest had normal outcomes (one infant outcome was not reported), and four of seven infants delivered after 15 minutes of maternal arrest had normal outcomes. Additional features favoring infant survival include absence of sustained prearrest maternal hypoxia, minimal or no signs of fetal distress before maternal cardiac arrest, aggressive and effective resuscitative efforts for the mother, and neonatal intensive care unit on site of the emergency cesarean delivery. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2349341428\">",
"    <span class=\"h3\">",
"     Minimum gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum gestational age for perimortem cesarean delivery is controversial. Although physiologically aortocaval compression begins as early as 20 weeks, there is some imprecision within the range of 20 to 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/8\">",
"     8",
"    </a>",
"    ]. Neonatal viability is also an imprecise assessment, as it is uncertain which extremely preterm infants, particularly those born at 23 and 24 weeks of gestation, have a reasonable chance of survival without severe deficits. Most centers would provide full neonatal support to infants at least 24 weeks of gestation and some centers provide this level of care to infants greater than 22 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .). Given these variables, perimortem hysterotomy is a reasonable option for pregnancies believed to be at least 22 to 24 weeks of gestation by the best available information or when the uterus is at or cephalad to the umbilicus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/6,20\">",
"     6,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057247\">",
"    <span class=\"h2\">",
"     Delivery issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, perimortem cesarean should be performed within five minutes after cardiac arrest, thus transporting the patient to an operating room is not a priority [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/23\">",
"     23",
"    </a>",
"    ]. An emergency cesarean delivery kit should be part of the resuscitation cart in patient care areas that commonly serve pregnant women or transported to the location of the pregnant patient who has arrested. In the United States, there are no published reports of physician liability for performing perimortem cesarean delivery without consent following maternal cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest compressions should be continued without interruption until return of spontaneous circulation and broad spectrum antibiotics should be administered to decrease the risk of postpartum infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link&amp;anchor=H9#H9\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest a vertical skin incision to provide fast entry, adequate uterine exposure, and access to the diaphragm, which may be useful for further resuscitative interventions (see",
"    <a class=\"local\" href=\"#H9057261\">",
"     'Additional interventions'",
"    </a>",
"    below). Bleeding may be minimal during the procedure due to hypoperfusion. Extraction of the placenta and closure of the hysterotomy are important steps to prevent subsequent hemorrhage when hemodynamic stability is eventually restored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057254\">",
"    <span class=\"h2\">",
"     Use of medications for CPR during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the lethality of cardiopulmonary arrest, the benefits from use of potentially life-saving drugs outweigh any known or possible fetal risks. All medications for treatment of cardiopulmonary arrest in the nonpregnant patient are used for the pregnant patient.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is commonly used in obstetrics for a variety of indications (prevention of eclamptic seizures, fetal neuroprotection before preterm delivery, tocolysis). If magnesium toxicity is suspected, magnesium sulfate infusion should be discontinued and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    (10 mL of a 10 percent solution) should be given early in the resuscitation process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACLS guidelines do NOT recommend routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    during CPR, but it may be useful in life-threatening hyperkalemia or tricyclic antidepressant overdose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=see_link\">",
"     \"Therapies of uncertain benefit in basic and advanced cardiac life support\"",
"    </a>",
"    .). However, if neither of these conditions is known or strongly suspected to be present, bicarbonate is not indicated and may worsen fetal acidosis. Since bicarbonate crosses the placenta very slowly, overcorrection of maternal acidosis will lead to pooling of carbon dioxide in the fetal compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arryhthmias are difficult to control, especially those resulting from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    toxicity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    , a primary drug in the ACLS arrhythmia treatment algorithm, is the favored treatment for severe bupivacaine-induced arrhythmias; administration of the local anesthetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    to treat local anesthetic toxicity is not indicated as it has had equivocal success [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/24\">",
"     24",
"    </a>",
"    ]. The arrhythmias are often recalcitrant to therapy; emergency cardiopulmonary bypass may be lifesaving until the drug dissociates from cardiac tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early administration of lipid emulsion (eg, 20 percent intralipid) is becoming a significant component in resuscitation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    -induced cardiotoxicity. This therapy, which theoretically acts as a lipid sink that binds lipid soluble local anesthetics, has rapidly gained acceptance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/26\">",
"     26",
"    </a>",
"    ] since the first case reports documenting its efficacy were published in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Although the timing of administration may be controversial since its \"lipid sink\" mechanism of action may interfere with lipophilic medications administered during ACLS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/29\">",
"     29",
"    </a>",
"    ], lipid rescue should be initiated at the first signs of severe systemic local anesthetic toxicity, while the airway is being secured. An intravenous bolus of 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    lean body mass of 20 percent lipid emulsion is given over one minute, followed by an infusion of 0.25",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    until at least 10 minutes following successful achievement of circulatory stability. If circulatory stability is not obtained within five minutes, a second 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    bolus may be administered, followed by an infusion of 0.5",
"    <span class=\"nowrap\">",
"     mL/kg/min.",
"    </span>",
"    The maximum total cumulative dose of lipid is 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the anesthetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    is formulated as a 10 percent lipid emulsion, it should not be used for lipid rescue, since the dose needed to treat local anesthetic toxicity would result in massive hypotension that may counteract any positive effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057261\">",
"    <span class=\"h1\">",
"     ADDITIONAL INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After 15 minutes of unsuccessful closed chest CPR, direct cardiac massage via thoracotomy or through the diaphragm (if the abdomen is open) can be implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/31\">",
"     31",
"    </a>",
"    ]. Direct cardiac massage results in near normal systemic perfusion throughout the compression cycle and with higher cranial and myocardial flow than achieved with external chest compressions of conventional CPR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Widespread availability of cardiothoracic surgery and perfusionist teams offers an alternative strategy for continued resuscitation during cardiopulmonary arrest in the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/6\">",
"     6",
"    </a>",
"    ]. Transesophageal echocardiography is a quick, portable, and reliable means of identifying potential causes of hemodynamic collapse during labor and delivery. It can help in the evaluation of the placement of venous and arterial cannulae for extracorporeal membranous oxygenation, the placement and effect of intraaortic balloon counterpulsation, or the effects of inotropic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/33\">",
"     33",
"    </a>",
"    ]. Intraaortic balloon pump, cardiopulmonary bypass, and extracorporeal membrane oxygenation have been used to treat patients with cardiovascular collapse, including those with pulmonary embolism, local anesthetic toxicity, illicit drug use such as cocaine, amniotic fluid embolism and pulseless electrical activity. Case reports have described successful resuscitation using cardiopulmonary bypass intraoperatively during cesarean delivery and postpartum in women with amniotic fluid embolism and pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, use of this technology is hampered by the preparation time required to institute the intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=see_link\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=see_link\">",
"     \"Amniotic fluid embolism syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The induction of mild to moderate hypothermia (target temperature 32 to 34&ordm;C for 24 hours) may be beneficial in patients after successful resuscitation from cardiac arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link&amp;anchor=H11#H11\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'Induced hypothermia'",
"    </a>",
"    .). It has been successfully used in a pregnant woman resuscitated after a cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For pregnant women with ST elevation myocardial infarction, percutaneous coronary intervention is the preferred reperfusion strategy since fibrinolytics are relatively contraindicated in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful fibrinolysis has been reported for massive pulmonary embolism and for ischemic stroke during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/37\">",
"     37",
"    </a>",
"    ]. Management of pulmonary embolism and ischemic stroke including fibrinolysis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H904493470\">",
"    <span class=\"h1\">",
"     MATERNAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter study reported outcomes of 55 women with a cardiac arrest during pregnancy, including 12 women who underwent perimortem cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20840/abstract/3\">",
"     3",
"    </a>",
"    ]. In total, only 15 percent (8 of 55) of the women survived. Perimortem cesarean delivery was not associated with a higher survival rate (17 versus 14 percent). However, none of the perimortem cesarean deliveries were performed within the recommended five minutes (see",
"    <a class=\"local\" href=\"#H2349341435\">",
"     '\"Five minute rule\"'",
"    </a>",
"    above). Cardiac output was regained in 67 percent (8 of 12) of women after perimortem cesarean delivery; two women (17 percent) and five infants (42 percent) survived.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9057268\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of cardiopulmonary arrest in pregnant women are pulmonary embolism, amniotic fluid embolism, hemorrhage, sepsis, cardiomyopathy, stroke, preeclampsia-eclampsia, and complications related to anesthesia (eg, difficult or failed intubation, local anesthetic toxicity, aspiration). (See",
"      <a class=\"local\" href=\"#H9057205\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192411829\">",
"    <span class=\"h2\">",
"     Resuscitation of the pregnant women",
"    </span>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H9057212\">",
"     'Resuscitation during pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Call a maternal code blue, which, ideally, activates a multi-disciplinary team",
"     </li>",
"     <li>",
"      Place firm support under the patient",
"     </li>",
"     <li>",
"      Modify the ABCs for pregnancy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Remove fetal and uterine monitoring devices, if present (See",
"      <a class=\"local\" href=\"#H2271109417\">",
"       'Defibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Displace the uterus laterally and to the left using a wedge or rolled",
"      <span class=\"nowrap\">",
"       towels/blankets",
"      </span>",
"      while leaving the upper body supine rather than tilting the entire patient (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9057219\">",
"       'Avoiding aortocaval compression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secure the airway using 100 percent oxygen, cricoid pressure, and a slightly smaller endotracheal tube (0.5 mm to 1.0 mm less in internal diameter compared to that used for nonpregnant women). (See",
"      <a class=\"local\" href=\"#H16030782\">",
"       'ABCs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For chest compressions, hand placement is more cephalad than that used for nonpregnant women. We suggest performing chest compressions slightly above the center of the sternum (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16030782\">",
"       'ABCs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimate the gestational age of the fetus (using prenatal record, physical examination, or ultrasound), as it is a factor in the decision making process. (See",
"      <a class=\"local\" href=\"#H2293214610\">",
"       'Determining gestational age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest perimortem cesarean delivery with delivery of the infant within five minutes of maternal cardiac arrest (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Maternal and neonatal outcomes are best when delivery occurs within five minutes of maternal cardiac arrest: normal neurological outcome is possible for both mother and child. (See",
"      <a class=\"local\" href=\"#H9057240\">",
"       'Delivery as part of the resuscitation process'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Zelop CM, Grimes EP. Cardiopulmonary Resuscitation in Pregnancy. In: The textbook of Emergency Cardiovascular Care and CPR, Field JM, Kudenchuk PJ, O'Connor RE (Eds), Wolters Kluwer, Philadelphia 2009. p.538.",
"    </li>",
"    <li>",
"     Lewis, G. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers&rsquo; Lives: Reviewing Maternal Deaths to make Motherhood Safer 2003-2005. The Seventh Confidential Enquiry into Maternal Deaths in the United Kingdom. RCOG Press. 2007.",
"    </li>",
"    <li>",
"     Dijkman, A, Huisman, CM, Smit, M, et al. Cardiac arrest in pregnancy: increasing use of perimortem caesarean section due to emergency skills training? Bjog; 117:282.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/4\">",
"      Catalano PM. Management of obesity in pregnancy. Obstet Gynecol 2007; 109:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/5\">",
"      Suresh MS, LaToya Mason C, Munnur U. Cardiopulmonary resuscitation and the parturient. Best Pract Res Clin Obstet Gynaecol 2010; 24:383.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson MD, Luppi CJ, Over DC. Cardiopulmonary Resuscitation. In: Obstetric Anesthesia and Uncommon problems, Gambling, DR, Douglas, MJ (Eds), Saunders, Philadelphia 1998. p.51.",
"    </li>",
"    <li>",
"     Doan-Wiggins L. Resuscitation of the pregnant patient suffering death. In: Cardiac Arrest: the science and practice of resuscitation medicine, Turrentine MA, Braems G, Ramirez MM (Eds), Williams and Wilkins, Philadelphia 1997. p.812.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/8\">",
"      Ueland K, Novy MJ, Peterson EN, Metcalfe J. Maternal cardiovascular dynamics. IV. The influence of gestational age on the maternal cardiovascular response to posture and exercise. Am J Obstet Gynecol 1969; 104:856.",
"     </a>",
"    </li>",
"    <li>",
"     Cummins RO, Hazinski MF, Zelop CM. Cardiac arrest associated with pregnancy. In: ACLS: The reference textbook, Cummins RO, Hazinski MF, Field J (Eds), AHA, Dallas 2005. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/10\">",
"      Kundra P, Khanna S, Habeebullah S, Ravishankar M. Manual displacement of the uterus during Caesarean section. Anaesthesia 2007; 62:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/11\">",
"      Rees GA, Willis BA. Resuscitation in late pregnancy. Anaesthesia 1988; 43:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/12\">",
"      Goodwin AP, Pearce AJ. The human wedge. A manoeuvre to relieve aortocaval compression during resuscitation in late pregnancy. Anaesthesia 1992; 47:433.",
"     </a>",
"    </li>",
"    <li>",
"     Nanson, J, Elcock, D, Williams, M, Deakin, CD. Do physiological changes in pregnancy change defibrillation energy requirements? British J of Anaesthesia 2001; 87:237.",
"    </li>",
"    <li>",
"     Troiano, NH. Cardiopulmonary resuscitation of the pregnant woman. J Perinat Neonatal Nurs 1989; 3:1.",
"    </li>",
"    <li>",
"     Dildy, GA, Clark, SL. Cardiac arrest during pregnancy. Obstet Gynec Clin North Am 1995; 22:303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/16\">",
"      Hill CC, Pickinpaugh J. Trauma and surgical emergencies in the obstetric patient. Surg Clin North Am 2008; 88:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/17\">",
"      O'Connor RL, Sevarino FB. Cardiopulmonary arrest in the pregnant patient: a report of a successful resuscitation. J Clin Anesth 1994; 6:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/18\">",
"      Cordero DR, Toffle RC, McCauley CS. Cardiopulmonary arrest in pregnancy: the role of caesarean section in the resuscitative protocol. W V Med J 1992; 88:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/19\">",
"      DePace NL, Betesh JS, Kotler MN. 'Postmortem' cesarean section with recovery of both mother and offspring. JAMA 1982; 248:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/20\">",
"      Katz V, Balderston K, DeFreest M. Perimortem cesarean delivery: were our assumptions correct? Am J Obstet Gynecol 2005; 192:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/21\">",
"      Katz VL, Dotters DJ, Droegemueller W. Perimortem cesarean delivery. Obstet Gynecol 1986; 68:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/22\">",
"      Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity--moving beyond gestational age. N Engl J Med 2008; 358:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/23\">",
"      Lipman S, Daniels K, Cohen SE, Carvalho B. Labor room setting compared with the operating room for simulated perimortem cesarean delivery: a randomized controlled trial. Obstet Gynecol 2011; 118:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/24\">",
"      Weinberg GL. Current concepts in resuscitation of patients with local anesthetic cardiac toxicity. Reg Anesth Pain Med 2002; 27:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/25\">",
"      Soltesz EG, van Pelt F, Byrne JG. Emergent cardiopulmonary bypass for bupivacaine cardiotoxicity. J Cardiothorac Vasc Anesth 2003; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/26\">",
"      Picard J, Ward SC, Zumpe R, et al. Guidelines and the adoption of 'lipid rescue' therapy for local anaesthetic toxicity. Anaesthesia 2009; 64:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/27\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology 2006; 105:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/28\">",
"      Litz RJ, Popp M, Stehr SN, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia 2006; 61:800.",
"     </a>",
"    </li>",
"    <li>",
"     Weinberg, GL. Lipid infusion therapy: translational to clinical practice. Anesthesia and Analgesia 2008; 106:1340. www.lipidrescue.org",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/30\">",
"      Weinberg GL. Treatment of local anesthetic systemic toxicity (LAST). Reg Anesth Pain Med 2010; 35:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/31\">",
"      Lee RV, Rodgers BD, White LM, Harvey RC. Cardiopulmonary resuscitation of pregnant women. Am J Med 1986; 81:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/32\">",
"      Babbs CF. Hemodynamic mechanisms in CPR: a theoretical rationale for resuscitative thoracotomy in non-traumatic cardiac arrest. Resuscitation 1987; 15:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/33\">",
"      Ecker JL, Solt K, Fitzsimons MG, MacGillivray TE. Case records of the Massachusetts General Hospital. Case 40-2012. A 43-year-old woman with cardiorespiratory arrest after a cesarean section. N Engl J Med 2012; 367:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/34\">",
"      Marty AT, Hilton FL, Spear RK, Greyson B. Postcesarean pulmonary embolism, sustained cardiopulmonary resuscitation, embolectomy, and near-death experience. Obstet Gynecol 2005; 106:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/35\">",
"      Stanten RD, Iverson LI, Daugharty TM, et al. Amniotic fluid embolism causing catastrophic pulmonary vasoconstriction: diagnosis by transesophageal echocardiogram and treatment by cardiopulmonary bypass. Obstet Gynecol 2003; 102:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20840/abstract/36\">",
"      Rittenberger JC, Kelly E, Jang D, et al. Successful outcome utilizing hypothermia after cardiac arrest in pregnancy: a case report. Crit Care Med 2008; 36:1354.",
"     </a>",
"    </li>",
"    <li>",
"     EEC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.8: Cardiac arrest associated with pregnancy. Circulation 2005; 112:IV150.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14184 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20840=[""].join("\n");
var outline_f20_22_20840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9057268\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271108705\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271108991\">",
"      PREVALENCE OF CARDIAC ARREST IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9057205\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9057212\">",
"      RESUSCITATION DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16030782\">",
"      ABCs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9057219\">",
"      Avoiding aortocaval compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2271109417\">",
"      Defibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2293214610\">",
"      Determining gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9057226\">",
"      Fetal monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9057240\">",
"      Delivery as part of the resuscitation process",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2349341435\">",
"      - \"Five minute rule\"",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2349341428\">",
"      - Minimum gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9057247\">",
"      Delivery issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9057254\">",
"      Use of medications for CPR during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9057261\">",
"      ADDITIONAL INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H904493470\">",
"      MATERNAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9057268\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192411829\">",
"      Resuscitation of the pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14184\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14184|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/48/29452\" title=\"table 1\">",
"      Causes of cardiac arrest in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34248?source=related_link\">",
"      Airway management of pregnant women at delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=related_link\">",
"      Cesarean delivery: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=related_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=related_link\">",
"      Limit of viability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=related_link\">",
"      Therapies of uncertain benefit in basic and advanced cardiac life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_22_20841="Clinical features and diagnosis of hairy cell leukemia";
var content_f20_22_20841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of hairy cell leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20841/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20841/contributors\">",
"     Martin S Tallman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20841/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20841/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20841/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/22/20841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hairy cell leukemia (HCL) is an uncommon chronic B cell lymphoproliferative disorder (lymphoid neoplasm) characterized by the accumulation of small mature B cell lymphoid cells with abundant cytoplasm and &ldquo;hairy&rdquo; projections within the peripheral blood, bone marrow, and splenic red pulp. This typically results in splenomegaly and a variable reduction in the production of normal red blood cells, platelets, mature granulocytes, and monocytes. The increased production of malignant cells, along with a reduction in these mature elements, results in a variety of systemic consequences, including splenomegaly, anemia, bleeding, and an increased risk of infection.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of HCL will be reviewed here; treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4378?source=see_link\">",
"     \"Treatment of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1445101937\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of HCL is largely unknown. However, studies indicate that most cases are associated with a V600E activating mutation in the",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinase BRAF (an isoform of RAF), implicating BRAF signaling in HCL. Response to BRAF inhibitor therapy has been described in a patient with refractory HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/1\">",
"     1",
"    </a>",
"    ], in line with the idea that oncogenic BRAF signaling enhances HCL proliferation and survival.",
"   </p>",
"   <p>",
"    Exposures to ionizing radiation, Epstein-Barr virus, organic chemicals, woodworking, and farming have been mentioned as possible causes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/2\">",
"     2",
"    </a>",
"    ]. A number of familial cases have been described, with family members sharing the same HLA haplotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85803855\">",
"    <span class=\"h2\">",
"     Cell of origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCL is postulated to arise from a late, activated memory B cell. The malignant cell in HCL has the following features that are consistent with a cell at a late stage of B cell development, such as a preplasma cell or postgerminal center memory B cell [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clonal immunoglobulin light and heavy chain gene rearrangements and monoclonal surface immunoglobulin expression [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/7-10\">",
"       7-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cell expresses pan B cell surface antigens (CD19, CD20, and CD22) and an early plasma cell marker (PCA-1). It does not express CD10 or CD21, markers of earlier stages of B cell development.",
"     </li>",
"     <li>",
"      The cell also expresses surface antigens that are not common on B cells, such as CD11c (monocytes and neutrophils), CD25 (activated T cells), and CD103 (intraepithelial T cells).",
"     </li>",
"     <li>",
"      Clonal karyotypic abnormalities are present in approximately two-thirds of patients. Abnormalities of chromosome 5 are present in approximately 40 percent, most commonly trisomy 5, pericentric inversions, and interstitial deletions involving band 5q13 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific details concerning immunophenotyping of the abnormal cell in HCL are presented below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Immunophenotype'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18129837\">",
"    <span class=\"h2\">",
"     BRAF mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;BRAF is a member of the serine-threonine kinase family, which plays a part in the",
"    <span class=\"nowrap\">",
"     RAS/RAF/MEK/MAPK",
"    </span>",
"    signaling pathway leading to enhanced cell proliferation and survival. An activating point mutation of the BRAF isoform of RAF (BRAF V600E) has been implicated in the pathogenesis of HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. While initial studies suggested that this mutation was present in all cases of HCL, subsequent data suggest that it is not present in HCL variant. (See",
"    <a class=\"local\" href=\"#H85803408\">",
"     'HCL variant'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, genomewide massively parallel sequencing of HCL cells and normal cells from the same patient identified a BRAF V600E mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/12,18\">",
"       12,18",
"      </a>",
"      ]. Sequencing of this gene in additional patients revealed the BRAF V600E mutation in all 47 patients with HCL and in none of the 195 patients with other peripheral B cell lymphomas or leukemias. The BRAF V600E mutation was present in the entire tumor cell clone in virtually all patients with HCL. These findings were confirmed in an independent cohort that demonstrated the BRAF V600E mutation in all 48 cases of HCL and none of the 114 patients with other lymphoproliferative disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/13\">",
"       13",
"      </a>",
"      ]. Other studies have demonstrated BRAF V600E mutations in a subset of patients with Erdheim-Chester disease and Langerhans cell histiocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/19,20\">",
"       19,20",
"      </a>",
"      ], as well as in subsets of many different solid tumors (eg, melanoma and colonic adenocarcinoma).",
"     </li>",
"     <li>",
"      A subsequent study reported mutated BRAF in 42 of 53 cases (79 percent) of classic HCL, but none of the 16 cases of HCL variant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/16\">",
"       16",
"      </a>",
"      ]. In addition, all 13 cases of HCL that underwent IGHV4-34 immunoglobulin rearrangement had unmutated (wildtype) BRAF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these findings suggested that BRAF mutations are a disease-defining event among patients with classical HCL who do not express IGHV4-34. They also suggest that HCL variant and HCL with IGHV4-34 represent entities that are distinct from classic HCL. The presence of BRAF V600E mutations in other entities is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link&amp;anchor=H452648797#H452648797\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85804865\">",
"    <span class=\"h2\">",
"     Other mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cell in HCL produces and assembles fibronectin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/21\">",
"     21",
"    </a>",
"    ] and elaborates several cytokines, such as basic fibroblast growth factor (bFGF, FGF-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/22\">",
"     22",
"    </a>",
"    ], transforming growth factor-beta (TGF-beta1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/23\">",
"     23",
"    </a>",
"    ], and tumor necrosis factor (TNF)-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/22,24-26\">",
"     22,24-26",
"    </a>",
"    ]. The first three may be responsible for the bone marrow fibrosis characteristically seen in HCL, while TNF may be responsible for the marrow suppression and consequent pancytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, bFGF has been shown to protect peripheral blood mononuclear cells from the inhibitory and apoptosis-inducing actions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    , and may explain resistance to this agent in some patients with HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCL has a gene expression profile that is distinct from that of other B cell lymphomas, including overexpression of the ANXA1 gene (annexin A1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/27\">",
"     27",
"    </a>",
"    ]. In a study of 500 B cell lymphoma samples, only those from patients with HCL stained positively for ANXA1; samples from patients with variant HCL and splenic marginal zone lymphoma, which are often difficult to distinguish from HCL, do not stain positively for ANXA1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/28\">",
"     28",
"    </a>",
"    ]. In another study, ANXA1 staining was present in 14 of 19 (74 percent) cases of HCL, but none of the eight patients with variant HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85803315\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCL is an uncommon malignancy, representing approximately 2 percent of all leukemias and less than 1 percent of lymphoid neoplasms. In the United States, the estimated incidence is three cases per million persons per year, which equates to 600 to 800 new cases each year [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/29\">",
"     29",
"    </a>",
"    ]. The median age at onset is 52 years. While HCL has been diagnosed in younger adults, it is almost never seen in children. There is a strong male predominance of approximately four to one [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/30\">",
"     30",
"    </a>",
"    ]. The incidence is approximately three times higher in Caucasians than in Blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Presenting complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with HCL present with symptoms related to splenomegaly or cytopenias (eg, anemia, thrombocytopenia, neutropenia, monocytopenia), including weakness and easy fatigability, infections of variable severity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemorrhagic findings such as gingival bleeding, ecchymoses, epistaxis, or menorrhagia. Combinations of these symptoms are common. HCL can present to the clinician in a number of different ways [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-quarter presents with abdominal fullness or discomfort due to splenomegaly, which may be massive. Spontaneous splenic rupture may occur and constitutes a medical emergency [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another one-quarter presents with systemic complaints, such as fatigue, weakness, and weight loss. Patients do not usually complain of fever or night sweats.",
"     </li>",
"     <li>",
"      Another one-quarter presents either with bruising and bleeding secondary to severe thrombocytopenia, or with recurrent infections, which may be life-threatening, secondary to granulocytopenia and monocytopenia.",
"     </li>",
"     <li>",
"      The remaining one-quarter is generally asymptomatic and comes to the clinician's attention because of an incidental finding of splenomegaly or cytopenias during evaluation for an unrelated cause.",
"     </li>",
"     <li>",
"      Occasional patients have vasculitis, usually polyarteritis nodosa or cutaneous leukocytoclastic vasculitis, or other autoimmune manifestations [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Rare patients describe bone pain or have bone lesions on imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination reveals palpable splenomegaly in 80 to 90 percent of cases, with the splenic edge extending more than 8 cm below the left costal margin in 25 percent; it is the most prominent physical finding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Hepatomegaly and lymphadenopathy are not major features of HCL, being present in approximately 20 and 10 percent of patients, respectively. B symptoms are usually not associated with HCL, and if fever is present it is likely indicative of a superimposed infection.",
"   </p>",
"   <p>",
"    Rare physical findings include soft tissue infiltration, vasculitic skin rash, ascites, and pleural effusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H20#H20\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sixty to 80 percent of patients with HCL present with pancytopenia, with hematocrits in the range of 20 to 35 percent, a total white blood cell count usually below",
"    <span class=\"nowrap\">",
"     4000/microL,",
"    </span>",
"    and platelet counts in the range of 20,000 to",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Monocytopenia and neutropenia are common. Lactate dehydrogenase (LDH) is usually normal. The approximate frequency of the major laboratory abnormalities in HCL is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia &mdash; 85 percent",
"     </li>",
"     <li>",
"      Thrombocytopenia &mdash; 80 percent",
"     </li>",
"     <li>",
"      Neutropenia &mdash; 80 percent",
"     </li>",
"     <li>",
"      Monocytopenia &mdash; 80 percent",
"     </li>",
"     <li>",
"      Azotemia &mdash; 30 percent",
"     </li>",
"     <li>",
"      Abnormal liver function tests &mdash; 20 percent",
"     </li>",
"     <li>",
"      Hypergammaglobulinemia &mdash; 20 percent",
"     </li>",
"     <li>",
"      Leukocytosis (total WBC",
"      <span class=\"nowrap\">",
"       &gt;10,000/microL)",
"      </span>",
"      &mdash; 10 to 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85803972\">",
"    <span class=\"h3\">",
"     Peripheral blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the peripheral blood is common in HCL. Circulating hairy cells can be identified in Romanowsky-stained peripheral blood films from approximately 90 percent of patients, where they usually comprise 20 percent or less of the total white blood cell count. However, in the 10 percent of patients who present with leukocytosis, the HCL cell is the predominant circulating white blood cell. A very small percent of patients presents with marked leukocytosis, with white blood cell counts",
"    <span class=\"nowrap\">",
"     &gt;200,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    HCL cell is a mononuclear cell, usually one to two times the size of a mature lymphocyte (",
"    <a class=\"graphic graphic_picture graphicRef81031 \" href=\"UTD.htm?41/56/42884\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/38\">",
"     38",
"    </a>",
"    ]. The nuclei are often eccentric in position, but may be central. The nuclei are most commonly ovoid, but may be round, spindled, or horseshoe shaped. The chromatin pattern is reticular or net-like in appearance; nucleoli are indistinct or absent.",
"   </p>",
"   <p>",
"    The cytoplasm is variable in amount, pale blue to blue-gray in color, often abundant, and occasionally described as \"fluffy\". The cytoplasmic outline is often indistinct with varying numbers of projections, best seen on phase-contrast microscopy, giving the cell a \"hairy\" appearance when the projections are thin, and a \"ruffled\" appearance when they are wider. The hairy projections are readily evident on electron microscopic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/39\">",
"     39",
"    </a>",
"    ] and particularly on scanning electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85804256\">",
"    <span class=\"h3\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow (BM) is often inaspirable (dry tap) due to HCL-induced marrow fibrosis, and the diagnosis relies on analysis of peripheral blood and trephine biopsies. The marrow is hypercellular in most patients, and hairy cell infiltration may be diffuse or interstitial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17\">",
"     17",
"    </a>",
"    ]. Unlike other low-grade B cell lymphoproliferative disorders, nodular patterns of marrow infiltration occur rarely, if at all. In patients with diffuse involvement, large areas of the BM may be replaced by hairy cells, with complete effacement of the BM. In one study, as an example, the median percent bone marrow involvement was 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17\">",
"     17",
"    </a>",
"    ]. When the BM is focally involved, there is some preservation of fat and hematopoietic elements, the infiltrates are randomly situated and may include paratrabecular locations. Mitotic figures are uncommon.",
"   </p>",
"   <p>",
"    The hairy cell nuclei are widely separated from each other by virtue of the cell's abundant cytoplasm, giving a halo or \"fried egg\" appearance to biopsy and tissue specimens (",
"    <a class=\"graphic graphic_picture graphicRef58853 \" href=\"UTD.htm?4/53/4953\">",
"     picture 2",
"    </a>",
"    ). Mast cells (tissue basophils) may be numerous. Extravasated red cells are frequently seen, and blood lakes similar to those observed in the spleen may also be present. However, the extent of involvement of the BM by HCL may be difficult to identify in routinely stained sections, and is usually accentuated when sections are examined by immunohistochemistry with antibodies to B cell associated antigens such as CD20.",
"   </p>",
"   <p>",
"    A minority of patients, perhaps 10 to 20 percent, exhibits a hypocellular BM. The hypocellularity may be profound with small numbers of hairy cells infiltrating around fat cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/41-47\">",
"     41-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staining of the BM trephine biopsy for reticulin almost always shows a moderate to marked increase in reticulin fibers. In some cases, the reticulin fibers appear to surround individual hairy cells, with the fibrosis extending into the adjacent, more normal appearing BM tissue. Osteosclerosis has been rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of bone marrow aspirate smears\", section on 'The dry tap'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85804497\">",
"    <span class=\"h3\">",
"     Spleen, liver, and lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination of the spleen will demonstrate tumor infiltration in virtually all cases. In rare instances in which liver biopsies are obtained for other indications, focal involvement of hepatic sinusoids is not unusual, but hepatomegaly is distinctly rare. Lymph nodes are typically not involved.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Spleen",
"      </strong>",
"      &mdash; The spleen demonstrates marked enlargement with diffuse expansion of the red pulp and atrophy of the white pulp in practically all cases of HCL [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/51\">",
"       51",
"      </a>",
"      ]. The cords and sinuses of the red pulp are infiltrated by tumor cells. The tumor infiltrate is comprised of a monotonous population of medium-sized cells with clear cytoplasm and may have interlocking cell borders, producing a &ldquo;fried egg&rdquo; appearance (",
"      <a class=\"graphic graphic_picture graphicRef58853 \" href=\"UTD.htm?4/53/4953\">",
"       picture 2",
"      </a>",
"      ). Dilated sinuses may be filled with red cells, forming &ldquo;blood lakes&rdquo; (also called &ldquo;pseudosinuses&rdquo;) lined by hairy cells. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Liver",
"      </strong>",
"      &mdash; Liver involvement, if present, is subtle and usually confined to sinusoids [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Lymph nodes",
"      </strong>",
"      &mdash; Infiltration of the lymph nodes can be seen in patients with advanced HCL [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/51\">",
"       51",
"      </a>",
"      ]. The tumor cells variably involve the interfollicular and paracortical zones. The follicles and sinuses are typically spared. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cytochemical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, demonstration of tartrate-resistant acid phosphatase (TRAP) activity on peripheral blood films, marrow aspirate smears, or touch preparations of BM was routinely used to confirm the diagnosis of HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/52\">",
"     52",
"    </a>",
"    ]. However, TRAP is a technically challenging cytochemical stain and, while sensitive for HCL, is not as specific as flow cytometry, which has made the use of TRAP staining largely obsolete. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Immunophenotype'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hairy cells exhibit a mature B cell phenotype and typically express one or more heavy chains [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/53\">",
"     53",
"    </a>",
"    ] and monotypic light chains. Hairy cells strongly express pan-B cell antigens including CD19, CD20, CD22, and CD25, and usually lack expression of CD5, CD10, CD21, and CD23 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17,54\">",
"     17,54",
"    </a>",
"    ]. Hairy cells characteristically express CD11c, CD103, CD123 (bright), and cyclin D1 (usually weak).",
"   </p>",
"   <p>",
"    A majority (74 percent) express annexin A1, which is not expressed in any other B cell lymphoma subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17,27,28\">",
"     17,27,28",
"    </a>",
"    ]. However, annexin A1 must be interpreted in conjunction with staining for a B cell antigen since it is also expressed by myeloid cells and by some T cells.",
"   </p>",
"   <p>",
"    The mucosal lymphocyte antigen, CD103, is a sensitive marker for HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/55\">",
"     55",
"    </a>",
"    ]. CD103 is a member of the integrin family and is also present on mucosa-associated T cells and some activated lymphocytes. The presence of CD103, when co-expressed with other pan-B cell markers, is highly suggestive of HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hairy cells also strongly express CD11c, a marker associated with myelomonocytic cells and CD25, the alpha chain of the interleukin-2 receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/54,57\">",
"     54,57",
"    </a>",
"    ]. B cell-associated immunostains, including anti-CD20 (L26) and DBA44, react with hairy cells in fixed, routinely processed tissue sections. Although these antibodies are not specific for HCL, they document the process as a B cell proliferation and highlight the extent of BM infiltration at the time of diagnosis and following therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85804586\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;While numerous genetic abnormalities have been described, none has been incorporated into the diagnostic criteria for HCL yet. As described above, initial studies suggest that the vast majority of cases demonstrate BRAF mutations. Further study is needed to define the sensitivity and specificity of these mutations for HCL before testing for BRAF mutations becomes a routine part of diagnosis. (See",
"    <a class=\"local\" href=\"#H18129837\">",
"     'BRAF mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Analysis of the immunoglobulin variable region genes shows somatic mutations in the majority (&gt;85 percent) of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/51,62\">",
"     51,62",
"    </a>",
"    ]. Unlike other lymphoid neoplasms, the HCL tumors cells often co-express multiple clonally related immunoglobulin isotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28949319\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCL is initially suspected from the presence of large numbers of mononuclear cells in the blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone marrow with cytoplasmic projections giving the cell a \"hairy\" or \"ruffled\" appearance (",
"    <a class=\"graphic graphic_picture graphicRef81031 \" href=\"UTD.htm?41/56/42884\">",
"     picture 1",
"    </a>",
"    ). Evaluation requires a bone marrow trephine biopsy and aspirate with immunophenotyping and flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. It is common for the bone marrow aspirate to result in a &ldquo;dry tap&rdquo; because the bone marrow cannot be aspirated due to the diffuse fibrosis. Splenectomy is usually not necessary, but can be diagnostic in patients presenting with a massively enlarged spleen. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Morphology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85803285\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HCL is usually made by bone marrow biopsy and aspirate with immunophenotyping by flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/51\">",
"     51",
"    </a>",
"    ]. The abnormal cells (ie, &ldquo;hairy&rdquo; cells) display expression of pan-B cell antigens (eg, CD19, CD20, CD22) along with positivity for CD103, CD11c, and CD25. Expression of annexin A1 in B cells is specific, but not sensitive for the diagnosis of HCL. On occasion, HCL may have an atypical immunophenotype and express markers such as CD5. In such cases, immunostaining for cyclin D1 can be performed to exclude the possibility of mantle cell lymphoma. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Immunophenotype'",
"    </a>",
"    above.)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of HCL includes other small B cell lymphoproliferative disorders associated with splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/63\">",
"     63",
"    </a>",
"    ], such as chronic lymphocytic leukemia (CLL), prolymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/64-66\">",
"     64-66",
"    </a>",
"    ], splenic marginal zone lymphoma (splenic lymphoma with villous lymphocytes) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/67-70\">",
"     67-70",
"    </a>",
"    ], the variant form of HCL (",
"    <a class=\"graphic graphic_picture graphicRef85966 \" href=\"UTD.htm?4/32/4615\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/71-73\">",
"     71-73",
"    </a>",
"    ], and mantle cell lymphoma (",
"    <a class=\"graphic graphic_table graphicRef88275 \" href=\"UTD.htm?0/28/461\">",
"     table 1",
"    </a>",
"    ). The differential can usually be made by employing specific immunostaining procedures.",
"   </p>",
"   <p>",
"    The causes of an enlarged spleen are multiple; most reflect the presence of hepatic or hematologic disease, infection, or inflammation. A general approach to the evaluation of patients with splenomegaly is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85803408\">",
"    <span class=\"h2\">",
"     HCL variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCL variant (HCL-v) is a rare chronic B cell lymphoproliferative disorder that was previously thought to be a subtype of HCL, but is now considered to be a distinct entity that is biologically unrelated to HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17,51\">",
"     17,51",
"    </a>",
"    ]. HCL-v exhibits morphologic features intermediate between hairy cells and prolymphocytes. Unlike HCL, HCL-v typically has prominent nucleoli and less marrow infiltration. This condition is often associated with extreme leukocytosis, often without the neutropenia, monocytopenia, anemia, and thrombocytopenia seen in HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCL and HCL-v are best distinguished from each other based upon immunophenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17\">",
"     17",
"    </a>",
"    ]. Both HCL and HCL-v express CD20, CD22, CD11c, and CD103. Unlike HCL, which typically has bright expression of CD123 and CD25, HCL-v does not express CD25 and is usually dim or negative for CD123. In addition, annexin A1 is expressed in approximately 75 percent of HCL cases and is universally negative in HCL-v [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17,27,28\">",
"     17,27,28",
"    </a>",
"    ]. It also appears that HCL-v lacks BRAF mutations, though further study is needed to confirm this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21206094\">",
"    <span class=\"h2\">",
"     Splenic marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both splenic marginal zone lymphoma (MZL) and HCL can present with splenomegaly and circulating lymphocytes with cytoplasmic projections. While the circulating lymphocytes in HCL usually have long cytoplasmic projections around the entire perimeter of the cell, splenic MZL cells usually have short polar villi, although this may be masked by poor slide preparation. Both HCL and splenic MZL typically express pan B cell antigens (CD20, CD22). Expression of CD103 is present in HCL, but absent in splenic MZL. MZL is negative for annexin A1 and positive in the majority if HCL. CD123 and CD25 are typically brightly expressed in HCL and variably expressed in MZL. Splenic involvement in HCL is typically limited to the red pulp. In contrast, both the splenic white pulp and red pulp are involved in MZL, and marginal zones are usually prominent due to expansion by cells with abundant pale cytoplasm. Bone marrow infiltrates, when present, are often nodular [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/51\">",
"     51",
"    </a>",
"    ], in distinction to the diffuse interstitial infiltrates of HCL, and sometimes include reactive-appearing follicles surrounded by marginal zones. The immunophenotype profile includes lack of staining for CD103, CD11c, and CD25, all of which are commonly expressed in HCL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/65\">",
"     65",
"    </a>",
"    ]. In difficult cases, pathologic evaluation of the bone marrow, spleen, and hilar lymph nodes may be used in concert to determine the most likely diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21206113\">",
"    <span class=\"h2\">",
"     Chronic lymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both HCL and chronic lymphocytic leukemia (CLL) can present with splenomegaly and circulating lymphoid cells. Compared with typical HCL cells, CLL cells usually have a regular, smooth cytoplasmic outline. The abnormal B cell in CLL usually stains positively for CD5, an antigen rarely expressed in HCL. Conversely, B cell CLL is usually negative for CD103, an antigen commonly expressed in HCL. Most cases of splenic involvement in CLL demonstrate diffuse infiltration of both the red and white pulp with effacement of the follicles, while HCL predominantly involves the red pulp. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21206307\">",
"    <span class=\"h2\">",
"     Prolymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both HCL and prolymphocytic leukemia (PLL) can present with splenomegaly and circulating lymphoid cells. In HCL, the malignant cells are usually present in small numbers in the peripheral blood. In PLL there is a marked elevation of the white blood cell count, with the characteristic morphology of prolymphocytes. Compared with typical HCL cells, prolymphocytes are larger cells with no cytoplasmic projections and somewhat immature-appearing nuclear chromatin, a prominent nucleolus, and a moderate amount of cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef85966 \" href=\"UTD.htm?4/32/4615\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945052\">",
"    <span class=\"h2\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma can present with splenomegaly and peripheral blood involvement, and have varied morphologic appearances. However, ruffled or &ldquo;hairy&rdquo; cytoplasm is not a feature of mantle cell lymphoma, and it has an immunophenotype (CD5+, cyclinD1+, CD25-, CD103-, annexin A1-) that is easily distinguished from HCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2089036\">",
"    <span class=\"h2\">",
"     Aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, the bone marrow biopsy of patients with HCL may resemble that seen in patients with aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/51\">",
"     51",
"    </a>",
"    ]. Such cases will demonstrate hypocellularity with a loss of hematopoietic elements, especially the granulocytic lineage. Immunostaining for a B cell antigen such as CD20 will identify an abnormal B cell infiltrate. The diagnosis of HCL can then be confirmed using immunohistochemical stains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H16#H16\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2089046\">",
"    <span class=\"h2\">",
"     Splenic diffuse red pulp small B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic diffuse red pulp small B cell lymphoma is a provisional entity in the WHO classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20841/abstract/51\">",
"     51",
"    </a>",
"    ]. It is a rare entity characterized by diffuse infiltration of the bone marrow, peripheral blood, and splenic red pulp by small monomorphous B lymphocytes, usually with villous projections. In contrast to HCL, these tumor cells are typically negative for annexin A1, CD25, CD103, CD123, and CD11c.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/12/13506?source=see_link\">",
"       \"Patient information: Hairy cell leukemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hairy cell leukemia (HCL) is an uncommon chronic B cell lymphoproliferative disorder (lymphoid neoplasm) representing approximately 2 percent of all leukemias and less than 1 percent of lymphoid neoplasms. Although it has been diagnosed in younger adults, HCL is typically a malignancy of older adults with a median age at onset of 52 years. (See",
"      <a class=\"local\" href=\"#H85803315\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with HCL have symptoms related to splenomegaly or cytopenias (eg, anemia, thrombocytopenia, neutropenia, monocytopenia), including weakness and easy fatigability, infections of variable severity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemorrhagic findings such as gingival bleeding, ecchymoses, epistaxis, or menorrhagia. Combinations of these symptoms are common. Approximately one-quarter is asymptomatic and comes to the clinician's attention because of incidental findings of splenomegaly or cytopenias during evaluation for an unrelated cause. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Presenting complaints'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upon initial evaluation, the majority of patients will demonstrate palpable splenomegaly. Hepatomegaly and lymphadenopathy are not major features of HCL. Sixty to 80 percent of patients will have pancytopenia at diagnosis. Monocytopenia and neutropenia are common. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HCL is made based upon evaluation of the lymphocyte morphology, immunophenotype, cytogenetic analysis, bone marrow histology, and spleen histology, when available. (See",
"      <a class=\"local\" href=\"#H85803285\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Involvement of the peripheral blood is common in HCL. The tumor cells usually comprise 20 percent or less of the total white blood cell count. The HCL cell is mononuclear and one to two times the size of a mature lymphocyte (",
"      <a class=\"graphic graphic_picture graphicRef81031 \" href=\"UTD.htm?41/56/42884\">",
"       picture 1",
"      </a>",
"      ). The nuclei are often eccentric, lack prominent nucleoli, and have a reticular chromatin pattern. The nucleus is surrounded by abundant pale blue to blue-gray cytoplasm resulting in a \"fried egg\" appearance. The cytoplasmic outline is indistinct with varying numbers of cytoplasmic projections giving the cell a \"hairy\" or \"ruffled\" appearance. (See",
"      <a class=\"local\" href=\"#H85803972\">",
"       'Peripheral blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The bone marrow is hypercellular in most patients, and hairy cell infiltration may be diffuse, focal, or interstitial. The hairy cell nuclei are widely separated from each other by virtue of the cell's abundant cytoplasm, giving a halo or \"fried egg\" appearance to biopsy and tissue specimens (",
"      <a class=\"graphic graphic_picture graphicRef58853 \" href=\"UTD.htm?4/53/4953\">",
"       picture 2",
"      </a>",
"      ). Staining of the BM trephine biopsy for reticulin almost always shows a moderate to marked increase in reticulin fibers. It is common for the bone marrow aspirate to result in a &ldquo;dry tap&rdquo; because the bone marrow cannot be aspirated due to the diffuse fibrosis. (See",
"      <a class=\"local\" href=\"#H85804256\">",
"       'Bone marrow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathologic evaluation of the spleen demonstrates marked enlargement with diffuse expansion of the red pulp and atrophy of the white pulp in practically all cases. The cords and sinuses of the red pulp are infiltrated by tumor cells, and dilated sinuses may be filled with red cells, forming &ldquo;blood lakes&rdquo;, which are called &ldquo;pseudosinuses&rdquo; when lined by hairy cells. (See",
"      <a class=\"local\" href=\"#H85804497\">",
"       'Spleen, liver, and lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tumor cells express pan-B cell antigens (eg, CD19, CD20, CD22) along with CD103, CD11c, CD25, and (often, but not always) annexin A1. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of HCL includes other small B cell lymphoproliferative disorders associated with splenomegaly such as the HCL variant, splenic marginal zone lymphoma, and chronic lymphocytic leukemia (",
"      <a class=\"graphic graphic_table graphicRef88275 \" href=\"UTD.htm?0/28/461\">",
"       table 1",
"      </a>",
"      ). Occasionally, the bone marrow biopsy of patients with HCL may resemble that seen in patients with aplastic anemia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/1\">",
"      Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/2\">",
"      Oleske D, Golomb HM, Farber MD, Levy PS. A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol 1985; 121:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/3\">",
"      Ward FT, Baker J, Krishnan J, et al. Hairy cell leukemia in two siblings. A human leukocyte antigen-linked disease? Cancer 1990; 65:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/4\">",
"      Colovic MD, Jankovic GM, Wiernik PH. Hairy cell leukemia in first cousins and review of the literature. Eur J Haematol 2001; 67:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/5\">",
"      Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer 2006; 6:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/6\">",
"      Miranda RN, Cousar JB, Hammer RD, et al. Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes. Hum Pathol 1999; 30:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/7\">",
"      Cleary ML, Wood GS, Warnke R, et al. Immunoglobulin gene rearrangements in hairy cell leukemia. Blood 1984; 64:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/8\">",
"      Foroni L, Catovsky D, Luzzatto L. Immunoglobulin gene rearrangements in hairy cell leukemia and other chronic B cell lymphoproliferative disorders. Leukemia 1987; 1:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/9\">",
"      Korsmeyer SJ, Greene WC, Cossman J, et al. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A 1983; 80:4522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/10\">",
"      Arons E, Roth L, Sapolsky J, et al. Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood 2011; 117:4844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/11\">",
"      Haglund U, Juliusson G, Stellan B, Gahrton G. Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions. Blood 1994; 83:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/12\">",
"      Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/13\">",
"      Boyd EM, Bench AJ, van 't Veer MB, et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol 2011; 155:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/14\">",
"      Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012; 119:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/15\">",
"      Schnittger S, Bacher U, Haferlach T, et al. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood 2012; 119:3151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/16\">",
"      Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012; 119:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/17\">",
"      Shao H, Calvo KR, Gr&ouml;nborg M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. Leuk Res 2013; 37:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/18\">",
"      Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 2012; 119:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/19\">",
"      Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/20\">",
"      Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/21\">",
"      Burthem J, Cawley JC. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood 1994; 83:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/22\">",
"      Gruber G, Schwarzmeier JD, Shehata M, et al. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. Blood 1999; 94:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/23\">",
"      Shehata M, Schwarzmeier JD, Hilgarth M, et al. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest 2004; 113:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/24\">",
"      Lindemann A, Ludwig WD, Oster W, et al. High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood 1989; 73:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/25\">",
"      Barak V, Nisman B, Polliack A. The tumor necrosis factor family and and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 1999; 62:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/26\">",
"      Eigler A, Waller-Fontaine K, Moeller J, et al. The hairy cell leukemia cell line Eskol spontaneously synthesizes tumor necrosis factor-alpha and nitric oxide. Leuk Res 1998; 22:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/27\">",
"      Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004; 199:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/28\">",
"      Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004; 363:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/29\">",
"      Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/30\">",
"      Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/31\">",
"      Dores GM, Matsuno RK, Weisenburger DD, et al. Hairy cell leukaemia: a heterogeneous disease? Br J Haematol 2008; 142:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/32\">",
"      Catovsky D. Hairy-cell leukaemia and prolymphocytic leukaemia. Clin Haematol 1977; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/33\">",
"      Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 1978; 89:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/34\">",
"      Grever MR. How I treat hairy cell leukemia. Blood 2010; 115:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/35\">",
"      Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum 1995; 25:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/36\">",
"      Westbrook CA, Golde DW. Autoimmune disease in hairy-cell leukaemia: clinical syndromes and treatment. Br J Haematol 1985; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/37\">",
"      Rosen DS, Smith S, Gurbuxani S, Yamini B. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine 2008; 9:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/38\">",
"      Summers TA, Jaffe ES. Hairy cell leukemia diagnostic criteria and differential diagnosis. Leuk Lymphoma 2011; 52 Suppl 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/39\">",
"      Daniel MT, Flandrin G. Fine structure of abmormal cells in hairy cell (tricholeukocytic) leukemia, with special reference to their in vitro phagocytic capacity. Lab Invest 1974; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/40\">",
"      Golomb HM, Braylan R, Polliack A. 'Hairy' cell leukaemia (leukaemic reticuloendotheliosis): a scanning electron microscopic study of eight cases. Br J Haematol 1975; 29:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/41\">",
"      Bartl R, Frisch B, Hill W, et al. Bone marrow histology in hairy cell leukemia. Identification of subtypes and their prognostic significance. Am J Clin Pathol 1983; 79:531.",
"     </a>",
"    </li>",
"    <li>",
"     Brunning RD, McKenna RW. Small lymphocytic leukemias and related disorders. In: Tumors of the bone marrow, Atlas of Tumor Pathology, Third Series, Fascicle 9, Armed Forces Institute of Pathology, Washington, DC 1994. p.254.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/43\">",
"      Burke JS, Rappaport H. The diagnosis and differential diagnosis of hairy cell leukemia in bone marrow and spleen. Semin Oncol 1984; 11:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/44\">",
"      Burke JS. The value of the bone-marrow biopsy in the diagnosis of hairy cell leukemia. Am J Clin Pathol 1978; 70:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/45\">",
"      Pangalis GA, Kittas C, Viniou N, et al. Hairy cell leukemia: bone marrow changes following splenectomy and alpha-interferon therapy. Leukemia 1987; 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/46\">",
"      Katayama I. Bone marrow in hairy cell leukemia. Hematol Oncol Clin North Am 1988; 2:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/47\">",
"      Lee WM, Beckstead JH. Hairy cell leukemia with bone marrow hypoplasia. Cancer 1982; 50:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/48\">",
"      VanderMolen LA, Urba WJ, Longo DL, et al. Diffuse osteosclerosis in hairy cell leukemia. Blood 1989; 74:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/49\">",
"      Verhoef GE, De Wolf-Peeters C, Zachee P, Boogaerts MA. Regression of diffuse osteosclerosis in hairy cell leukaemia after treatment with interferon. Br J Haematol 1990; 76:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/50\">",
"      Leung R, Lopes D, Lam C, et al. Diffuse osteosclerosis complicating hairy cell leukemia. J Clin Oncol 2010; 28:e203.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/52\">",
"      Yam LT, Li CY, Lam KW. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med 1971; 284:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/53\">",
"      Forconi F, Sahota SS, Raspadori D, et al. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood 2001; 98:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/54\">",
"      Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993; 82:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/55\">",
"      M&ouml;ller P, Mielke B, Moldenhauer G. Monoclonal antibody HML-1, a marker for intraepithelial T cells and lymphomas derived thereof, also recognizes hairy cell leukemia and some B-cell lymphomas. Am J Pathol 1990; 136:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/56\">",
"      Cornfield DB, Mitchell Nelson DM, Rimsza LM, et al. The diagnosis of hairy cell leukemia can be established by flow cytometric analysis of peripheral blood, even in patients with low levels of circulating malignant cells. Am J Hematol 2001; 67:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/57\">",
"      Barak V, Ginzburg M, Kalickman I, Polliack A. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 1992; 7:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/58\">",
"      Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84:4310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/59\">",
"      Hakimian D, Tallman MS, Kiley C, Peterson L. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1993; 82:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/60\">",
"      Hounieu H, Chittal SM, al Saati T, et al. Hairy cell leukemia. Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. Am J Clin Pathol 1992; 98:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/61\">",
"      Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/62\">",
"      Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009; 114:4696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/63\">",
"      Kroft SH, Finn WG, Peterson LC. The pathology of the chronic lymphoid leukaemias. Blood Rev 1995; 9:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/64\">",
"      Galton DA, Goldman JM, Wiltshaw E, et al. Prolymphocytic leukaemia. Br J Haematol 1974; 27:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/65\">",
"      Melo JV, Catovsky D, Gregory WM, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 1987; 65:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/66\">",
"      Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986; 63:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/67\">",
"      Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994; 84:3828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/68\">",
"      Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994; 83:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/69\">",
"      Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991; 78:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/70\">",
"      Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'H&eacute;matologie Cellulaire (GFHC). Br J Haematol 1996; 93:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/71\">",
"      Catovsky D, O'Brien M, Melo JV, et al. Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. Semin Oncol 1984; 11:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/72\">",
"      Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res 1980; 4:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/73\">",
"      Sainati L, Matutes E, Mulligan S, et al. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990; 76:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20841/abstract/74\">",
"      Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009; 114:4687.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4532 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20841=[""].join("\n");
var outline_f20_22_20841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1445101937\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85803855\">",
"      Cell of origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18129837\">",
"      BRAF mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85804865\">",
"      Other mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85803315\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Presenting complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85803972\">",
"      - Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85804256\">",
"      - Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85804497\">",
"      - Spleen, liver, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cytochemical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85804586\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28949319\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85803285\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85803408\">",
"      HCL variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21206094\">",
"      Splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21206113\">",
"      Chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21206307\">",
"      Prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H945052\">",
"      Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2089036\">",
"      Aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2089046\">",
"      Splenic diffuse red pulp small B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4532|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/56/42884\" title=\"picture 1\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/53/4953\" title=\"picture 2\">",
"      Hairy cell leukemia spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/32/4615\" title=\"picture 3\">",
"      B cell leukemias morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/28/461\" title=\"table 1\">",
"      DDx HCL path",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=related_link\">",
"      Evaluation of bone marrow aspirate smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/12/13506?source=related_link\">",
"      Patient information: Hairy cell leukemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4378?source=related_link\">",
"      Treatment of hairy cell leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_22_20842="Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology";
var content_f20_22_20842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Lisa L Wang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Murali Chintagumpala, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Mark C Gebhardt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/22/20842/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/22/20842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteosarcomas are primary malignant tumors of bone that are characterized by the production of osteoid or immature bone by the malignant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Osteosarcomas are uncommon tumors. Approximately 750 to 900 new cases are diagnosed each year in the United States, of which 400 arise in children and adolescents younger than 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Despite their rarity, osteosarcomas are the most common primary malignancy of bone in children and adolescents (",
"    <a class=\"graphic graphic_figure graphicRef67051 \" href=\"UTD.htm?32/12/32974\">",
"     figure 1",
"    </a>",
"    ), and the fifth most common malignancy among adolescents and young adults aged 15 to 19 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survival of patients with malignant bone sarcomas has improved dramatically with effective chemotherapy. Prior to the use of chemotherapy, 80 to 90 percent of patients with osteosarcoma developed metastatic disease despite achieving local tumor control and died of their disease. It was surmised (and subsequently demonstrated) that the majority of patients had subclinical metastatic disease that was present at the time of diagnosis, even in the absence of overt clinical metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy can successfully eradicate these deposits if initiated at a time when disease burden is low. As a result, all patients with osteosarcoma are treated with adjuvant chemotherapy, and most receive this treatment modality in the preoperative period. With multimodality therapy, at least two-thirds of patients with non-metastatic extremity osteosarcomas will be long-term survivors, up to 50 percent of those with limited pulmonary metastases may be cured of their disease, and long-term relapse-free survival can be expected in about 25 percent of all patients who present with more extensive metastatic disease.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the epidemiology, clinical presentation, diagnosis, staging, and histopathology of patients with osteosarcoma. Diagnostic evaluation and biopsy techniques for primary bone tumors, an overview of treatment and outcomes, principles guiding surgical management of bone sarcomas, and chemotherapy in the treatment of osteosarcoma are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=see_link\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, osteosarcoma is an uncommon tumor; it accounts for only 1 percent of all cancers diagnosed annually in the US. In contrast to Ewing sarcoma, which is extremely rare in older adults, there is a bimodal age distribution of osteosarcoma incidence, with peaks in early adolescence and in adults over the age of 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/10\">",
"     10",
"    </a>",
"    ]. There are differences in tumor site and survival according to age at presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone sarcomas account for about 6 percent of all childhood cancers, and osteosarcomas account for approximately 3 percent of childhood cancers overall [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/11\">",
"     11",
"    </a>",
"    ]. However, osteosarcoma is the most common primary bone tumor affecting children and young adults. Osteosarcomas comprise 56 percent of all bone cancers in individuals under the age of 20, while Ewing sarcoma accounts for 34 to 36 percent, and chondrosarcomas are responsible for less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, the peak incidence is between 13 and 16 years of",
"    <a class=\"external\" href=\"file://onlinelibrary.wiley.com/doi/10.1002/cncr.24121/pdf\">",
"     age",
"    </a>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef67051 \" href=\"UTD.htm?32/12/32974\">",
"     figure 1",
"    </a>",
"    ), a time that appears to coincide with the adolescent growth spurt. For unclear reasons, osteosarcomas are more common in boys than in girls, and in blacks and other races as compared to Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/4,10,13\">",
"     4,10,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common sites of osteosarcoma in children are the metaphyses of long bones, especially the distal femur (75 percent of cases in one large population-based series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/10\">",
"     10",
"    </a>",
"    ]), proximal tibia, and proximal humerus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteosarcomas in adults are often considered secondary neoplasms, attributed to sarcomatous transformation of Paget disease of bone or some other benign bone lesion. In the US, over one-half of all osteosarcomas arising in patients over the age of 60 arise are secondary [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, in Asia, Paget's disease is less frequent, and a higher percentage of osteosarcomas in patients over the age of 60 arise primarily [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/17\">",
"     17",
"    </a>",
"    ]. Osteosarcomas arising in the setting of Paget's disease (Pagetic sarcomas) have a worse prognosis overall. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Compared to cases diagnosed in children, osteosarcomas arising in adults more commonly occur in axial locations (although as in children, the lower leg bones are the single most common site [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/10\">",
"     10",
"    </a>",
"    ]), and in areas that have been previously irradiated or that have underlying bone abnormalities.",
"   </p>",
"   <p>",
"    As is seen in children, males are affected more often than females [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. However, in contrast to children, osteosarcoma is more common in whites than in blacks or individuals of other races [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the majority of osteosarcomas are sporadic, while inherited predisposition accounts for a minority of cases. In older adults, about one-third of cases arise in the setting of Paget disease of bone or as a second or later cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several predisposing factors have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Prior irradiation or chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteosarcoma is the most frequent second primary cancer occurring during the first 20 years following radiation therapy for a solid cancer in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Early estimates suggested that approximately 3 percent of osteosarcomas could be attributed to prior irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/20,22-24\">",
"     20,22-24",
"    </a>",
"    ]. However, a higher incidence is likely to be revealed, as more patients survive long enough after primary irradiation to develop this complication. The interval between irradiation and the appearance of a secondary osteosarcoma ranges from 4 to over 40 years, averaging 12 to 16 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior exposure to chemotherapy, particularly alkylating agents, is also associated with secondary osteosarcomas and may potentiate the effect of previous radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. At least one report suggests that treatment with anthracyclines may shorten the interval to development of a secondary bone tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Paget disease and other benign bone lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of osteosarcoma in patients older than 40 years of age are frequently associated with Paget disease, a focal skeletal disorder characterized by an accelerated rate of bone turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the incidence of bone tumors is markedly increased in patients with Paget disease, they only occur in 0.7 to 1 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/26\">",
"     26",
"    </a>",
"    ]. Sarcomatous transformation is most often seen in long-standing Paget disease, but is not necessarily related to the extent of skeletal involvement. Although histologically indistinguishable from other osteosarcomas, multiple bone involvement is common, and the prognosis is poor overall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of Paget disease is unclear, but genetic factors are thought to play a pathogenetic role. Both Paget disease and pagetic osteosarcomas are associated with loss of heterozygosity of chromosome 18, possibly involving the same site of a postulated tumor suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to Paget disease, other benign bone lesions are associated with an increased risk of malignant degeneration to a primary bone tumor. These include chronic osteomyelitis, multiple hereditary exostoses, fibrous dysplasia, sites of bone infarcts, and sites of metallic implants for benign conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Osteochondromas (solitary or multiple) and enchondromas (solitary or multiple [Ollier disease]) pose a risk of malignant degeneration to a chondrosarcoma. &nbsp;Malignant degeneration is exceedingly rare for a solitary osteochondroma, but it can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link\">",
"     \"Chondrosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inherited conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic conditions with a known predisposition to osteosarcoma include hereditary retinoblastoma, Li-Fraumeni syndrome, Rothmund-Thomson syndrome, and the related Bloom and Werner syndromes. Because of the association of these genetic conditions with osteosarcomas, particularly in the setting of multiple primary malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/33\">",
"     33",
"    </a>",
"    ], careful detailing of family history is important for patients with newly diagnosed osteosarcoma.",
"   </p>",
"   <p>",
"    The genetic abnormality associated with heritable forms of retinoblastoma (ie, germline mutations of the retinoblastoma gene) are associated with an increased risk of developing second primary tumors, 60 percent of which are soft tissue sarcomas and osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/24,34,35\">",
"     24,34,35",
"    </a>",
"    ]. Patients with the sporadic type of retinoblastoma are at a much lower risk. As an example, in one study of 1604 patients with retinoblastoma, the cumulative incidence of a second cancer at 50 years after diagnosis was 51 percent for hereditary cases, compared to only 5 percent for nonhereditary (sporadic) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of retinoblastoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Li-Fraumeni syndrome is a familial cancer syndrome in which affected family members display a spectrum of cancers, including breast, soft tissue, adrenocortical, and brain tumors, leukemias, and osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/36\">",
"     36",
"    </a>",
"    ]. Many of these patients carry germline inactivating mutations in the p53 tumor suppressor gene, which is involved in cell cycle regulation and maintaining the integrity of the genome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this important association, the number of osteosarcomas that are attributable to Li-Fraumeni syndrome is small [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In one series of 235 unselected children with osteosarcoma, only 3 percent carried constitutional germline mutations in p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rothmund-Thomson syndrome (RTS, also called poikiloderma congenitale) is an autosomal recessive condition characterized by distinctive skin findings (atrophy, telangiectasias, pigmentation), sparse hair, cataracts, small stature, skeletal anomalies, and a significantly increased risk for osteosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In one cohort of 41 patients with RTS, 13 (32 percent) developed osteosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/41\">",
"     41",
"    </a>",
"    ]. Clinically, these tumors tend to develop at a younger age than seen in the general population.",
"   </p>",
"   <p>",
"    A specific loss of function mutation in the RECQL4 gene has been identified in approximately two-thirds of patients with RTS and is closely associated with the risk for osteosarcoma. In one series of 33 patients with RTS, none of the 10 patients without a truncating mutation in this gene developed osteosarcoma, while among the 23 patients with truncating mutation, the incidence of osteosarcoma was five cases per year with 230 person-years of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/43\">",
"     43",
"    </a>",
"    ]. Other members of the RecQ gene family are mutated in Bloom syndrome and Werner syndrome, two diseases with overlapping clinical features, including a predisposition to develop osteosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the etiology of osteosarcoma is unclear, a relationship between rapid bone growth and the development of osteosarcoma is suggested by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The peak incidence of osteosarcoma occurs during the adolescent growth spurt.",
"     </li>",
"     <li>",
"      The tumor appears most frequently at sites where the greatest increase in bone length and size occurs (the metaphyseal portions of the distal femur, proximal tibia, and proximal humerus) (",
"      <a class=\"graphic graphic_figure graphicRef76662 \" href=\"UTD.htm?22/53/23391\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Osteosarcomas occur at an earlier age in girls, corresponding to their more advanced skeletal age and earlier adolescent growth spurt.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data have led to speculation that bone tumors arise from an aberration of the normal process of bone growth and remodeling at a time when rapidly proliferating cells are particularly susceptible to oncogenic agents, mitotic errors, or other events leading to neoplastic transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/44\">",
"     44",
"    </a>",
"    ]. However, studies examining the relationship between factors related to growth and development and the risk of bone sarcomas have revealed no consistent pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific nature of this aberration or aberrations that leads to tumorigenesis remains elusive and is the subject of intense investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/19,47\">",
"     19,47",
"    </a>",
"    ]. In contrast to other sarcomas, there are no characteristic translocations or other molecular genetic abnormalities in osteosarcomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Genetics and molecular pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most osteosarcomas have a complex unbalanced karyotype. The highest frequency of loss of heterozygosity (which implies the loss of a putative tumor suppressor gene) in osteosarcomas is reported for chromosomes 3q, 13q (the location of the retinoblastoma gene), 17p (the location of the p53 gene), and 18q, the chromosomal region that has been linked to osteosarcomas arising in the setting of Paget disease (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Paget disease and other benign bone lesions'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/27,28,48-50\">",
"     27,28,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combined inactivation of the retinoblastoma and p53 tumor suppressor pathways is common in osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/19,47,51\">",
"     19,47,51",
"    </a>",
"    ]. The potential contribution of p53 pathway abnormalities to tumorigenesis is particularly intriguing, given the increased incidence of osteosarcoma in families with the Li-Fraumeni syndrome, an inherited condition in which p53 is mutationally inactivated. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Inherited conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Normal or \"wild type\" p53 appears to play a role in the normal development and physiology of bone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/52\">",
"     52",
"    </a>",
"    ], since p53-null mice display failure of skull growth and delayed longitudinal bone growth in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/53\">",
"     53",
"    </a>",
"    ]. Furthermore, bone cell lysates from p53-null mice also fail to activate normal apoptotic pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/47\">",
"     47",
"    </a>",
"    ]. The contribution of p53 and other genetic abnormalities to the pathogenesis of osteosarcoma is beyond the scope of this discussion; an excellent review is available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As will be discussed below, the majority of patients are presumed to have metastatic disease at presentation, with the majority being subclinical. Gene expression profiling through the use of DNA microarray analysis is beginning to uncover the molecular events that dictate metastatic potential, findings that may pave the way for future molecularly targeted therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with osteosarcoma present with localized pain, typically of several months' duration. Pain frequently begins after an injury, and may wax and wane over time. Systemic symptoms such as fever, weight loss, and malaise are generally absent. The most important finding on physical examination is a soft tissue mass, which is frequently large and tender to palpation. Osteosarcomas have a predilection for the metaphyseal region of the long bones (",
"    <a class=\"graphic graphic_figure graphicRef50795 \" href=\"UTD.htm?13/34/13864\">",
"     figure 3",
"    </a>",
"    ). The most common sites of involvement, in descending order, are: distal femur, proximal tibia, proximal humerus, middle and proximal femur, and other bones [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory evaluation is usually normal, except for elevations in alkaline phosphatase (in approximately 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/12\">",
"     12",
"    </a>",
"    ], lactate dehydrogenase (LDH, in approximately 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/57\">",
"     57",
"    </a>",
"    ], and erythrocyte sedimentation rate. Laboratory abnormalities do not correlate with disease extent, although a very high LDH level is associated with a poor clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the time of presentation, between 10 and 20 percent of patients have demonstrable macrometastatic disease and are classified as stage III according to the staging system used by the Musculoskeletal Tumor Society (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Staging system'",
"    </a>",
"    below). Distant metastases most commonly involve the lungs, but can also involve bone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occult micrometastases are presumed to be present in the majority of those who appear to have clinically localized disease, since before the era of adjuvant chemotherapy, over 80 percent of patients with osteosarcoma developed metastatic disease despite achieving local tumor control. It was postulated that these patients had subclinical metastases that were present at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/60\">",
"     60",
"    </a>",
"    ]. With routine use of systemic adjuvant chemotherapy, at least two-thirds of children and adolescents with nonmetastatic osteosarcoma will be long-term survivors, implying the success of chemotherapy in eradication of micrometastases. Prognosis is worse in adults with osteosarcoma, particularly those over the age of 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first diagnostic test to arouse suspicion for a primary bone tumor is generally a plain radiograph of the affected area [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/62\">",
"     62",
"    </a>",
"    ]. Characteristic features of conventional osteosarcomas (which account for the majority of cases, see below) include destruction of the normal trabecular bone pattern, indistinct margins, and no endosteal bone response. The affected bone is characterized by a mixture of radiodense and radiolucent areas, with periosteal new bone formation, lifting of the cortex, and formation of Codman's triangle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70494 \" href=\"UTD.htm?23/21/23903\">",
"     image 1",
"    </a>",
"    ). The associated soft tissue mass is variably ossified in a radial or \"sunburst\" pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The correct histologic diagnosis of osteosarcoma may be predicted in up to two-thirds of patients who have a characteristic radiographic appearance, clinical features, and tumor location [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/63\">",
"     63",
"    </a>",
"    ]. However, no radiographic finding is pathognomonic, and biopsy is required for definitive diagnosis. The differential diagnosis includes other malignant bone tumors (ie, Ewing sarcoma, lymphoma, and metastases), benign bone tumors (eg, chondroblastoma, osteoblastoma), and nonneoplastic conditions, such as osteomyelitis, eosinophilic granuloma, and aneurysmal bone cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, no abnormalities will be evident on plain radiographs. In such cases, magnetic resonance imaging (MRI) should be obtained if clinical suspicion for a bone tumor is high. Even for patients with characteristic plain radiographic findings, MRI is indicated for surgical planning (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Staging system'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Staging work-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with overt metastatic disease at presentation have a significantly worse outcome than those with localized disease. Because a significant proportion of patients with metastases (including up to one-half of those with limited pulmonary involvement) may be amenable to cure, a thorough staging workup is imperative to facilitate surgical planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging work-up should include the following (",
"    <a class=\"graphic graphic_table graphicRef55623 \" href=\"UTD.htm?17/11/17597\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI of the entire length of the involved long bone. A multi-institutional study of 387 patients that included both children and adults concluded that CT and MRI were equally accurate for local staging of bone and soft tissue tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/65\">",
"       65",
"      </a>",
"      ]. However, MRI is preferred in most cases because of its superior definition of soft tissue extension, particularly to the neurovascular bundle, joint and marrow involvement, and the presence of skip lesions (ie, medullary disease within the same bone, but not in direct contiguity with the primary lesion) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68702 \" href=\"UTD.htm?32/49/33552\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT scans are best suited to evaluate the thorax for metastatic disease, which is essential because approximately 80 percent of osteosarcoma metastases involve the lungs [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/60,67\">",
"       60,67",
"      </a>",
"      ]. Because of the possibility of false-positive results, histologic confirmation is indicated for suspected sites of metastatic disease, particularly if a given lesion was not detected on plain films.",
"      <br/>",
"      <br/>",
"      However, CT may underestimate the extent of pulmonary involvement by metastatic tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. In one study, metastases would have been missed in more than one-third of cases by any method other than manual palpation of the lung during open thoracotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/68\">",
"       68",
"      </a>",
"      ]. These data raise doubt as to the advisability of minimal access procedures (eg, thoracoscopic metastasectomy) when the goal is resection of all pulmonary metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/70-72\">",
"       70-72",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Distinguishing metastatic lesions from benign nodules can be difficult, particularly in adults who have a high prevalence of granulomatous disease and in children living in areas with endemic fungal disease, especially histoplasmosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and treatment of pulmonary histoplasmosis\", section on 'When to suspect histoplasmosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=see_link&amp;anchor=H2539290#H2539290\">",
"       \"Differential diagnosis and evaluation of multiple pulmonary nodules\", section on 'Malignant versus benign'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      While calcification can be a sign of benign disease, it may also be seen in metastases from osteosarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/73\">",
"       73",
"      </a>",
"      ]. Criteria to guide the evaluation of suspected pulmonary metastases are available from the European and American Osteosarcoma Study Group, as are being used in the EURAMOS 1 (AOST0331) trial (",
"      <a class=\"graphic graphic_table graphicRef75576 \" href=\"UTD.htm?1/57/1947\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radionuclide bone scanning with technetium is the preferred method for evaluating the entire skeleton for the presence of multiple lesions. Although a positron emission tomography (PET) scan may have greater utility for assessing the response to preoperative chemotherapy, at least one study suggests it is inferior to radionuclide bone scanning for the detection of osseous metastases from osteosarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/75\">",
"       75",
"      </a>",
"      ] and to spiral CT for detecting pulmonary metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/76\">",
"       76",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The role of PET and integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      imaging in patients with osteosarcoma is incompletely characterized, and there is no consensus on their use [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. Guidelines from the National Comprehensive Cancer Network (NCCN) suggest a PET scan",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bone scan in the workup of a suspected osteosarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/78\">",
"       78",
"      </a>",
"      ]. Imaging guidelines from the Children&rsquo;s Oncology Group Bone Tumor Committee recommend radionuclide bone scan",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PET scan for whole body staging (",
"      <a class=\"graphic graphic_table graphicRef55623 \" href=\"UTD.htm?17/11/17597\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/64\">",
"       64",
"      </a>",
"      ]. Regardless of which is chosen, the same imaging modality should be used throughout treatment and during posttreatment surveillance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of a primary bone tumor is suspected, referral should be made to a facility with expertise in pediatric oncology for further management, including a diagnostic biopsy. The biopsy should be carried out by an orthopedic surgeon who is experienced in the management of osteosarcoma and ideally by the same surgeon who will perform the definitive surgery. If a core needle biopsy is planned by an interventional radiologist, the orthopaedic surgeon and radiologist should communicate about the placement of the biopsy tract. Proper planning of the biopsy with careful consideration of the future definitive surgery is important so as not to jeopardize the subsequent treatment, particularly a limb salvage procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/79\">",
"     79",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Musculoskeletal Tumor Society (MSTS) staging system is most often used for bone sarcomas and was developed by Enneking at the University of Florida [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. This is a surgical staging system and is not used to decide medical (chemotherapy) treatment for patients with osteosarcoma.",
"   </p>",
"   <p>",
"    The MSTS staging system characterizes nonmetastatic malignant bone tumors by grade (low-grade [stage I] versus high-grade [stage II]) and further subdivides these stages according to the local anatomic extent (intracompartmental [A] versus extracompartmental [B]). For bone tumors, the compartmental status is determined by whether the tumor extends through the cortex of the involved bone; the majority of high grade osteosarcoma are extracompartmental. Patients with distant metastases are categorized as stage III.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HISTOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic diagnosis of an osteosarcoma is based on the presence of a malignant sarcomatous stroma, associated with the production of tumor osteoid and bone. Osteosarcomas are thought to arise from a mesenchymal stem cell that is capable of differentiating towards fibrous tissue, cartilage, or bone. As a result, they share many features with chondrosarcomas and fibrosarcomas, tumors of the same family of bone sarcomas (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"UTD.htm?41/39/42620\">",
"     table 3",
"    </a>",
"    ), with which osteosarcoma can be easily confused. However, chondrosarcomas and fibrosarcomas are distinguished by their lack of woven bone matrix, which is required for the diagnosis of osteosarcoma.",
"   </p>",
"   <p>",
"    Because some osteosarcomas have a limited degree of osteoid production and variable histomorphology, immunohistochemistry may be required for confirmation of the diagnosis. In contrast to Ewing sarcoma and many soft tissue sarcomas, osteosarcomas are not associated with any characteristic chromosomal translocations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Conventional osteosarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest group are the conventional (intramedullary high-grade) osteosarcomas, which account for approximately 90 percent of all osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/83\">",
"     83",
"    </a>",
"    ]. These tumors typically involve the metaphysis of long bones (",
"    <a class=\"graphic graphic_figure graphicRef76662 \" href=\"UTD.htm?22/53/23391\">",
"     figure 2",
"    </a>",
"    ) and are most common in adolescents and young adults.",
"   </p>",
"   <p>",
"    Depending upon the predominant cellular component, conventional osteosarcomas are subclassified as osteoblastic (accounting for 50 percent of conventional osteosarcomas), chondroblastic (25 percent), or fibroblastic (25 percent) (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"UTD.htm?41/39/42620\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/62\">",
"     62",
"    </a>",
"    ]. Despite histologic differences, their clinical behavior and management are similar.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoblastic osteosarcoma is characterized by abundant osteoid production that forms a fine or coarse lacelike pattern around the tumor cells; massive amounts may result in distortion of the malignant stromal cells (",
"      <a class=\"graphic graphic_picture graphicRef87011 \" href=\"UTD.htm?34/26/35238\">",
"       picture 1",
"      </a>",
"      ). Some tumors contain thick trabeculae of osteoid that form an irregular anastomosing network. The degree of mineralization is variable.",
"     </li>",
"     <li>",
"      Fibroblastic osteosarcomas are predominantly composed of high-grade spindle cell stroma that contains only focal osteoid production (",
"      <a class=\"graphic graphic_picture graphicRef87013 \" href=\"UTD.htm?22/15/22773\">",
"       picture 2",
"      </a>",
"      ). More pleomorphic tumors may resemble malignant fibrous histiocytoma, but the distinction can be made by the identification of osteoid.",
"     </li>",
"     <li>",
"      In chondroblastic osteosarcomas, cartilaginous matrix production is evident throughout most of the tumor. While the majority of the tumor tends to be of lower grade, the chondroid areas may contain cytologically atypical cells that are characteristic of higher-grade tumors. These chondroblastic foci are admixed with malignant spindle cells that produce osteoid trabecula (",
"      <a class=\"graphic graphic_picture graphicRef87012 \" href=\"UTD.htm?26/50/27431\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Histologic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the three subcategories of conventional osteosarcoma, there are several variants:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small cell",
"     </li>",
"     <li>",
"      Telangiectatic",
"     </li>",
"     <li>",
"      Multifocal",
"     </li>",
"     <li>",
"      Malignant fibrous histiocytoma [MFH] subtype",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These variants were originally thought to carry a worse prognosis. However, with modern aggressive therapy, they appear to behave similarly. Other subtypes (the juxtacortical parosteal and periosteal osteosarcomas) are associated with a more indolent biologic behavior. Parosteal osteosarcomas are more common in older patients and periosteal osteosarcoma has a similar age distribution to classic osteosarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Small cell osteosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell osteosarcoma is noteworthy for the confusion that may arise in its distinction from other \"small round blue cell tumors\" such as Ewing sarcoma by conventional light microscopy of hematoxylin and eosin (H&amp;E) stained sections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/84\">",
"     84",
"    </a>",
"    ]. Immunohistochemical staining, cytogenetics, and molecular genetic studies may be required to establish the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Telangiectatic osteosarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectatic osteosarcomas are high-grade, vascular tumors which contain little osteoid. Because of their purely lytic appearance on plain radiographs, they can be confused with aneurysmal bone cysts or giant cell tumors of bone (GCTB). Grossly they appear as a \"multicystic bag of blood\", and a solid mass of tumor is usually absent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/83\">",
"     83",
"    </a>",
"    ]. As a result, it may be difficult to obtain diagnostic tissue on biopsy. Histologically, the minimal osteoid formation and numerous multinucleated giant cells (",
"    <a class=\"graphic graphic_picture graphicRef87014 \" href=\"UTD.htm?17/42/18089\">",
"     picture 4",
"    </a>",
"    ) are reminiscent of a benign GCTB. However, the cells are highly pleomorphic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=see_link\">",
"     \"Giant cell tumor of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The age distribution and treatment are identical to classic high-grade osteosarcoma. The response to chemotherapy and survival are similar to conventional osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Multifocal osteosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients present with multiple synchronous sites at diagnosis, all resembling the primary tumor. It is difficult to determine whether these represent synchronous multiple primary lesions or considered metastases. Regardless of their designation, the prognosis is usually dismal. Multicentric osteosarcoma may also be metachronous in that other bony lesions occur years after treatment of the first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Malignant fibrous histiocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;MFH of bone appears similar to osteosarcoma, but without osteoid production. Although they tend to have a lower rate of tumor necrosis following induction chemotherapy, long-term survival rates are similar to conventional osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Surface (juxtacortical) osteosarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to these intramedullary variants, the surface osteosarcomas differ with respect to prognosis and therapy. These osteosarcomas include the parosteal low-grade type, the intermediate-grade periosteal type, and the high-grade surface osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Surgery alone may be curative for the low-grade and intermediate-grade varieties, as long as they do not enter the marrow cavity or have a de-differentiated component [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parosteal osteosarcoma &mdash; The most common of these entities, typical parosteal osteosarcoma, is a surface lesion composed of low-grade fibroblastic cells that produce woven or lamellar bone. It occurs in an older age group than conventional intramedullary osteosarcoma, usually between the ages of 20 and 40 years. The posterior aspect of the distal femur is the most commonly involved site, but other long bones may be affected. The tumor arises from the cortex as a broadly based lesion. With time, however, this lesion may invade the cortex and enter the endosteal cavity. Treatment for conventional parosteal osteosarcomas is surgical resection alone with expected survival rates of approximately 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/92,93\">",
"       92,93",
"      </a>",
"      ]; however, de-differentiated parosteal osteosarcomas may require adjuvant chemotherapy.",
"     </li>",
"     <li>",
"      Periosteal osteosarcoma &mdash; Periosteal osteosarcoma is a moderate-grade, chondroblastic surface osteosarcoma frequently located in the proximal tibia, which has the same age distribution as conventional intramedullary osteosarcoma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68702 \" href=\"UTD.htm?32/49/33552\">",
"       image 2",
"      </a>",
"      ). The likelihood of metastases is greater than that for the low-grade parosteal tumors, but lower than the classic intramedullary osteosarcoma.",
"      <br/>",
"      <br/>",
"      The role of adjuvant chemotherapy for periosteal osteosarcomas is controversial. Adjuvant chemotherapy is recommended in many centers because of the estimated 20 percent metastatic rate. However, retrospective reports indicate more favorable outcomes than seen with classic osteosarcomas (84 percent ten-year survival rate in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/94\">",
"       94",
"      </a>",
"      ]), a lack of benefit when patients who received adjuvant chemotherapy were compared to those treated by surgery alone [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/94,95\">",
"       94,95",
"      </a>",
"      ], and a concerning number of second malignant neoplasms in patients treated with adjuvant chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/94\">",
"       94",
"      </a>",
"      ]. Randomized trials have not been conducted, which limits the conclusions that can be drawn from the available literature.",
"     </li>",
"     <li>",
"      High-grade surface osteosarcoma &mdash; Conventional high-grade osteosarcomas may also develop on the surface of the bone, where they may be confused with parosteal or periosteal osteosarcoma. They are treated similar to conventional intramedullary osteosarcomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Osteosarcoma of the jaw",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another distinct variant is osteosarcoma of the jaw, which tends to occur in older patients, has an indolent course, and is more often associated with local recurrences than with distant metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Extraosseous osteosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraosseous osteosarcoma is a malignant tumor arising in the soft tissue, without involving the bone or periosteum, that produces osteoid, bone, or chondroid material (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83187 \" href=\"UTD.htm?8/61/9172\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83419 \" href=\"UTD.htm?0/6/111\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/96-101\">",
"     96-101",
"    </a>",
"    ]. Most arise in the setting of prior radiation exposure.",
"   </p>",
"   <p>",
"    In contrast to osseous osteosarcomas, extraskeletal osteosarcomas present in older age groups, they have a different anatomic predilection (the most common site is in the thigh) and show relative chemoresistance to doxorubicin-based chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/22/20842/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. They are generally treated as a soft tissue sarcoma with aggressive behavior.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29529482\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteosarcomas are uncommon primary malignant tumors of bone that are characterized by the production of osteoid or immature bone by the malignant cells. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The age distribution of osteosarcoma incidence is bimodal, with peaks in early adolescence and in adults over the age of 65. Osteosarcoma is the most common primary bone tumor affecting children and young adults; the peak age is between 13 and 16. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Children'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In children, the majority of osteosarcomas are sporadic. A minority of cases are associated with inherited predisposition syndromes such as hereditary retinoblastoma, Li-Fraumeni syndrome, Rothmund-Thomson syndrome, and the related Bloom and Werner syndromes. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Osteosarcomas in adults are often considered secondary neoplasms, attributed to sarcomatous transformation of Paget disease of bone or some other benign bone lesion. In the US, over one-half of all osteosarcomas arising in patients over the age of 60 are secondary, while in, Asia, Paget disease is less frequent and a higher percentage arise primarily. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Adults'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Paget disease and other benign bone lesions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority of patients with osteosarcoma present with localized pain, typically of several months' duration. The most important finding on physical examination is a soft tissue mass, which is frequently large and tender to palpation. At presentation, between 10 and 20 percent have demonstrable metastatic disease, most often involving the lung. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Biopsy is required for definitive diagnosis. Proper planning of the biopsy with careful consideration of future definitive surgery is important so as not to jeopardize subsequent treatment, particularly the opportunity for limb salvage. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The histologic diagnosis of an osteosarcoma is based on the presence of a malignant sarcomatous stroma, associated with the production of tumor osteoid and bone. Conventional (intramedullary high-grade) osteosarcomas account for approximately 90 percent of all osteosarcomas. Other less common histologic variants are small cell, telangiectatic, multifocal, surface (juxtacortical), and extraosseous osteosarcomas, malignant fibrous histiocytoma, and osteosarcoma of the jaw. Jaw osteosarcoma is more common in older patients. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Histologic classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once the diagnosis of an osteosarcoma is established, the staging evaluation should include MRI of the entire length of the involved bone, CT of the thorax, radionuclide bone scanning with technetium,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a PET scan. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Staging work-up'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Huvos A. Bone Tumors: Diagnosis, Treatment, Prognosis, 2nd, WB Saunders, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/2\">",
"      Sissons HA. The WHO classification of bone tumors. Recent Results Cancer Res 1976; :104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/3\">",
"      McKenna R, Schwinn C, Soong K, et al. Sarcomas of the osteogenic series (osteosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone): an analysis of 552 cases. J Bone Joint Surg Am 1966; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 (Pub #99-4649), Ries LA, Smith MAS, Gurney JG, et al (Eds), SEER program, National Cancer Institute, Bethesda, MD 1999. p.99.",
"    </li>",
"    <li>",
"     Data from the American Cancer Society file://www.cancer.org/docroot/home/index.asp (Accessed on June 01, 2011).",
"    </li>",
"    <li>",
"     Smith MA, Gurney JG, Ries LA. Cancer in adolescents 15 to 19 years old. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 (Pub #99-4649), Ries LA, Smith MAS, Gurney JG, et al (Eds), SEER program, National Cancer Institute, Bethesda, MD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/7\">",
"      Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/8\">",
"      CADE S. Osteogenic sarcoma; a study based on 133 patients. J R Coll Surg Edinb 1955; 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/9\">",
"      Dahlin DC, Unni KK. Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol 1977; 1:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/10\">",
"      Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115:1531.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/publications/childhood/introduction.pdf (Accessed on May 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/12\">",
"      Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 1979; 43:2178.",
"     </a>",
"    </li>",
"    <li>",
"     Bleyer A, O&rsquo;Leary M, Barr R, Ries LAG (eds). Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH Pub. No. 06-5767, National Cancer Institute; Bethesda, MD 2006.",
"    </li>",
"    <li>",
"     Pathology and Genetics of tumours of soft tissue and bone, Fletcher CDM, Unni KK, Mertens F (Eds), IARC Press, Lyon, France 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/15\">",
"      Kram&aacute;rov&aacute; E, Stiller CA. The international classification of childhood cancer. Int J Cancer 1996; 68:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/16\">",
"      Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 1986; 57:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/17\">",
"      Nishida Y, Isu K, Ueda T, et al. Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group. J Surg Oncol 2009; 100:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/18\">",
"      Argenson JN, Flecher X, Parratte S, Aubaniac JM. Anatomy of the dysplastic hip and consequences for total hip arthroplasty. Clin Orthop Relat Res 2007; 465:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/19\">",
"      Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002; :40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/20\">",
"      Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/21\">",
"      Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998; 77:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/22\">",
"      Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/23\">",
"      Newton WA Jr, Meadows AT, Shimada H, et al. Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer 1991; 67:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/24\">",
"      Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/25\">",
"      Grimer RJ, Cannon SR, Taminiau AM, et al. Osteosarcoma over the age of forty. Eur J Cancer 2003; 39:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/26\">",
"      Hadjipavlou A, Lander P, Srolovitz H, Enker IP. Malignant transformation in Paget disease of bone. Cancer 1992; 70:2802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/27\">",
"      Hansen MF, Nellissery MJ, Bhatia P. Common mechanisms of osteosarcoma and Paget's disease. J Bone Miner Res 1999; 14 Suppl 2:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/28\">",
"      Nellissery MJ, Padalecki SS, Brkanac Z, et al. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet 1998; 63:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/29\">",
"      Mankin HJ, Hornicek FJ. Paget's sarcoma: a historical and outcome review. Clin Orthop Relat Res 2005; 438:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/30\">",
"      Desai P, Perino G, Present D, Steiner GC. Sarcoma in association with bone infarcts. Report of five cases. Arch Pathol Lab Med 1996; 120:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/31\">",
"      Smith GD, Chalmers J, McQueen MM. Osteosarcoma arising in relation to an enchondroma. A report of three cases. J Bone Joint Surg Br 1986; 68:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/32\">",
"      Staals EL, Bacchini P, Mercuri M, Bertoni F. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am 2007; 89:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/33\">",
"      Hauben EI, Arends J, Vandenbroucke JP, et al. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 2003; 11:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/34\">",
"      Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 1987; 56:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/35\">",
"      Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A 1985; 82:6216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/36\">",
"      Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/37\">",
"      Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/38\">",
"      Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992; 326:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/39\">",
"      McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994; 12:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/40\">",
"      Carnevale A, Lieberman E, C&aacute;rdenas R. Li-Fraumeni syndrome in pediatric patients with soft tissue sarcoma or osteosarcoma. Arch Med Res 1997; 28:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/41\">",
"      Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 2001; 102:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/42\">",
"      Leonard A, Craft AW, Moss C, Malcolm AJ. Osteogenic sarcoma in the Rothmund-Thomson syndrome. Med Pediatr Oncol 1996; 26:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/43\">",
"      Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 2003; 95:669.",
"     </a>",
"    </li>",
"    <li>",
"     Gorlick, R, Bielack, et al. Osteosarcoma: Biology, diagnosis, treatment, and remaining challenges. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo, PA, Poplack, DG (Eds), Lippincott, Williams and Wilkins, Philadelphia PA 2011. p.1015.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/45\">",
"      Buckley JD, Pendergrass TW, Buckley CM, et al. Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group. Cancer 1998; 83:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/46\">",
"      Troisi R, Masters MN, Joshipura K, et al. Perinatal factors, growth and development, and osteosarcoma risk. Br J Cancer 2006; 95:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/47\">",
"      Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003; 9:5442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/48\">",
"      Kruzelock RP, Murphy EC, Strong LC, et al. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res 1997; 57:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/49\">",
"      Yamaguchi T, Toguchida J, Yamamuro T, et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 1992; 52:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/50\">",
"      Tarkkanen M, Karhu R, Kallioniemi A, et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 1995; 55:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/51\">",
"      Bridge JA, Nelson M, McComb E, et al. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 1997; 95:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/52\">",
"      Chandar N, Donehower L, Lanciloti N. Reduction in p53 gene dosage diminishes differentiation capacity of osteoblasts. Anticancer Res 2000; 20:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/53\">",
"      Ohyama K, Chung CH, Chen E, et al. p53 influences mice skeletal development. J Craniofac Genet Dev Biol 1997; 17:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/54\">",
"      Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/55\">",
"      Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004; 10:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/56\">",
"      Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997; 44:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/57\">",
"      Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991; :8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/58\">",
"      Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 1997; 8:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/59\">",
"      Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer 2005; 104:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/60\">",
"      Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001; 19:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/61\">",
"      Longhi A, Errani C, Gonzales-Arabio D, et al. Osteosarcoma in patients older than 65 years. J Clin Oncol 2008; 26:5368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/62\">",
"      Papagelopoulos PJ, Galanis EC, Vlastou C, et al. Current concepts in the evaluation and treatment of osteosarcoma. Orthopedics 2000; 23:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/63\">",
"      Kesselring FO, Penn W. Radiological aspects of 'classic' primary osteosarcoma: value of some radiological investigations: A review. Diagn Imaging 1982; 51:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/64\">",
"      Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/65\">",
"      Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 1997; 202:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/66\">",
"      Sajadi KR, Heck RK, Neel MD, et al. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop Relat Res 2004; :92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/67\">",
"      Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer 1975; 32:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/68\">",
"      Kayton ML, Huvos AG, Casher J, et al. Computed tomographic scan of the chest underestimates the number of metastatic lesions in osteosarcoma. J Pediatr Surg 2006; 41:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/69\">",
"      Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997; 113:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/70\">",
"      Gilbert JC, Powell DM, Hartman GE, et al. Video-assisted thoracic surgery (VATS) for children with pulmonary metastases from osteosarcoma. Ann Surg Oncol 1996; 3:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/71\">",
"      Yim AP, Lin J, Chan AT, et al. Video-assisted thoracoscopic wedge resections of pulmonary metastatic osteosarcoma: should it be performed? Aust N Z J Surg 1995; 65:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/72\">",
"      McCormack PM, Bains MS, Begg CB, et al. Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg 1996; 62:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/73\">",
"      Picci P, Vanel D, Briccoli A, et al. Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol 2001; 12:1601.",
"     </a>",
"    </li>",
"    <li>",
"     Protocol information available online at file://www.cancer.gov/clinicaltrials/search/view?cdrid=438714&amp;version=healthprofessional (Accessed on June 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/75\">",
"      Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/76\">",
"      Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/77\">",
"      Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med 2003; 44:930.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available online at www.nccn.org (Accessed on October 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/79\">",
"      Peabody TD, Simon MA. Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors. Orthop Clin North Am 1996; 27:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/80\">",
"      Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; :9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/81\">",
"      Wolf RE, Enneking WF. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am 1996; 27:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/82\">",
"      Fletcher JA, Gebhardt MC, Kozakewich HP. Cytogenetic aberrations in osteosarcomas. Nonrandom deletions, rings, and double-minute chromosomes. Cancer Genet Cytogenet 1994; 77:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/83\">",
"      Inwards CY, Unni KK. Classification and grading of bone sarcomas. Hematol Oncol Clin North Am 1995; 9:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/84\">",
"      Nakajima H, Sim FH, Bond JR, Unni KK. Small cell osteosarcoma of bone. Review of 72 cases. Cancer 1997; 79:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/85\">",
"      Martin SE, Dwyer A, Kissane JM, Costa J. Small-cell osteosarcoma. Cancer 1982; 50:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/86\">",
"      Stea B, Cavazzana A, Kinsella TJ. Small-cell osteosarcoma: correlation of in vitro and clinical radiation response. Int J Radiat Oncol Biol Phys 1988; 15:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/87\">",
"      Rosen G, Huvos AG, Marcove R, Nirenberg A. Telangiectatic osteogenic sarcoma. Improved survival with combination chemotherapy. Clin Orthop Relat Res 1986; :164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/88\">",
"      Picci P, Bacci G, Ferrari S, Mercuri M. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Ann Oncol 1997; 8:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/89\">",
"      Schajowicz F, McGuire MH, Santini Araujo E, et al. Osteosarcomas arising on the surfaces of long bones. J Bone Joint Surg Am 1988; 70:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/90\">",
"      Raymond AK. Surface osteosarcoma. Clin Orthop Relat Res 1991; :140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/91\">",
"      Kaste SC, Fuller CE, Saharia A, et al. Pediatric surface osteosarcoma: clinical, pathologic, and radiologic features. Pediatr Blood Cancer 2006; 47:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/92\">",
"      Sheth DS, Yasko AW, Raymond AK, et al. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer 1996; 78:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/93\">",
"      Okada K, Unni KK, Swee RG, Sim FH. High grade surface osteosarcoma: a clinicopathologic study of 46 cases. Cancer 1999; 85:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/94\">",
"      Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. Cancer 2011; 117:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/95\">",
"      Grimer RJ, Bielack S, Flege S, et al. Periosteal osteosarcoma--a European review of outcome. Eur J Cancer 2005; 41:2806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/96\">",
"      Bane BL, Evans HL, Ro JY, et al. Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer 1990; 65:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/97\">",
"      Lidang Jensen M, Schumacher B, Myhre Jensen O, et al. Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases. Am J Surg Pathol 1998; 22:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/98\">",
"      Ahmad SA, Patel SR, Ballo MT, et al. Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol 2002; 20:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/99\">",
"      Lee JS, Fetsch JF, Wasdhal DA, et al. A review of 40 patients with extraskeletal osteosarcoma. Cancer 1995; 76:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/100\">",
"      Torigoe T, Yazawa Y, Takagi T, et al. Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group. J Orthop Sci 2007; 12:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/22/20842/abstract/101\">",
"      Lee S, Lee MR, Lee SJ, et al. Extraosseous osteosarcoma: single institutional experience in Korea. Asia Pac J Clin Oncol 2010; 6:126.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7722 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20842=[""].join("\n");
var outline_f20_22_20842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29529482\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Prior irradiation or chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Paget disease and other benign bone lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inherited conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS AND STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Staging work-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HISTOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Conventional osteosarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Histologic variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Small cell osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Telangiectatic osteosarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Multifocal osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Malignant fibrous histiocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Surface (juxtacortical) osteosarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Osteosarcoma of the jaw",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Extraosseous osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29529482\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7722\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7722|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/21/23903\" title=\"diagnostic image 1\">",
"      Xray osteosarc distal femur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/49/33552\" title=\"diagnostic image 2\">",
"      Periosteal osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/61/9172\" title=\"diagnostic image 3\">",
"      Extraosseous osteosarcoma with metastatic disease to the lungs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/6/111\" title=\"diagnostic image 4\">",
"      Surgical specimen of extraosseous osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7722|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/12/32974\" title=\"figure 1\">",
"      Bone sarcoma incidence SEER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/53/23391\" title=\"figure 2\">",
"      Components of a long bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/34/13864\" title=\"figure 3\">",
"      Bone tumor locations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7722|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/26/35238\" title=\"picture 1\">",
"      Osteoblastic osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/15/22773\" title=\"picture 2\">",
"      Fibroblastic osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/50/27431\" title=\"picture 3\">",
"      Chondroblastic osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/42/18089\" title=\"picture 4\">",
"      Telangiectatic osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7722|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/11/17597\" title=\"table 1\">",
"      Imaging guidelines for newly diagnosed osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/57/1947\" title=\"table 2\">",
"      Criteria for pulmonary metastatic disease in osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/39/42620\" title=\"table 3\">",
"      Classify primary malignant bone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=related_link\">",
"      Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=related_link\">",
"      Giant cell tumor of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=related_link\">",
"      Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=related_link\">",
"      Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_22_20843="Iron treatment ex thalassemics";
var content_f20_22_20843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Algorithm for iron treatment in ex-Thalassemics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Hepatic iron concentration",
"       </td>",
"       <td class=\"subtitle1\">",
"        First choice",
"       </td>",
"       <td class=\"subtitle1\">",
"        Second choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;15 mg/g dry weight",
"       </td>",
"       <td>",
"        Intensive phlebotomy",
"       </td>",
"       <td>",
"        Iron chelation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 15 mg/g dry weight",
"       </td>",
"       <td>",
"        Phlebotomy",
"       </td>",
"       <td>",
"        Iron chelation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        1.6 to 7 mg/g dry weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        HCV-PCR positive",
"       </td>",
"       <td class=\"sublist_other\">",
"        Phlebotomy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Iron chelation therapy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        HCV-PCR negative",
"       </td>",
"       <td class=\"sublist_other\">",
"        No therapy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Phlebotomy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver biopsy is performed and hepatic iron concentration determined at eighteen months after bone marrow transplantation and the patient is off any therapy for at least six months (patient is out from any therapy since at least six months). Chimeric patients and those with chronic GVHD are excluded.",
"    <div class=\"footnotes\">",
"     * Deferoxamine is not given if the hepatic iron concentration is less than 4 mg/g dry weight.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20843=[""].join("\n");
var outline_f20_22_20843=null;
var title_f20_22_20844="Rotavirus vaccines summary";
var content_f20_22_20844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of rotavirus vaccines licensed in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pentavalent human-bovine reassortant vaccine (PRV, RV5)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Attenuated human rotavirus vaccine (HRV, RV1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trade name",
"      </td>",
"      <td>",
"       RotaTeq",
"      </td>",
"      <td>",
"       Rotarix",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serotypes contained",
"      </td>",
"      <td>",
"       G1, G2, G3, G4, G6, P[5], P[8]",
"      </td>",
"      <td>",
"       G1, P[8]",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dose",
"      </td>",
"      <td>",
"       2 mL",
"      </td>",
"      <td>",
"       1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Administration",
"      </td>",
"      <td>",
"       Ready-to-use",
"      </td>",
"      <td>",
"       Requires reconstitution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Number of doses",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recommended schedule",
"      </td>",
"      <td>",
"       2, 4, 6 months",
"      </td>",
"      <td>",
"       2, 4 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Minimum age first dose",
"      </td>",
"      <td>",
"       6 weeks",
"      </td>",
"      <td>",
"       6 weeks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Maximum age first dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       United States",
"      </td>",
"      <td class=\"sublist_other\">",
"       14 weeks, 6 days",
"      </td>",
"      <td class=\"sublist_other\">",
"       14 weeks, 6 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Europe",
"      </td>",
"      <td class=\"sublist_other\">",
"       12 weeks",
"      </td>",
"      <td class=\"sublist_other\">",
"       12 weeks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Minimal interval between doses",
"      </td>",
"      <td>",
"       4 weeks",
"      </td>",
"      <td>",
"       4 weeks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Maximum age last dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       United States",
"      </td>",
"      <td class=\"sublist_other\">",
"       8 months, 0 days",
"      </td>",
"      <td class=\"sublist_other\">",
"       8 months, 0 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Europe",
"      </td>",
"      <td class=\"sublist_other\">",
"       6 months",
"      </td>",
"      <td class=\"sublist_other\">",
"       6 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oral applicator",
"      </td>",
"      <td>",
"       Latex-free",
"      </td>",
"      <td>",
"       Contains latex*",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Contraindicated in children with a severe (anaphylactic) allergy to latex.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20844=[""].join("\n");
var outline_f20_22_20844=null;
var title_f20_22_20845="Recommendations for ER and PR testing by IHC in breast cancer";
var content_f20_22_20845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of guideline recommendations for ER and PR testing by immunohistochemistry in breast cancer patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Optimal algorithm for ER/PR testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive for ER or PR if finding of &ge;1 percent of tumor cell nuclei are immunoreactive.",
"       </td>",
"       <td rowspan=\"2\">",
"        These definitions depend on laboratory documentation of the following:",
"        <ol>",
"         <li>",
"          Proof of initial testing validation using clinically validated antibody",
"         </li>",
"         <li>",
"          Ongoing internal quality assurance procedures",
"         </li>",
"         <li>",
"          Participation in external proficiency testing",
"         </li>",
"         <li>",
"          Biennial accreditation by valid accrediting agency",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negative for ER or PR if finding of &lt;1 percent of tumors cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PR (positive intrinsic controls are seen).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Optimal testing conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Large, preferably multiple core biopsies of tumor are preferred for testing if they are representative of the tumor (grade and type) at resection.",
"       </td>",
"       <td>",
"        Specimen should be rejected and repeated on a separate sample if any of the following conditions exist:",
"        <ol>",
"         <li>",
"          External controls are not as expected (scores recorded daily show variation)",
"         </li>",
"         <li>",
"          Artifacts involve most of sample",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specimen may also be rejected and repeated on another sample if:",
"        <ol>",
"         <li>",
"          Slide has no staining of included normal epithelial elements and/or normal positive control on same slide",
"         </li>",
"         <li>",
"          Specimen decalcified using strong acids",
"         </li>",
"         <li>",
"          Specimen shows an ER-/PR+ phenotype (to rule out a false-negative ER assay or a false-positive PR assay)",
"         </li>",
"         <li>",
"          Sample has prolonged cold ischemia time or fixation duration &lt;6 hours or &gt;72 hours and is negative on testing in the absence of internal control elements",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Interpretation follows guideline recommendation.",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Positive ER or PR requires &ge;1 percent of tumor cells are immunoreactive; both average intensity and extent of staining are reported",
"         </li>",
"         <li>",
"          Image analysis is a desirable method of quantifying percent of tumor cells which are immunoreactive",
"         </li>",
"         <li>",
"          H Score, Allred Score or Quick Score may be provided",
"         </li>",
"         <li>",
"          Negative ER or PR requires &lt;1 percent of tumor cells with ER or PR staining",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interpreters have method to maintain consistency and competency documented regularly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accession slip and report must include guideline-detailed elements.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Optimal tissue handling requirements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <p>",
"         Time from tissue acquisition to fixation should be as short as possible. Samples for ER and PR testing are fixed in 10 percent neutral buffered fomalin (NBF) for 6 to 72 hours. Samples should be sliced at 5 mm intervals after appropriate gross inspection and margins designation and placed in sufficient volume of NBF to allow adequate tissue penetration.",
"        </p>",
"        <p>",
"         If tumor comes from remote location, it should be bisected through the tumor on removal and sent to the laboratory immersed in a sufficient volume of NBF. Cold ischemia time, fixative type, and time the sample was placed in NBF must be recorded.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Storage of slides for more than six weeks prior to analysis is not recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Time tissue is removed from patient, time tissue is placed in fixative, duration of fixation and fixative type must be recorded and noted on accession slip or in report.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Guidelines from a combined panel from the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP).",
"    <div class=\"footnotes\">",
"     ER: estrogen receptor; NBF: neutral buffered formalin; PR: progesterone receptor.",
"    </div>",
"    <div class=\"reference\">",
"     Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20845=[""].join("\n");
var outline_f20_22_20845=null;
var title_f20_22_20846="Contents: Skin cancer";
var content_f20_22_20846=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Skin cancer",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Skin cancer",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Melanoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/42/44711\">",
"           Adjuvant immunotherapy for melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/28/2506\">",
"           Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27081\">",
"           Cutaneous melanoma: Management of in transit metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34007\">",
"           Cutaneous melanoma: Management of local recurrence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/8/8328\">",
"           Cytotoxic chemotherapy for metastatic melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/2/26664\">",
"           Evaluation and treatment of regional lymph nodes in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/5/15450\">",
"           Imaging studies in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/26/6569\">",
"           Inherited susceptibility to melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/61/26585\">",
"           Initial surgical management of melanoma of the skin and unusual sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7625\">",
"           Interleukin-2 and other immunotherapies for advanced melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39927\">",
"           Management of brain metastases in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/30/19944\">",
"           Molecularly targeted therapy for metastatic melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/58/4010\">",
"           Mucosal melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/59/8122\">",
"           Ocular melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/12/15558\">",
"           Overview of the management of advanced melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22009\">",
"           Pathologic characteristics of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/11/1206\">",
"           Pathologic evaluation of regional lymph nodes in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18073\">",
"           Primary prevention of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24410\">",
"           Risk factors for the development of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8713\">",
"           Role of radiation therapy in the management of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16650\">",
"           Screening and early detection of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35065\">",
"           Staging work-up and surveillance after treatment of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/8/2183\">",
"           Surgical management of metastatic melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/34/1576\">",
"           The molecular biology of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42488\">",
"           Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nonmelanoma skin cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/35/6712\">",
"           Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/11/7351\">",
"           Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/39/14970\">",
"           Epidemiology and clinical features of basal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/56/25482\">",
"           Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/5/44121\">",
"           Nevoid basal cell carcinoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/31/3577\">",
"           Staging and treatment of Merkel cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/61/14293\">",
"           Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13690\">",
"           Treatment and prognosis of basal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31209\">",
"           Treatment and prognosis of cutaneous squamous cell carcinoma",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-B11C94568A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_22_20846=[""].join("\n");
var outline_f20_22_20846=null;
var title_f20_22_20847="Palpation of anserine bursa";
var content_f20_22_20847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the anserine bursa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anserine bursa is located between the medial collateral ligament and the conjoined tendon formed by the gracilis, sartorius, and semitendinosis tendons. The entire tibial plateau is palpated to distinguish the localized tenderness of anserine bursitis from the more extensive tenderness of the medial collateral ligament. The patella and the tibial tubercle are marked with a pen. Tenderness at the level of the tibial tubercle is compared with tenderness at the medial joint line and the medial femoral condyle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_22_20847=[""].join("\n");
var outline_f20_22_20847=null;
